VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 29 (11-20 diciembre / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

The Science of Disease Prevention: Inside GSK's Vaccine Manufacturing Facility in Belgium

Dec 11. The worst of COVID-19 may be behind us, with about 5.55 billion people across the world receiving at least one dose of the COVID vaccine as of March 2023, according to a report in the New York Times. One would think that, after surviving a pandemic that, at its height, killed as many as three million people worldwide, people would have developed a stronger faith—or at least found a newfound appreciation for—the power and efficacy of vaccines.

But, surprisingly, the opposite seems to have happened. In a wide-ranging study evaluating people's confidence of vaccines in 2019 and 2022 (before and after the pandemic), researchers found that vaccine confidence seems to have "significantly declined" since the onset of COVID-19.

"A study has shown that vaccine confidence in the public has declined compared to before

"Despite abundant epidemiological evidence of the safety and effectiveness of COVID-19 vaccines, only approximately 1 in 5 participants of the 2022 cohort self-assessed their vaccine confidence as having increased since the pandemic," the study said. "(T)he majority of participants reported that their confidence remained unchanged or even decreased. These observations are compatible with studies carried out in the early months of the COVID-19 pandemic indicating that, in contrast to previous evidence that the perceived threat from a disease should improve public vaccine confidence, willingness to receive a COVID-19 vaccine started decreasing even before the vaccines were developed."

This skepticism and disturbing decrease in trust and confidence in vaccines is exactly what pharmaceutical companies like GSK is working hard to combat. The London-based biopharma giant is at the forefront of developing and distributing life-saving vaccines for millions of people around the world. One of the 10 largest pharmaceutical companies in the world, GSK is in the business of saving lives through its portfolio of vaccines, specialty, and general medicines.

GSK vs COVID

Although GSK wasn't one of the companies that offered branded vaccines against COVID-19 from 2021 onwards—companies like Pfizer, Sinopharma, AstraZeneca, Johnson & Johnson, and Moderna—what many people don't know is that it was actually involved in the process of developing a vaccine in collaboration with other pharmaceutical companies.

"COVID was a global emergency and every organization noted this was really the time for organizations to come together to join hands, and provide solutions," said Piyali Mukherjee, GSK's vice president and head of global medical affairs, during a media briefing here. Mukherjee said GSK is a leader in adjuvant technology, or the ingredient added in vaccines to create a stronger immune response in people.

"What we did at GSK is we established partnerships providing adjuvants to different companies…to develop a COVID vaccine," she said. "The partnership was with Sanofi and (Korean company) SK Biosciences. So I would say that the way that we work was that we worked in partnership with different other companies to bring solutions (to these issues)."

GSK conducted the briefing in its sprawling facilities in this town, about 30 kilometers from the Belgian capital

of Brussels. Inaugurated in 1993, the Wavre site measures about 23 square kilometers, or about the size of 70 soccer fields, which would make it the biggest vaccine manufacturing site in the world. Most of GSK's vaccines are made here and then shipped worldwide.

Officials shared key figures in its business, particularly its vaccines unit: over 20 vaccines in its portfolio, some 500 million vaccine doses produced and delivered in 2020 alone, and about 20 more vaccine candidates currently in the pipeline. GSK says about four in 10 children vaccinated worldwide receive a GSK vaccine.

GSK used to have a unit that manufactured consumer healthcare products but spun it off into its own company called Haleon in 2022. This new company has a portfolio of brands that include Centrum, Sensodyne, Voltaren, and Panadol.



PHOTO: GSK

"It happened last year but it was a year or two before that when we had announced that strategy," said Madeleine Breckon, VP for product and pipeline vaccines communications and government affairs. "It really was to focus in on the biopharma elements of the business. Because as a business, there're obviously strengths, and being a very diversified business, you've got the kind of fast moving consumer goods as well as the R&D, but as our portfolio was developing, it really did require that we focus in on the science, really investing in our R&D portfolio, and that focus on vaccines, as well as HIV, immunology, and respiratory, and oncology as well."

Breckon added that since GSK announced the split of its consumer healthcare business, other pharmaceutical companies followed suit.

"It's become a bit of a trend across the pharmaceutical industry," she said. "Johnson and Johnson has also chosen to split theirs. And I think Sanofi announced most recently that they would do the same. So I think that it kind of allowed us to have more investments in research and development. It definitely was strategically the right thing to do to focus the organization into those (areas)."

The numbers bear this out. According to GSK's own study, between 3.5 to five million deaths are prevented annually through vaccination, and about $52 on average is the return for every one dollar invested in vaccinations for 94 low-and middle countries between 2013 to 2030.

Selling vaccines

The importance of vaccines cannot be overstated, but often, it's difficult to communicate just how essential it is in keeping people healthy without discussing the diseases that it actually protects us from. This is where strict regulations and national guidelines come into play. The pharmaceutical industry is one of the most heavily regulated in the world, almost equal to businesses such as energy and petroleum, motor vehicle manufacturing, air transportation, and banking and finance, so there are safeguards in place to ensure that the companies do not resort to scare tactics or fear-mongering in order to sell their products. GSK is no different.

"Anything we do, especially when it's sold to the public, but also even how we engage with doctors is really regulated and it's important that we do that," Breckon said. "When it comes to disease awareness, I think

there is a role for that. For example, meningitis is an incredibly serious disease, but it's also very, very rare. So that's an example wherein parents and governments…they do a lot of their own disease awareness around the risks of certain diseases and illnesses, where you might need to explain what the potential consequences are."

"We are based in the U.K. and we do have a very, very strict code of governance policies, which is aligned to the UK government's policies, but when we are operating in any other country, we have to follow the country code as well," Mukherjee added. "And we always follow the strictest code that is in any of our communication, which is generally done only to the doctors unless again, it depends on the country specific policies."

In the Philippines, GSK is involved in the country's national immunization program (NIP) primarily through pneumococcal vaccine for children. Adult immunization is still relatively new in the country, especially before the onset of COVID-19. Only three adult-related vaccines are currently offered in the country's NIP: the first two are pneumococcal and influenza-related issues, both of which are recommended only for those 60 years old and above, and third is for pregnant women.

According to GSK's own studies, adults could stand to benefit greatly from vaccines especially since the world is moving slowly towards higher life expectancy in humans. According to Mukherjee, people aged 60 years old and above are expected to outnumber those aged 10 to 24 by the year 2050. And by 2100, almost 30 percent of the population will be above 60 years old.

"In addition to other lifestyle factors like stopping smoking, a healthy diet, and exercise, vaccination can support healthy aging in older patients," she said.

PHOTO: GSK

The rest of the visit to GSK's facilities here and in nearby Rixensart was devoted to the company demonstrating its world-class, almost obsessive, processes in developing, manufacturing, and packaging its vaccines. GSK employs about 9,000 employees, including 1,800 scientists from all over the world.

As expected, vaccine production and packaging are done in environments that significantly lessen or outright eliminates the possibility of contaminants getting into the vaccines. Workers put on special personal protective wear, wash their hands in a way that rivals the way surgeons prepping for a major operation do it, and use special equipment that minimizes contact with human skin that could possibly be a source of microscopic pollutants. It was eye-opening to be reminded of the lengths these pharmaceutical companies go through in order to ensure the safety of the life-saving vaccines that they produce.

The takeaway is that while these companies are still businesses that are required to be profitable in order to be sustainable, the work that they do is so important that the phrase "life and death" isn't just hyperbole but reality. It's a mystery then, why, despite incontrovertible scientific evidence backing the effectivity of vaccines, there are those who still choose to question and outright deny their value.

In any case, GSK remains committed in its goal of "positively impacting the health of 2.5 billion people over the next 10 years." And after COVID-19, it and many of the world's other pharmaceutical companies are better able to respond to the next big health crisis.

"I think that the world and the vaccine companies are more prepared because now we have at least in the toolbox the technologies, and are able to respond faster," said Yannick Vanloubbeeck, head of immunology, research and development, GSK Belgium. "The other thing is very important: it is about the science, and making sure that we remain aware of the evolutions and the trends in how pathogens are evolving and arising. I think that, globally, and it's not only the sole property or mission of vaccine companies. I think the entire world has improved in the monitoring of pathogens and they are developing new tools to address these new threats. I'm not saying that these are efficient and available now, but at least the pandemic has incentivized the need to invest and to monitor these types of things.

"So combining both together, I think there's hope that the company will be more ready tomorrow to fight against any new threats," he added "But again, everything we do is data driven. And so as soon as a new virus or bacteria emerges, we have to generate the vaccine candidate, generate the right data, and hope that the vaccine will be successful."

Fuente: Esquire. Disponible en https://acortar.link/uSpjmu

Descubren una nueva y mejor forma de desarrollar vacunas

12 dic. Investigadores de Alemania han desarrollado un nuevo sistema para mostrar epítopos en células de mamíferos para estudios de inmunización y creen que este método puede ayudar enormemente a los científicos en los esfuerzos de inmunización, según publican en la revista 'Biology Methods & Protocols'. Promover que las células sanguíneas produzcan anticuerpos contra una proteína vírica específica es un paso importante en el desarrollo de vacunas para uso humano.

Archivo - Un trabajador sanitario prepara la primera dosis de la vacuna de Pfizer-BioNTech contra la COVID-19, en 2021, en el Hospital Severo Ochoa de Leganés, Leganés, Madrid, (España). A. Pérez Meca - Europa Press - Archivo

Esto puede suponer un reto para los investigadores porque que los sujetos desarrollen anticuerpos depende de cómo los científicos diseñen y administren los antígenos, que son partes del virus que administran para comprobar la eficacia de la vacuna.

Un aspecto muy importante de la investigación sobre virus es cómo expresar y purificar el antígeno para la vacunación. Los animales inmunizados con antígenos preparados producen anticuerpos específicos contra el antígeno, pero los científicos tienen que aislar el antígeno para asegurarse de que desarrollan la vacuna dirigida a la enfermedad específica que desean combatir.

Una vez que los investigadores purifican el antígeno, pueden desarrollar vacunas que lleven a los sujetos a producir los anticuerpos deseados. Pero este aislamiento lleva mucho tiempo cuando se trata de desarrollar antígenos producidos en laboratorio, ya que los virus suelen mutar rápidamente.

Los científicos pueden tardar varias semanas en desarrollar los antígenos adecuados. En este caso, desarrollaron un nuevo método para inducir respuestas inmunitarias específicas.

Mediante la fusión de proteínas antigénicas en una proteína de anclaje unida a la membrana derivada de la tetraspanina, los investigadores crearon proteínas de fusión que se muestran predominantemente en la superficie de las células humanas.

La exposición de las proteínas en la superficie mediante una proteína portadora induce la producción de anticuerpos dirigidos contra los antígenos pertinentes apropiados. Una ventaja adicional es que estos antígenos tienen la misma conformación y modificaciones que las proteínas correspondientes del virus, ya que son fabricados por células similares a las del cuerpo humano, que el virus infecta de forma natural.

Esta nueva tecnología de visualización podría ser una técnica de inmunización potencialmente mucho más fiable. En este estudio, los investigadores lograron inducir anticuerpos contra distintas proteínas, centrándose en el dominio de unión al receptor del SARS-CoV-2, el virus causante de la enfermedad por coronavirus 2019 (COVID-19).

La proteína de anclaje desarrollada permite a los científicos dirigirse a una enfermedad específica con fines de inmunización sin necesidad de purificar el antígeno. Los investigadores están convencidos de que esta técnica puede acelerar enormemente el proceso de inmunización.

"Este trabajo, que se basa en el dominio de unión al receptor del SARS-CoV-2, es sólo el principio de una técnica de inmunización muy interesante --afirma Daniel Ivanusic, uno de los autores del artículo--. La aplicación más desafiante, significativa y emocionante para nosotros empleando la tecnología tANCHOR es inducir anticuerpos neutralizantes contra el VIH-1. Creo que será fantástico", augura.

Fuente: Infosalus. Disponible en https://acortar.link/8Gt1uj

Statement on the antigen composition of COVID-19 vaccines

Dec 13. **Key points:**

⇒ SARS-CoV-2 continues to circulate and evolve with important genetic and antigenic evolution of the spike protein.

⇒ Monovalent XBB.1.5 COVID-19 vaccines across different platforms elicit broadly cross-reactive neutralizing antibody responses against circulating SARS-CoV-2 variants.

⇒ Given the current SARS-CoV-2 evolution and the breadth in immune responses demonstrated by monovalent XBB.1.5 vaccines against circulating variants, the TAG-CO-VAC advises retaining the current COVID-19 vaccine antigen composition, i.e. a monovalent XBB.1.5 as the COVID-19 vaccine antigen.

The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to meet regularly to assess the implications of SARS-CoV-2 evolution for COVID-19 vaccine antigen composition and advise WHO on whether changes are needed to the antigen composition of future COVID-19 vaccines. In May 2023, the TAG-CO-VAC recommended the use of a monovalent XBB.1 descendent lineage, such as XBB.1.5, as the vaccine antigen. Several manufacturers (using mRNA and protein-based and viral vector vaccine platforms) have updated COVID-19 vaccine antigen composition to monovalent XBB.1.5 formulations which have been approved for use by regulatory authorities.

The TAG-CO-VAC reconvened on 4-5 December 2023 to review the genetic and antigenic evolution of SARS-CoV-2, the performance of currently approved vaccines against circulating SARS-CoV-2 variants, and the implications for COVID-19 vaccine antigen composition. The t wice-yearly evidence review by the TAG-CO-VAC is based on the need for continued monitoring of the evolution of SARS-CoV-2 and the kinetics of vaccine-derived immunity.

Evidence reviewed

The published and unpublished evidence reviewed by the TAG-CO-VAC included: (1) SARS-CoV-2 evolution, including genetic and antigenic characteristics of earlier and current SARS-CoV-2 variants, and the impact of SARS-CoV-2 evolution on cross-neutralization and cross-protection following vaccination and/or infection; (2) Vaccine effectiveness (VE) of currently approved vaccines during periods of XBB descendent lineage circulation; (3) Antigenic cartography analyzing antigenic relationships of SARS-CoV-2 variants using naïve animal sera and human sera following vaccination and/or infection; (4) Preliminary immunogenicity data on the performance of currently approved vaccines against circulating SARS-CoV-2 variants using animal and human sera; and (5) Cellular (T and B cell) immune responses following vaccination and/or infection. Further details on the publicly available data reviewed by the TAG-CO-VAC can be found in the accompanying data annex. Unpublished and/or confidential data reviewed by the TAG-CO-VAC are not shown.

Summary of available evidence

⇒ SARS-CoV-2 continues to circulate and evolve. Based on available sequences, there is heterogeneity in circulating variants across WHO regions.

⇒ There continues to be important genetic and antigenic evolution of the spike protein of SARS-CoV-2.

⇒ As of 2 December 2023, XBB descendent lineages including XBB.1.5, XBB.1.16, EG.5, HK.3 and HV.1 accounted for 73% of genetic sequences available in GISAID, and this proportion has declined since then. SARS-CoV-2 variant of interest BA.2.86, with the earliest sample collected in July 2023, has 36 amino acid substitutions relative to XBB.1.5, including in key antigenic sites in the spike protein. The proportion of BA.2.86 and its descendent lineages, including JN.1 (which has one additional substitution in the spike protein as compared to BA.2.86 (L455S)), has been increasing steadily. As of 2 December 2023, BA.2.86 and its descendent lineages, including JN.1, accounted for 17% of sequences available in GISAID, more than half of which were JN.1.

⇒ Several of these XBB- and BA.2.86 derived variants (e.g., EG.5, HV.1, HK.3, JN.1) have independently-evolved changes in the spike protein at a neutralizing antibody epitope involving amino acid residues 455 and/or 456. This highlights the current immune pressure on this epitope.

⇒ In naïve animals, monovalent XBB.1.5 vaccines elicited neutralizing antibodies that cross-reacted well with XBB descendent lineages (e.g., EG.5, HV.1, HK.3). However, BA.2.86 and JN.1 were not neutralized well, indicating that BA.2.86 and JN.1 are antigenically distinguishable from XBB.1.5 in this model.

⇒ In contrast, sera from humans vaccinated with XBB.1.5 monovalent vaccines, with or without recent prior infection, neutralized XBB descendent lineages including EG.5, HK.3, HV.1, as well as BA.2.86 and JN.1. However, there are only limited data on cross neutralization of JN.1.

⇒ The differences observed in cross-reactivity to BA.2.86 and JN.1 in naïve animals, as compared to human sera, likely reflect the cumulative infection- and vaccine-derived immune responses to SARS-CoV-2 in the human population.

In vaccine effectiveness studies, protection conferred by bivalent (index virus and BA.1- or BA.4/5) mRNA vaccines and a Beta-based protein vaccine against severe disease during periods of XBB descendent lineage circulation remains high. Protection against symptomatic disease and infection is lower and wanes more rapidly over several months. Monovalent XBB.1.5 vaccines were only recently introduced, so VE estimates for vaccines with this composition are still very limited. Preclinical and clinical immunogenicity data of monovalent XBB.1.5 vaccines indicate that higher neutralizing antibody titres against circulating SARS-CoV-2 variants are expected to be associated with higher VE estimates as compared to COVID-19 vaccines with an index virus-based or bivalent (BA.1- or BA.4/5- containing) vaccine antigen composition.

The TAG-CO-VAC acknowledges several limitations of the available data:

⇒ There are persistent and increasing gaps in genetic/genomic surveillance of SARS-CoV-2 globally, including low numbers of samples sequenced and limited geographic diversity.

⇒ The timing, specific mutations and associated antigenic characteristics, and the potential public health risks of future variants remain unknown.

⇒ Although neutralizing antibody titres have been shown to be important correlates of protection from SARS-CoV-2 infection and of estimates of vaccine effectiveness, there are multiple components of immune protection elicited by infection and/or vaccination. Data on the immune responses following XBB descendent lineage infection or XBB.1.5 vaccination are largely restricted to neutralizing antibodies and data on other aspects of the immune response, including cellular immunity, are limited.

⇒ Estimates of VE against currently circulating SARS-CoV-2 variants, including XBB descendent lineages, are limited in terms of the number of studies, geographic diversity, vaccine platforms evaluated, populations assessed, duration of follow-up and comparative estimates for monovalent XBB.1.5 vaccines versus other formulations.

Recommendations for COVID-19 vaccine antigen composition

Given the current SARS-CoV-2 evolution and the breadth in immune responses demonstrated by monovalent XBB.1.5 vaccines against circulating variants, the TAG-CO-VAC advises retaining the current COVID-19 vaccine antigen composition, i.e. a monovalent XBB.1.5 (e.g., hCoV-19/USA/RI-CDC-2-6647173/2022, GenBank: OQ054680.1, GISAID: EPI_ISL_16134259 or WHO Biohub: 2023-WHO-LS-01, GenBank: OQ983940, GISAID EPI_ISL_16760602) as the COVID-19 vaccine antigen.

Other formulations and/or platforms that achieve robust neutralizing antibody responses against currently circulating variants, including XBB- and BA.2.86 descendent lineages, can also be considered. In accordance with WHO SAGE policy, vaccination programmes can continue to use any of the WHO emergency-use listed or prequalified COVID-19 vaccines.

Further data requirements and considerations

Given the limitations of the evidence upon which the recommendations above are derived and the anticipated continued evolution of the virus, the TAG-CO-VAC strongly encourages generation of the following data:

⇒ Immune responses and clinical endpoints (i.e. VE) in varied human populations who receive COVID-19 vaccines with a monovalent XBB.1.5 vaccine antigen composition, across different vaccine platforms, as well as further data on the performance of all currently approved COVID-19 vaccines against emerging SARS-CoV-2 variants.

⇒ Strengthened epidemiological and virological surveillance, as per the Standing Recommendations for COVID-19 in accordance with the International Health Regulations (2005), to determine if emerging variants are antigenically distinct and able to displace circulating variants.

⇒ Clinical evaluation of new vaccine antigens, particularly those emerging from XBB and BA.2.86 descendent lineages.

As previously stated, the TAG-CO-VAC continues to encourage the further development of vaccines that may improve protection against infection and reduce transmission of SARS-CoV-2.

Fuente: World Health Organization. Disponible en https://acortar.link/ry4d38

Belize: Health ministry introduces Pneumococcal conjugate vaccine

Dec 14. The Ministry of Health & Wellness (MOHW) in Belize has introduced the paediatric pneumococcal conjugate vaccine (PCV) into the national vaccination schedule, targeting children below five years of age.

Worldwide, 164 countries out of 194 World Health Organization member states (84.5 per cent) have introduced PCV into their National Immunization Programs, including Barbados, Trinidad and Tobago, Curaçao, The Bahamas, Aruba, Anguilla, Jamaica, Montserrat, Bermuda, Turks and Caicos, Brazil, Ecuador and Colombia.

In Belize, from 2018 to 2022, almost 6,000 cases of pneumonia were diagnosed. The most affected age groups are children below five years and the elderly 60+ years.

The PCV vaccine protects against infection by the pneumococcus bacteria, one of the most common causes of pneumonia in children. It also protects against other infections caused by the pneumococcus, such as meningitis and bacteraemia.

The Paediatric PCV primary vaccination schedule is three doses administered at two, four and six months. For children 12 months to 59 months old, two doses are recommended. The interval between doses is two months.

The PCV vaccine will be available at health facilities in urban and rural communities during mobile clinics and other outreach vaccination sessions.

The Ministry of Health reminds the public of the interventions to prevent, protect and treat children from pneumonia. These include uptake of routine immunisations (pertussis, measles, Hib and PCV), exclusive breastfeeding for the first six months of life, proper sanitation, and frequent hand washing with soap.

Fuente: Caribbean Loop News. Disponible en https://acortar.link/1d2OIC

Pneumococcal News: How the Pneumococcal Conjugate Vaccine Has Changed and Its Impact on Infection Rates



Dec 15. Vaccinations are a crucial part of any pediatrician's practice. The world of immunizations has been in the spotlight recently, with the new COVID-19 messenger RNA (mRNA) and monoclonal respiratory syncytial virus (RSV) antibody shots making a splash in the news.

But what about the mainstay vaccinations that are part of any child's standard immunization schedule? Some of them have updates, too!

Dr. Inci Yildirim, from Yale University, and colleagues share how changes to the pneumococcal conjugate vaccines (PCV) have influenced the rates of invasive pneumococcal disease (IPD) in their article, "Invasive Pneumococcal Disease After Two Decades of Pneumococcal Conjugate Vaccine Use," being released early this week in Pediatrics (10.1542/peds.2023-063039). (We want to disclose that 3 of the authors are employees and shareholders of Pfizer Inc., which manufactures PCV, and that Pfizer provided funding for this study.)

In 2000, the first generation of PCV, the 7-valent or PCV7, was introduced in the US. It protected against 7 serotypes (types) of pneumococcus: serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Ten years later in 2010, the 13-valent, PCV13, became the new standard of care. It added 6 additional serotypes: 1, 3, 5, 6A, 7F, and 19A. In this study, the authors analyzed surveillance data for cases of invasive Streptococcal pneumoniae disease (IPD), defined as bacteremia, pneumonia, or meningitis, among children <18 years of age living in Massachusetts from 2002 to 2021.

In general, the vaccine works—really well! The incidence of IPD decreased by 72% between 2002 and 2021, and this rate of decline improved even more when PCV13 replaced PCV7. The reduction in IPD rate is serotype-specific, meaning there are fewer cases of pneumococcal disease from the specific serotypes the vaccines are targeting.

But what about the children who are still getting IPD? Who are they and where are these cases coming from? The authors classify them into two main buckets:

⇒ Cases caused by pneumococcal serotypes that are included in the vaccine.

⇒ Cases caused by pneumococcal serotypes that were never included in the vaccine.

Their results are as follows:

⇒ In the PCV7 era (2002–2010), nearly 60% of all IPD cases were from 3 serotypes (3, 7F, and 19A), all of which were subsequently included in PCV13.

⇒ In the PCV13 era (2010–2021), IPD cases were largely from serotype 3 and serotypes not included in PCV13.

⇒ Serotype 3 remains responsible for many breakthrough IPD cases, or IPD in children who were sufficiently immunized by PCV.

⇒ Children with chronic medical conditions, such as neuromuscular, pulmonary, cardiac, and immune-compromising diseases, remained at increased risk for IPD, both before and after the implementation of PCV-13, consistently accounting for approximately 25% of all IPD cases.

⇒ From May 2020 to June 2021, or during the peak of the COVID pandemic, incidence of IPD was at an all-time low.

How can this data translate to patient care and inform goals for future work?

⇒ Future Vaccines: Knowing which serotypes are causing disease by doing surveillance studies such as this one is important for future vaccine development. For example, the non-PCV13 serotypes that have made up many cases of IPD in the PCV13 era should be considered as ones that should be included in future versions of PCV.

⇒ Serotype 3: Although this serotype was included in both PCV7 and PCV13, it still contributed to a large proportion of breakthrough infections. Future studies should try to understand why there were so many breakthrough infections.

⇒ Vulnerable Populations: The medical conditions that placed children at increased risk for IPD were all common, with asthma, prematurity, and neuromuscular disorders as the most prevalent, highlighting the importance of vaccination efforts in these populations. The authors speculate this may be due to these children's chronic inflammatory status, but there is a need to better understand why they are at such risk.

Newer iterations of PCV, such as PCV15 and PCV20, are now being distributed. It will be important to continue to track serotype information to further optimize vaccines, which will ultimately result in fewer invasive diseases in children.

Fuente: AAP Journal Blog . Disponible en https://acortar.link/PtBq1j

Desarrollan una vacuna que se inhala para prevenir la COVID-19

16 dic. Científicos chinos han desarrollado una vacuna para la COVID-19 que se inhala y llega a los pulmones en forma de polvo seco y cuyo compuesto provoca una importante respuesta inmunitaria que previene la infección en ratones, hámsters y primates no humanos.

Los detalles de esta candidata a vacuna, desarrollada por el equipo de Guanghui Ma, de la Academia China de Ciencias de Beijing, se han publicado este miércoles en la revista *Nature*.

Desde el inicio de la pandemia, a principios de 2020, se han hecho numerosos esfuerzos para desarrollar y aprobar vacunas contra el virus del SARS-CoV-2 causante de la COVID-19.

La mayoría de las vacunas que han tenido éxito se administran mediante inyecciones intramusculares que provocan la producción de anticuerpos y reducen los síntomas de la enfermedad.

Pero estas vacunas no son capaces de prevenir la infección porque no logran inmunizar a los tejidos de las vías respiratorias (por donde entra el virus al organismo).

Además, estas vacunas líquidas tienen que conservarse y almacenarse en frío, lo que tiene un coste adicional.

El artículo de *Nature* detalla el trabajo del equipo de Guanghui Ma, quien ha desarrollado una vacuna inhalable en aerosol de polvo seco contra el SARS-CoV-2 que se administra en una sola dosis y confiere inmunidad en las mucosas.

La vacuna encapsula una proteína bacteriana no tóxica llamada CTB, modificada para mostrar el antígeno del dominio de unión al receptor del SARS-CoV-2, dentro de microcápsulas lo suficientemente pequeñas como para entrar y depositarse en las profundidades de los pulmones.

Esta estructura nano favorece la llegada del compuesto a los alvéolos, la liberación sostenida del antígeno y la inducción de la respuesta inmunitaria.

Además, el equipo probó la vacuna tanto con virus ancestrales como con la variante Ómicron, para probar su eficacia contra múltiples cepas.

En una dosis única, el prototipo se administró eficazmente en el tejido mucoso de los pulmones y mostró una liberación sostenida del antígeno y una captación satisfactoria por las células presentadoras de antígeno.

También indujo un aumento a largo plazo de la producción de IgG e inmunoglobulina A (IgA) en ratones, hámsteres y primates no humanos, lo que proporciona una protección eficaz contra la infección por SARS-CoV-2.

Además, el polvo demostró ser estable a temperatura ambiente tras un mes de almacenamiento, lo que podría reducir los costes de almacenamiento y transporte de la distribución de la vacuna, haciéndola así más accesible.

Para los autores, esta vacuna inhalada es una "prometedora" vía para prevenir el Covid-19 porque se dirige directamente a las células pulmonares, induciendo una respuesta inmunitaria más robusta que las vacunas anteriores.

A su juicio, estos resultados respaldan el uso de esta vacuna, cuyo sistema de administración en aerosol tiene potencial como herramienta para combatir tanto la Covid-19 como otras enfermedades respiratorias, concluye el estudio.

En un "News & Views" publicada en Nature, los expertos en prevención pandémica del Centro de Investigación Inmunológica de la Universidad McMaster de Ontario (Canadá), Zhou Xing y Mangalakumari Jeyanathan, apuntan que, "aunque la seguridad y la potencia inmunitaria de la vacuna aún no se ha comprobado en ensayos clínicos en humanos, si tienen éxito, ofrecería una forma racionalizada de administrar una vacuna capaz de inmunizar la mucosa respiratoria".

Ambos investigadores destacan también que a diferencia de otros métodos de administración como el spray nasal o el nebulizador, que necesitan mantener la cadena del frío para su conservación, el inhalador de polvo seco es una solución que permanece estable a temperatura ambiente durante al menos un mes.

Fuente: Expreso. Disponible en https://acortar.link/sowlwZ

Las vacunas contra la COVID-19 reducen el riesgo de enfermedades graves en la población pediátrica

18 dic. Según un nuevo estudio de los Centros para el Control y la Prevención de Enfermedades (CDC) de Estados Unidos, dos dosis de la vacuna de ARN mensajero contra la COVID-19 reducen 40% las hospitalizaciones y las consultas en urgencias relacionadas con esta enfermedad en la población pediátrica de entre 6 meses y 4 años de edad.[1]

¿Por qué es importante este estudio?

La infección por SARS-CoV-2 puede afectar gravemente a la poblacion pediátrica con determinadas afecciones crónicas.

Metodología

Los investigadores evaluaron la eficacia de las vacunas contra la COVID-19 para evitar las consultas en urgencias y las hospitalizaciones asociadas a la enfermedad entre julio de 2022 y septiembre de 2023.

Utilizaron datos de la New Vaccine Surveillance Network (Nueva Red de Vigilancia de Vacunas), que lleva a cabo una vigilancia prospectiva basada en la población para detectar enfermedades respiratorias agudas en la población en 7 centros médicos pediátricos.

El periodo evaluado fue el primer año en que se autorizaron las vacunas para la población de 6 meses a 4 años; durante ese periodo surgieron varias subvariantes de ómicron.

Los investigadores utilizaron datos de 7.434 lactantes y niños; los datos incluían el estado vacunal de los pacientes y los resultados de sus pruebas de detección de SARS-CoV-2.

Resultados principales

De los 7.434 lactantes y niños que padecían una enfermedad respiratoria aguda y fueron hospitalizados o acudieron a urgencias, 387 tenían COVID-19.

La población que recibió dos dosis de la vacuna contra la COVID-19 tuvo 40% menos probabilidades de ser hospitalizado o tener una consulta en urgencias relacionada con la COVID-19, en comparación con la población no vacunada.

Una dosis de la vacuna contra la COVID-19 redujo 31% las consultas en urgencias y las hospitalizaciones.

Limitaciones

El número de niños con anticuerpos e inmunidad contra el SARS-CoV-2 ha aumentado, por lo que es posible que las tasas de eficacia de la vacuna del estudio ya no sean tan relevantes. Los menores con enfermedades crónicas preexistentes pueden tener más probabilidades de vacunarse y recibir atención médica. Las bajas tasas de vacunación pueden haber impedido a los investigadores realizar un análisis más detallado. La vacuna de Pfizer-BioNTech requiere tres dosis, mientras que la de Moderna requiere dos; esto puede haber sesgado la eficacia estimada de la vacuna de Pfizer-BioNTech.

Conclusiones

Los resultados de este estudio apoyan la recomendación de vacunar a la población pediátrica ≥6 meses contra la COVID-19 y destacan la importancia de completar una serie primaria para los niños pequeños.

Fuente: Medscape. Disponible en https://acortar.link/1VRE9x

FDA accepts Merck's pneumococcal vaccine BLA for priority review

The regulatory agency is anticipated to provide a decision on approval of Merck's V116 vaccine on 17 June 2024.

Credit: JHVEPhoto / Shutterstock.com.

Dec 20. The US Food and Drug Administration (FDA) has accepted the new biologics licence application (BLA) for MSD's investigational 21-valent pneumococcal conjugate vaccine, V116, for priority review.

The vaccine is intended to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.

The regulatory agency will give its decision on 17 June 2024 under the Prescription Drug User Fee Act.

MSD's application is partially based on findings from the Phase III STRIDE-3 clinical trial that analysed the safety, immunogenicity and tolerability of V116 versus PCV20 pneumococcal 20-valent conjugate vaccine in adults who have not previously received pneumococcal vaccination.

Additional data from Phase III studies, including STRIDE-4, STRIDE-5, and STRIDE-6, further support the vaccine use in vaccine-naïve and vaccine-experienced adults.

V116 is administered as a single dose.

MSD Research Laboratories' global clinical development head, senior vice-president and chief medical officer Dr Eliav Barr stated: "Invasive pneumococcal disease poses a greater risk to older adults or those with weakened immune systems, in part due to disease-causing serotypes not covered by currently licensed pneumococcal conjugate vaccines.

"If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed to address the serotypes that cause most adult invasive pneumococcal disease.

"We look forward to discussing the data that support our filing with the FDA and are working with urgency to bring this potential new preventative measure to adult patients."

The latest development comes after the European Commission approved the company's Keytruda plus chemotherapy for two indications in gastrointestinal cancers.

The combination regimen is approved as first-line therapy for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Keytruda plus gemcitabine and cisplatin is indicated as first-line therapy in adults with locally advanced unresectable or metastatic biliary tract carcinoma.

Fuente: Pharmaceutical Technology. Disponible en https://acortar.link/UnB2vV

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

https://ediciones.finlay.edu.cu/

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/12/11 to 2023/12/20. “vaccine” (Title/Abstract) 837records.

CEA vaccines.
Bhagat A, Lyerly HK, Morse MA, Hartman ZC. Hum Vaccin Immunother. 2023 Dec 15;19(3):2291857. doi: 10.1080/21645515.2023.2291857. Epub 2023 Dec 13. PMID: 38087989

Tumor vaccines: Toward multidimensional anti-tumor therapies.
Tan Y, Chen H, Gou X, Fan Q, Chen J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2271334. doi: 10.1080/21645515.2023.2271334. Epub 2023 Oct 31. PMID: 37905395

Construction and application of adenoviral vectors.
Zhang H, Wang H, An Y, Chen Z. Mol Ther Nucleic Acids. 2023 Sep 9;34:102027. doi: 10.1016/j.omtn.2023.09.004. eCollection 2023 Dec 12. PMID: 37808925

HV&I reviewer highlight.
Ellis R, Weiss A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270862. doi: 10.1080/21645515.2023.2270862. Epub 2023 Oct 26. PMID: 37883655

Therapeutic cancer vaccines: advancements, challenges, and prospects.
Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Signal Transduct Target Ther. 2023 Dec 13;8(1):450. doi: 10.1038/s41392-023-01674-3. PMID: 38086815

Typhoid fever.
Meiring JE, Khanam F, Basnyat B, Charles RC, Crump JA, Debellut F, Holt KE, Kariuki S, Mugisha E, Neuzil KM, Parry CM, Pitzer VE, Pollard AJ, Qadri F, Gordon MA. Nat Rev Dis Primers. 2023 Dec 14;9(1):71. doi: 10.1038/s41572-023-00480-z. PMID: 38097589

Human vaccines and immunotherapeutics: News September 2023.
Ellis R, Weiss A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267898. doi: 10.1080/21645515.2023.2267898. Epub 2023 Oct 16. PMID: 37843423

Vaccine acceptance, determinants, and attitudes toward vaccine among people experiencing homelessness: a systematic review and meta-analysis.
Nguyen DA, Alagbo HO, Hassan TA, Mera-Lojano LD, Abdelaziz EO, The NPN, Makram AM, Makram OM, Elsheikh R, Huy NT. BMC Infect Dis. 2023 Dec 15;23(1):880. doi: 10.1186/s12879-023-08878-6. PMID: 38102542

Brain-wide circuit-specific targeting of astrocytes.
Thompson A, Arano R, Saleem U, Preciado R, Munoz L, Nelson I, Ramos K, Kim Y, Li Y, Xu W. Cell Rep Methods. 2023 Dec 18;3(12):100653. doi: 10.1016/j.crmeth.2023.100653. Epub 2023 Dec 4. PMID: 38052209

COVID-19 vaccines should be evaluated from the societal perspective.
Sevilla JP. J Med Econ. 2024 Jan-Dec;27(1):1-9. doi: 10.1080/13696998.2023.2287935. Epub 2023 Dec 15. PMID: 38014424

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A, Lecrenier N, Naficy A, Curran D, Posiuniene I. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278362. doi: 10.1080/21645515.2023.2278362. Epub 2023 Nov 15. PMID: 37965770

Human vaccines & immunotherapeutics: News October 2023.
Ellis R, Weiss A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2282040. doi: 10.1080/21645515.2023.2282040. Epub 2023 Nov 15. PMID: 37966454

The safety of BCG revaccination in the context of COVID-19.
Sánchez-García A, Támez-Guerra R, González-Saldivar G, Rodríguez-Gutiérrez R, Ramírez-García LA, Barrera FJ, González-González JG. Hum Vaccin Immunother. 2023 Dec 15;19(3):2271760. doi: 10.1080/21645515.2023.2271760. Epub 2023 Nov 8. PMID: 37936434

COVISHIELD vaccine-induced thyroiditis: a case report.
Sachin J, Shukla R, Anil A, Saravanan A, Santhyavu S, Varthya SB, Ambwani S, Singh S. J Med Case Rep. 2023 Dec 15;17(1):542. doi: 10.1186/s13256-023-04279-0. PMID: 38098118

Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Parikh R, Singer D, Chmielewski-Yee E, Dessart C. Hum Vaccin Immunother. 2023 Dec 15;19(3):2263979. doi: 10.1080/21645515.2023.2263979. Epub 2023 Nov 15. PMID: 37967254

Identifying beliefs driving COVID-19 vaccination: Lessons for effective messaging.
MacEwan SR, Kenah E, Dixon GN, Stevens J, Eiterman LP, Powell JR, Gage CB, Rush LJ, Panchal AR, McAlearney AS. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266929. doi: 10.1080/21645515.2023.2266929. Epub 2023 Nov 10. PMID: 37947193

Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
Wang B, McDonough J, Chen G, Ong JJ, Marshall H. Vaccine. 2023 Dec 12;41(51):7608-7617. doi: 10.1016/j.vaccine.2023.11.024. Epub 2023 Nov 22. PMID: 37996291

Antibody and B-cell Immune Responses Against Bordetella Pertussis Following Infection and Immunization.
Abu-Raya B, Esser MJ, Nakabembe E, Reiné J, Amaral K, Diks AM, Imede E, Way SS, Harandi AM, Gorringe A, Le Doare K, Halperin SA, Berkowska MA, Sadarangani M. J Mol Biol. 2023 Dec 15;435(24):168344. doi: 10.1016/j.jmb.2023.168344. Epub 2023 Nov 4. PMID: 37926426

Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity.
Colombo L, Hadigal S, Nauta J, Kondratenko A, Rogoll J, Van de Witte S. Expert Rev Vaccines. 2024 Jan-Dec;23(1):88-101. doi: 10.1080/14760584.2023.2293241. Epub 2023 Dec 15. PMID: 38088157

Breakthrough COVID-19 infections and perceived vaccine effectiveness.
Neely SR, Hao F. Vaccine. 2023 Dec 18;41(52):7689-7694. doi: 10.1016/j.vaccine.2023.11.032. Epub 2023 Nov 22. PMID: 37996290

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines.
Wu NC, Ellebedy AH. Trends Immunol. 2023 Dec 15:S1471-4906(23)00255-7. doi: 10.1016/j.it.2023.11.001. Online ahead of print. PMID: 38103991

FDA Approves First Chikungunya Vaccine.
Harris E. JAMA. 2023 Dec 19;330(23):2241. doi: 10.1001/jama.2023.23505. PMID: 38019496

Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies.
Yang X, Shi N, Liu C, Zhang J, Miao R, Jin H. Vaccine. 2023 Dec 11:S0264-410X(23)01397-X. doi: 10.1016/j.vaccine.2023.11.051. Online ahead of print. PMID: 38081754

Covid-19 Vaccine Hesitancy and Under-Vaccination among Marginalized Populations in the United States and Canada: A Scoping Review.
Newman PA, Dinh DA, Nyoni T, Allan K, Fantus S, Williams CC, Tepjan S, Reid L, Guta A. J Racial Ethn Health Disparities. 2023 Dec 20. doi: 10.1007/s40615-023-01882-1. Online ahead of print. PMID: 38117443

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL; ConquerRSV Study Group. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. PMID: 38091530

Antigen-specific T cell responses in SARS-CoV-2 mRNA-vaccinated children.
Philpott JD, Miller J, Boribong BP, Charles S, Davis JP, Kazimierczyk S, Jimena B, Leonard MM, Shreffler WG, Fasano A, Yonker LM, Jain N. Cell Rep Med. 2023 Dec 19;4(12):101298. doi: 10.1016/j.xcrm.2023.101298. Epub 2023 Nov 27. PMID: 38016480

A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons.
Levin MJ, Divino V, Postma MJ, Pelton SI, Zhou Z, DeKoven M, Mould-Quevedo J. Expert Rev Vaccines. 2024 Jan-Dec;23(1):124-136. doi: 10.1080/14760584.2023.2293237. Epub 2023 Dec 19. PMID: 38073493

Vaccine inequity: a threat to Africa's recovery from COVID-19.
Wei CR, Kamande S, Lang'at GC. Trop Med Health. 2023 Dec 19;51(1):69. doi: 10.1186/s41182-023-00564-2. PMID: 38111032

Immunity to measles in COVID-19 era.
Ferrari C, Somma G, Coppeta L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2274724. doi: 10.1080/21645515.2023.2274724. Epub 2023 Nov 3. PMID: 37922407

Hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination.
Wiwanitkit S, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2279390. doi: 10.1080/21645515.2023.2279390. Epub 2023 Nov 16. PMID: 37970640

Artificial viruses: A nanotechnology based approach.
Shaik S, Kumar R, Chaudhary M, Kaur C, Khurana N, Singh G. Daru. 2023 Dec 18. doi: 10.1007/s40199-023-00496-6. Online ahead of print. PMID: 38105369

Influenza B virus neuraminidase: a potential target for next-generation vaccines?
Do THT, Wheatley AK, Kent SJ, Koutsakos M. Expert Rev Vaccines. 2024 Jan-Dec;23(1):39-48. doi: 10.1080/14760584.2023.2290691. Epub 2023 Dec 14. PMID: 38037386

Assessing vaccine hesitancy and health literacy using a new Italian vaccine confidence index and a modified Italian medical term recognition test: A cross-sectional survey on Italian parents.
Arzilli G, Stacchini L, Casigliani V, Mazzilli S, Aquino F, Oradini-Alacreu A, Bruni B, Quattrone F, Papini F, Sironi D, Porretta AD, Privitera GP, Rizzo C, Tavoschi L, Lopalco PL. Hum Vaccin Immunother. 2023 Dec 15;19(3):2271765. doi: 10.1080/21645515.2023.2271765. Epub 2023 Oct 31. PMID: 37906161

COVID-19, Vaccine Hesitancy, and HIV Pre-exposure Prophylaxis Among Black Sexual Minority Men.
Turpin RE, Mandell CJ, Camp AD, Davidson Mhonde RR, Dyer TV, Mayer KH, Liu H, Coates T, Boekeloo BO. J Acquir Immune Defic Syndr. 2023 Dec 15;94(5):387-394. doi: 10.1097/QAI.0000000000003305. PMID: 37732879

Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity.
Connors J, Cusimano G, Mege N, Woloszczuk K, Konopka E, Bell M, Joyner D, Marcy J, Tardif V, Kutzler MA, Muir R, Haddad EK. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267295. doi: 10.1080/21645515.2023.2267295. Epub 2023 Oct 26. PMID: 37885158

Longitudinal analysis of behavioral factors and techniques used to identify vaccine hesitancy among Twitter users: Scoping review.
Khan S, Biswas MR, Shah Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278377. doi: 10.1080/21645515.2023.2278377. Epub 2023 Nov 20. PMID: 37981842

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A, Lichterman JN, Zhong JY, Shoag JE, Garcia JA, Zhang T, Barata PC. Hum Vaccin Immunother. 2023 Dec 15;19(3):2276629. doi: 10.1080/21645515.2023.2276629. Epub 2023 Nov 10. PMID: 37947202

Preclinical support for tumor protein D52 as a cancer vaccine antigen.
Bright RK. Hum Vaccin Immunother. 2023 Dec 15;19(3):2273699. doi: 10.1080/21645515.2023.2273699. Epub 2023 Oct 30. PMID: 37904517

Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.
Hsiao A, Yee A, Fireman B, Hansen J, Lewis N, Klein NP. N Engl J Med. 2023 Dec 14;389(24):2245-2255. doi: 10.1056/NEJMoa2302099. PMID: 38091531

Facing the escalating burden of dengue: Challenges and perspectives.
Malavige GN, Sjö P, Singh K, Piedagnel JM, Mowbray C, Estani S, Lim SCL, Siquierra AM, Ogg GS, Fraisse L, Ribeiro I. PLOS Glob Public Health. 2023 Dec 15;3(12):e0002598. doi: 10.1371/journal.pgph.0002598. eCollection 2023. PMID: 38100392

Inhaled vaccine prevents COVID in monkeys.
Petrić Howe N. Nature. 2023 Dec 14. doi: 10.1038/d41586-023-04040-z. Online ahead of print. PMID: 38097790

Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies.
Hollister J, Caban-Martinez AJ, Ellingson KD, Beitel S, Fowlkes AL, Lutrick K, Tyner HL, Naleway AL, Yoon SK, Gaglani M, Hunt D, Meece J, Mayo Lamberte J, Schaefer Solle N, Rose S, Dunnigan K, Khan SM, Kuntz JL, Fisher JM, Coleman A, Britton A, Thiese MS, Hegmann KT, Pavuk M, Ramadan FA, Fuller S, Nematollahi A, Sprissler R, Burgess JL. Environ Res. 2023 Dec 15;239(Pt 1):117297. doi: 10.1016/j.envres.2023.117297. Epub 2023 Oct 8. PMID: 37816422

Behavioural evidence on COVID-19 vaccine uptake.
Robertson DA, Timmons S, Lunn PD. Public Health. 2023 Dec 16;227:49-53. doi: 10.1016/j.puhe.2023.10.046. Online ahead of print. PMID: 38104419

Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation.
Generotti A, Contreras R, Zounes B, Schade E, Kemme A, Rane Y, Liu X, Elwood D, Schultheis K, Marston J, McCoy J, Broderick K, Fisher P. Mol Ther Nucleic Acids. 2023 Oct 31;34:102070. doi: 10.1016/j.omtn.2023.102070. eCollection 2023 Dec 12. PMID: 38034030

Tackling vaccine inequity in 2023: have we made progress?
Torreele E. Expert Rev Vaccines. 2024 Jan-Dec;23(1):1-4. doi: 10.1080/14760584.2023.2292771. Epub 2023 Dec 11. PMID: 38078804

High vaccine confidence and strong approval of the mandatory immunization schedule among Bulgarian general practitioners in 2022.
Dimitrova V, Stoitsova S, Rangelov V, Raycheva R, Martinova M, Nenova G, Iakimova M, Georgieva I, Georgiev I, Krumova S, Minkova A, Vladimirova N, Nikolaeva-Glomb L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2265640. doi: 10.1080/21645515.2023.2265640. Epub 2023 Oct 17. PMID: 37846744

Awareness of and attitude toward COVID-19 vaccination among individuals with COPD and the strategies to overcome vaccine hesitation: A mini review.
Liang Y, Sun Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2286686. doi: 10.1080/21645515.2023.2286686. Epub 2023 Dec 7. PMID: 38059434

Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques.
McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann NP, Miller J, Jacob-Dolan C, Powers O, Hope D, Wu C, Pereira J, Murdza T, Mazurek CR, Hoyt A, Boon ACM, Davis-Gardner M, Suthar MS, Martinot AJ, Boursiquot M, Cook A, Pessaint L, Lewis MG, Andersen H, Tolboom J, Serroyen J, Solforosi L, Costes LMM, Zahn RC, Barouch DH. Nature. 2023 Dec 14. doi: 10.1038/s41586-023-06951-3. Online ahead of print. PMID: 38096903

Impact of COVID-19 pandemic and vaccine perceptions on HPV vaccine hesitancy.
Schelbar N, Ward CN, Phillips E, Herr MJ, Acevedo S, Conner H, Greiner A, Corriveau E. Am J Otolaryngol. 2023 Dec 13;45(2):104172. doi: 10.1016/j.amjoto.2023.104172. Online ahead of print. PMID: 38103489

From bench to bedside via bytes: Multi-omic immunoprofiling and integration using machine learning and network approaches.
Xiao H, Rosen A, Chhibbar P, Moise L, Das J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2282803. doi: 10.1080/21645515.2023.2282803. Epub 2023 Dec 15. PMID: 38100557

Mothers' perceptions and attitudes about HPV vaccination initiation among 9- and 10-year-olds.
Kohler RE, Wagner RB, Careaga K, Btoush R, Greene K, Kantor L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270842. doi: 10.1080/21645515.2023.2270842. Epub 2023 Nov 13. PMID: 37955127

Evolution of global scientific collaboration in mRNA vaccine research: Insights from bibliometric and social network analysis (2010~2023).
Chen J, Pan L, Lu Y, Zhang T, Xu D, Yan S, Ouyang Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2276624. doi: 10.1080/21645515.2023.2276624. Epub 2023 Nov 14. PMID: 37964602

The HLA-II immunopeptidome of SARS-CoV-2.
Weingarten-Gabbay S, Chen DY, Sarkizova S, Taylor HB, Gentili M, Hernandez GM, Pearlman LR, Bauer MR, Rice CM, Clauser KR, Hacohen N, Carr SA, Abelin JG, Saeed M, Sabeti PC. Cell Rep. 2023 Dec 19;43(1):113596. doi: 10.1016/j.celrep.2023.113596. Online ahead of print. PMID: 38117652

Genomic analysis of penicillin-binding proteins and recombination events in an emerging amoxicillin- and meropenem-resistant PMEN3 (Spain^{9V}-3, ST156) variant in Taiwan and comparison with global descendants of this lineage.
Chen Y-Y, Chi H, Liao W-C, Li S-W, Yang Y-C, Lin H-C, Chang H-P, Pan Y-J, Chiang R-L, Hsieh Y-C. Microbiol Spectr. 2023 Dec 12;11(6):e0184023. doi: 10.1128/spectrum.01840-23. Epub 2023 Nov 6. PMID: 37930013

Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis.
Singh RB, Li J, Parmar UPS, Jeng BH, Jhanji V. Br J Ophthalmol. 2023 Dec 18;108(1):17-22. doi: 10.1136/bjo-2022-322512. PMID: 36575625

Construction of an indicator framework for vaccine inclusion in public health programs: A Delphi-entropy method study.
Wang Q, Dai P, Jia M, Jiang M, Li J, Yang W, Feng L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2272539. doi: 10.1080/21645515.2023.2272539. Epub 2023 Oct 31. PMID: 37905961

Maternal immunization in women living with HIV.
Dauby N, Gagneux-Brunon A, Martin C, Mussi-Pinhata MM, Goetghebuer T. AIDS. 2024 Feb 1;38(2):137-144. doi: 10.1097/QAD.0000000000003758. Epub 2023 Dec 20. PMID: 38116721

Vaccination against HPV: Easier said than done?
Stoeklé HC, Sekkate S, Ayoubi JM, Bennouna J, Beuzeboc P, Hervé C. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266935. doi: 10.1080/21645515.2023.2266935. Epub 2023 Oct 12. PMID: 37822281

Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.

Chen GL, Qiu YZ, Wu KQ, Wu Y, Wang YH, Zou YY, Peng CG, Zhao J, Su C, Ma JH, Ni SN, Wang X, Jin TH, Jiang Q, Guo T, Xu Y, Huang CC, Zhang Q, Liu KL, Ji L, Yang HY, Li CL, Su YW, Lu X, Li LJ. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18. PMID: 38111106

COVID-19 in patients with classic and variant hairy cell leukemia.
Kreitman RJ, Yu T, James L, Feurtado J, Eager H, Ortiz OS, Gould M, Mauter J, Zhou H, Burbelo PD, Cohen JI, Wang HW, Yuan CM, Arons E. Blood Adv. 2023 Dec 12;7(23):7161-7168. doi: 10.1182/bloodadvances.2023011147. PMID: 37729613

Vaccine value profile for Neisseria gonorrhoeae.
Lyu Y, Choong A, Chow EPF, Seib KL, Marshall HS, Unemo M, de Voux A, Wang B, Miranda AE, Gottlieb SL, Mello MB, Wi T, Baggaley R, Marshall C, Abu-Raddad LJ, Abara WE, Chen XS, Ong JJ. Vaccine. 2023 Dec 13:S0264-410X(23)00086-5. doi: 10.1016/j.vaccine.2023.01.053. Online ahead of print. PMID: 38123397

Urban and rural healthcare providers' perspectives on HPV vaccination in Minnesota.
Polter EJ, Christianson B, Steinberg A, Doan M, Ljungman H, Sundaram ME, VanWormer JJ, Williams CL, McLean HQ, Bendixsen C. Hum Vaccin Immunother. 2023 Dec 15;19(3):2291859. doi: 10.1080/21645515.2023.2291859. Epub 2023 Dec 14. PMID: 38095606

Prevalence and genotype distribution of HPV6/11/16/18 infections among 180,276 outpatient females from a Women's and Children's Central Hospital, 2015-2021, Chengdu, China.
Wei X, Zhang J, Mei Y, Dai Q, Yang X, Wang X. Sci Rep. 2023 Dec 14;13(1):22249. doi: 10.1038/s41598-023-48222-1. PMID: 38097632

Systematic review of influenza vaccine effectiveness against laboratory-confirmed influenza among older adults living in aged care facilities.
Moa A, Kunasekaran M, Akhtar Z, Costantino V, MacIntyre CR. Hum Vaccin Immunother. 2023 Dec 15;19(3):2271304. doi: 10.1080/21645515.2023.2271304. Epub 2023 Nov 6. PMID: 37929779

Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses.
Qiu J, Zhang S, Feng Y, Su X, Cai J, Chen S, Liu J, Huang S, Huang H, Zhu S, Wen H, Li J, Yan H, Diao Z, Liang X, Zeng F. Expert Rev Vaccines. 2024 Jan-Dec;23(1):69-81. doi: 10.1080/14760584.2023.2289566. Epub 2023 Dec 14. PMID: 38055218

Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development.
Kondapuram SK, Ramachandran HK, Arya H, Coumar MS. Life Sci. 2023 Dec 15;335:122260. doi: 10.1016/j.lfs.2023.122260. Epub 2023 Nov 12. PMID: 37963509

Continued Progress in the Development of Safe and Effective RSV Immunizations.
Cohn AC, Hall AJ. N Engl J Med. 2023 Dec 14;389(24):2289-2290. doi: 10.1056/NEJMe2311862. PMID: 38091535

Efficacy of a *Pseudomonas aeruginosa* serogroup O9 vaccine.
Moustafa DA, DiGiandomenico A, Raghuram V, Schulman M, Scarff JM, Davis MR Jr, Varga JJ, Dean CR, Goldberg JB. Infect Immun. 2023 Dec 12;91(12):e0024723. doi: 10.1128/iai.00247-23. Epub 2023 Nov 22. PMID: 37991349

Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
Qin SX, Cheng FWT, Kwok WC, Fung LWY, Ma TT, Yiu HHE, Bloom C, McDonald CF, Cheung CL, Lai FTT, Chui CSL, Li X, Wong CKH, Wan EYF, Wong ICK, Chan EWY. Drug Saf. 2023 Dec 12. doi: 10.1007/s40264-023-01364-7. Online ahead of print. PMID: 38085500

Virus-like particles as powerful vaccination strategy against human viruses.
Hadj Hassine I, Ben M'hadheb M, Almalki MA, Gharbi J. Rev Med Virol. 2023 Dec 20:e2498. doi: 10.1002/rmv.2498. Online ahead of print. PMID: 38116958

Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models.
Andrade VM, Maricic I, Kalia R, Jachimowicz L, Bedoya O, Kulp DW, Humeau L, Smith TRF. Hum Vaccin Immunother. 2023 Dec 15;19(3):2281733. doi: 10.1080/21645515.2023.2281733. Epub 2023 Nov 27. PMID: 38012018

In-silico development of multi-epitope subunit vaccine against lymphatic filariasis.
Singh P, Shaikh S, Gupta S, Gupta R. J Biomol Struct Dyn. 2023 Dec 20:1-15. doi: 10.1080/07391102.2023.2294838. Online ahead of print. PMID: 38117103

Benefits of Combining Molecular Biology and Controlled Human Infection Model Methodologies in Advancing Vaccine Development.
ElSherif M, Halperin SA. J Mol Biol. 2023 Dec 15;435(24):168322. doi: 10.1016/j.jmb.2023.168322. Epub 2023 Oct 20. PMID: 37866477

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers.
Çulpan HC, Aydın SN, Uygur A, Sayılı U, Şeker E, Balkan ILİ, Karaali R, Budak B, Keskindemirci Y, Saltoğlu N, Can G. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275445. doi: 10.1080/21645515.2023.2275445. Epub 2023 Nov 15. PMID: 37964650

Monitoring and reporting the US COVID-19 vaccination effort.
Scharf LG, Adeniyi K, Augustini E, Boyd D, Corvin L, Kalach RE, Fast H, Fath J, Harris L, Henderson D, Hicks-Thomson J, Jones-Jack N, Kellerman A, Khan AN, McGarvey SS, McGehee JE, E Miner C, Moore LB, Murthy BP, Myerburg S, Neuhaus E, Nguyen K, Parker M, Pierce-Richards S, Samchok D, Shaw LK, Spoto S, Srinivasan A, Stearle C, Thomas J, Winarsky M, Zell E. Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.12.005. Online ahead of print. PMID: 38097453

COVID-19 vaccine hesitancy among pregnant women attending public antenatal clinics in Dar es Salaam, Tanzania.
Yussuph ZH, Alwy Al-Beity FM, August F, Anaeli A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269777. doi: 10.1080/21645515.2023.2269777. Epub 2023 Nov 9. PMID: 37942618

Do Pentavalent (DTwP-Hib-HBV) vaccines have sex-differential nonspecific effects? An observational study.
Aamand T, Fisker AB, Correia C, Fernandes M, Clipet-Jensen C, Thysen SM. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288297. doi: 10.1080/21645515.2023.2288297. Epub 2023 Dec 6. PMID: 38054431

Optimizing Education to Improve COVID-19 Vaccination Rates in a Federally Qualified Health Center.
Perkins JR, Jaqua EE, Nguyen VT, Franz DA, Elkins J, Morton KR. Perm J. 2023 Dec 15;27(4):143-150. doi: 10.7812/TPP/23.088. Epub 2023 Nov 1. PMID: 37908131

Vaccination and Nutritional Outcomes of Hemodialysis Patients Infected With SARS-CoV-2.
Villaverde-Núñez A, Ramírez López MT, Rodríguez CA, Hammel IC, Pérez Ramos C, Álvarez Villarreal M, Ruíz Fernández S, Arriero López B, Hernández Cordobés G, Manzano Guerrero N, Baena Ruíz L, Guerra Llamas MI. Nurs Res. 2023 Dec 19. doi: 10.1097/NNR.0000000000000707. Online ahead of print. PMID: 38112624

Immune targets to stop future SARS-CoV-2 variants.
Silva Souza M, Pires Farias J, Barros Luiz W, Birbrair A, Durães-Carvalho R, de Souza Ferreira LC, Amorim JH. Microbiol Spectr. 2023 Dec 12;11(6):e0289223. doi: 10.1128/spectrum.02892-23. Epub 2023 Nov 15. PMID: 37966210

Characteristics and economic burden of hospitalized patients with herpes zoster in China, before vaccination.
Chen P, Chen Z, Xiao Y, Chen X, Li J, Tang Y, Shen M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2268990. doi: 10.1080/21645515.2023.2268990. Epub 2023 Oct 30. PMID: 37899682

RSV awareness, risk perception, causes, and terms: Comment.
Wiwanitkit S, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2277086. doi: 10.1080/21645515.2023.2277086. Epub 2023 Nov 14. PMID: 37964610

International Experience and China's Path: The History and Insights of the Development of Chinese Regulations for the Manufacture and Control of Live Poliovirus Vaccine.
Wu M. Chin Med Sci J. 2023 Dec 11. doi: 10.24920/004284. Online ahead of print. PMID: 38073062

The Oxford Needle Experience (ONE) scale: a UK-based and US-based online mixed-methods psychometric development and validation study of an instrument to assess needle fear, attitudes and expectations in the general public.
Kantor J, Vanderslott S, Morrison M, Pollard AJ, Carlisle RC. BMJ Open. 2023 Dec 13;13(12):e074466. doi: 10.1136/bmjopen-2023-074466. PMID: 38097240

Development and evaluation of a bivalent vaccine based on recombinant newcastle disease virus expressing infectious bursal disease virus VP2L-CH3-CH4 in SPF chickens.
Sun WY, Cao XL, Wang YX, Guo XC, Liu JM, Xue ZQ, Li HJ, Wang W, Zhang TT, Li Q, Qin RH, Jin YH, Li YN, Ren GP. Vet Microbiol. 2023 Dec 12;288:109950. doi: 10.1016/j.vetmic.2023.109950. Online ahead of print. PMID: 38101079

Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data.

Li Y, Lundin SK, Li J, Tao W, Dang Y, Chen Y, Tao C. Expert Rev Vaccines. 2024 Jan-Dec;23(1):53-59. doi: 10.1080/14760584.2023.2292203. Epub 2023 Dec 14. PMID: 38063069

Resurgence of syphilis: focusing on emerging clinical strategies and preclinical models.
Xiong S, Liu Z, Zhang X, Huang S, Ding X, Zhou J, Yao J, Li W, Liu S, Zhao F. J Transl Med. 2023 Dec 18;21(1):917. doi: 10.1186/s12967-023-04685-4. PMID: 38105236

Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable.
de Waure C, Gärtner BC, Lopalco PL, Puig-Barbera J, Nguyen-Van-Tam JS. Expert Rev Vaccines. 2024 Jan-Dec;23(1):27-38. doi: 10.1080/14760584.2023.2290194. Epub 2023 Dec 12. PMID: 38084895

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus.
Lee J, Zepeda SK, Park YJ, Taylor AL, Quispe J, Stewart C, Leaf EM, Treichel C, Corti D, King NP, Starr TN, Veesler D. Cell Host Microbe. 2023 Dec 13;31(12):1961-1973.e11. doi: 10.1016/j.chom.2023.10.018. Epub 2023 Nov 20. PMID: 37989312

Expression and purification of epitope vaccine against four virulence proteins from Helicobacter pylori and construction of label-free electrochemical immunosensor.
Du C, Zhang Z, Qiao W, Jia L, Zhang F, Chang M, Liu X, Guo L, Li Y. Biosens Bioelectron. 2023 Dec 15;242:115720. doi: 10.1016/j.bios.2023.115720. Epub 2023 Oct 4. PMID: 37804573

UK media responses to HIV through the lens of COVID-19: a study of multidirectional memory.
Pheasant-Kelly F. Med Humanit. 2023 Dec 19;49(4):735-751. doi: 10.1136/medhum-2022-012575. PMID: 37863647

Insights and expectations of healthcare professionals on the implementation of the updated pediatric regional immunization Calendar in Calabria, Italy.
Giuffrida S, Seta G, Gurnari A, Fiasca F, Marchetti F. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275475. doi: 10.1080/21645515.2023.2275475. Epub 2023 Oct 30. PMID: 37904511

A scoping review of the reasons for and approaches to non-uptake of pertussis and influenza vaccinations in pregnant women in the United Kingdom and Ireland.
McCarron SA, Bradley DT, Hart ND. BMC Pregnancy Childbirth. 2023 Dec 12;23(1):857. doi: 10.1186/s12884-023-06171-7. PMID: 38087222

COVID-19 Vaccine Acceptance in Pregnant Women in the United States: A Systematic Review and Meta-Analysis.
Patel A, Puglisi JL, Patel S, Tarn DM. J Womens Health (Larchmt). 2023 Dec 19. doi: 10.1089/jwh.2023.0498. Online ahead of print. PMID: 38112561

Effect of immunization registry-based provider reminder to initiate HPV vaccination at age 9, Washington state.
Christensen T, Zorn S, Bay K, Treend K, Averette C, Rhodes N. Hum Vaccin Immunother. 2023 Dec 15;19(3):2274723. doi: 10.1080/21645515.2023.2274723. Epub 2023 Nov 6. PMID: 37929936

Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for arboviruses with clinical and immunological insights.
Le Hir A, Durand GA, Boucraut J, Garnier A, Mura M, Diamantis S, Carles M, Durand C, Schweitzer C, Audouard C, Decroix V, Boyez R, Van Dendriessche A, Leclancher A, Kaphan E, du Closel LB, Verdon R, du Cheyron D, Vabret A, Vergnon D, Grard G, Charrel R, de Lamballerie X, Eldin C. J Travel Med. 2023 Dec 20:taad160. doi: 10.1093/jtm/taad160. Online ahead of print. PMID: 38123499

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine.
Yong X, Liu J, Zeng Y, Nie J, Cui X, Wang T, Wang Y, Chen Y, Kang W, Yang Z, Liu Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267869. doi: 10.1080/21645515.2023.2267869. Epub 2023 Oct 19. PMID: 37854013

Evidence supporting the initiation of HPV vaccination starting at age 9: Collection overview.
Perkins RB, Humiston S, Oliver K. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269026. doi: 10.1080/21645515.2023.2269026. Epub 2023 Oct 12. PMID: 37824444

Adherence to recommended vaccination policies for pre- and post-solid organ transplantation patients: A national questionnaire survey in Japan.
Tanaka T, Kakiuchi S, Tashiro M, Fujita A, Ashizawa N, Eguchi S, Kenmochi T, Egawa H, Izumikawa K. Vaccine. 2023 Dec 18;41(52):7682-7688. doi: 10.1016/j.vaccine.2023.11.033. Epub 2023 Nov 25. PMID: 38007343

Determinants of human papillomavirus vaccine hesitancy among Lebanese parents.
Zakhour R, Tamim H, Faytrouni F, Makki M, Hojeij R, Charafeddine L. PLoS One. 2023 Dec 13;18(12):e0295644. doi: 10.1371/journal.pone.0295644. eCollection 2023. PMID: 38091310

Exploring dermatologists' perspectives on vaccines in dermatology: a qualitative study.
Smith KN, Algarin YA, Archila M, Barbieri JS, Goldman N, Perez-Chada LM, Noe MH. Arch Dermatol Res. 2023 Dec 12;316(1):36. doi: 10.1007/s00403-023-02777-1. PMID: 38085346

Progress toward the development of Lassa vaccines.
Ly H. Expert Rev Vaccines. 2024 Jan-Dec;23(1):5-7. doi: 10.1080/14760584.2023.2290683. Epub 2023 Dec 11. PMID: 38044877

Innovation-driven trend shaping COVID-19 vaccine development in China.
Zhang Y, Zhao Y, Liang H, Xu Y, Zhou C, Yao Y, Wang H, Yang X. Front Med. 2023 Dec 16. doi: 10.1007/s11684-023-1034-6. Online ahead of print. PMID: 38102402

Live-Virus Shingles Vaccine Provided Some Long-Term Protection.
Harris E. JAMA. 2023 Dec 19;330(23):2241. doi: 10.1001/jama.2023.23507. PMID: 38019488

Knowledge-map analysis and bladder cancer immunotherapy: Comment.
Daungsupawong H, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285094. doi: 10.1080/21645515.2023.2285094. Epub 2023 Nov 20. PMID: 37981858

Antibody Titers against Mpox Virus after Vaccination.
Kottkamp AC, Samanovic MI, Duerr R, Oom AL, Belli HM, Zucker JR, Rosen JB, Mulligan MJ; NYC OSMI Study Group. N Engl J Med. 2023 Dec 14;389(24):2299-2301. doi: 10.1056/NEJMc2306239. PMID: 38091537

Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
Nishiyama T, Miyamatsu Y, Park H, Nakamura N, Yokokawa Shibata R, Iwami S, Nagasaki Y. Vaccine. 2023 Dec 18;41(52):7655-7662. doi: 10.1016/j.vaccine.2023.11.040. Epub 2023 Nov 25. PMID: 38008663

Measles Outbreaks Grow Amid Declining Vaccination Rates.
Harris E. JAMA. 2023 Dec 19;330(23):2242. doi: 10.1001/jama.2023.23511. PMID: 38019492

Acceptance of influenza vaccination and associated factors among teachers in China: A cross-sectional study based on health belief model.
Gu W, Liu Y, Chen Q, Wang J, Che X, Du J, Zhang X, Xu Y, Zhang X, Jiang W, Wang J, Xie Q, Lu Z, Yang Y, Gu L, Chen J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270325. doi: 10.1080/21645515.2023.2270325. Epub 2023 Oct 31. PMID: 37905951

Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
Bajracharya D, Jansen RJ. Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.12.008. Online ahead of print. PMID: 38103963

Short-term and long-term behavioral effects of vaccination mandates.
Baser O, Rodchenko K, Chen L, Yapar N. Hum Vaccin Immunother. 2023 Dec 15;19(3):2294525. doi: 10.1080/21645515.2023.2294525. Epub 2023 Dec 19. PMID: 38114192

Monkeypox (Mpox) Vaccine Hesitancy Among Mpox Cases: A Qualitative Study.
Agroia H, Smith E, Vaidya A, Rudman S, Roy M. Health Promot Pract. 2023 Dec 15:15248399231215054. doi: 10.1177/15248399231215054. Online ahead of print. PMID: 38102810

Immunisation with Neospora caninum subunits rsNcSAG4 and rsNcGRA1 (NcSAG4 and NcGRA1 epitopes construct) in BALB/c mice: the profile of the immune response and controlling the vertical transmission.
Fernandes Fidelis C, Silva de Araújo L, Prates-Patarroyo PA, Martins-Kalks KH, Licursi de Oliveira L, Vargas Viloria MI, Tafur-Gómez GA, Patarroyo Salcedo JH. Parasitol Res. 2023 Dec 19;123(1):58. doi: 10.1007/s00436-023-08020-0. PMID: 38110570

End of season 2022/2023 quadrivalent influenza vaccine effectiveness in preventing influenza in primary care in Portugal.
Kislaya I, Torres AR, Gomes L, Melo A, Machado A, Henriques C, Verdasca N, Guiomar R, Rodrigues AP, Surveillance Network NI. Hum Vaccin Immunother. 2023 Dec 15;19(3):2263219. doi: 10.1080/21645515.2023.2263219. Epub 2023 Nov 15. PMID: 37964588

Is vaccine hesitancy related to mental health after the adjustment of the zero-COVID-19 strategy in the elderly? A mediation analysis in China.

Zhang E, Wang X, Dai Z, Zhang X, Shang S, Fang Q. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288726. doi: 10.1080/21645515.2023.2288726. Epub 2023 Dec 6. PMID: 38055950

Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity.
Sun Y, Tian Y, Wu S, Huang A, Hu Y, Liao Z, Swift M, Deng S, Yang X, Zhang B, Zhang Z, Wu B, Huang J, Jiang K, Huang F, Jin H, Wan C, Yang K. Cell Rep Med. 2023 Dec 19;4(12):101303. doi: 10.1016/j.xcrm.2023.101303. Epub 2023 Nov 28. PMID: 38029750

Varicella Zoster vaccination in hemodialysis patients: The state of the art.
Gobbi L, Martino FK, Sgrò E, Nalesso F, Calo' LA. Hum Vaccin Immunother. 2023 Dec 15;19(3):2286689. doi: 10.1080/21645515.2023.2286689. Epub 2023 Nov 27. PMID: 38010087

Design of a multi-epitope vaccine (vme-VAC/MST-1) against cholera and vibriosis based on reverse vaccinology and immunoinformatics approaches.
Marques PH, Rodrigues TCV, Santos EH, Bleicher L, Aburjaile FF, Martins FS, Oliveira CJF, Azevedo V, Tiwari S, Soares S. J Biomol Struct Dyn. 2023 Dec 19:1-16. doi: 10.1080/07391102.2023.2293256. Online ahead of print. PMID: 38112302

Assessment of willingness and determinants to receive the COVID-19 vaccine among the general population of the Somali region, Eastern Ethiopia: a 2021 cross-sectional study.
Wolde M, Wasihun Y, Melesse A, Tadesse T, Sharma R, Mon HS, Challa A, Simireta T, Addisu H. BMJ Open. 2023 Dec 19;13(12):e080733. doi: 10.1136/bmjopen-2023-080733. PMID: 38114284

Vaccine conspiracy association with higher COVID-19 vaccination side effects and negative attitude towards booster COVID-19, influenza and monkeypox vaccines: A pilot study in Saudi Universities.
Alshehri S, Sallam M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275962. doi: 10.1080/21645515.2023.2275962. Epub 2023 Nov 9. PMID: 37941437

The use of electroporation to deliver DNA-based vaccines.
Kisakov DN, Belyakov IM, Kisakova LA, Yakovlev VA, Tigeeva EV, Karpenko LI. Expert Rev Vaccines. 2024 Jan-Dec;23(1):102-123. doi: 10.1080/14760584.2023.2292772. Epub 2023 Dec 18. PMID: 38063059

Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries.
Banerjee P, Huber J, Denti V, Sauer M, Weeks R, Dhaliwal BK, Shet A. Glob Health Action. 2023 Dec 31;16(1):2281065. doi: 10.1080/16549716.2023.2281065. Epub 2023 Dec 12. PMID: 38084434

"I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Côte d'Ivoire.
Naugle D, Tibbels N, Dosso A, Benie W, Nana M. Vaccine. 2023 Dec 12;41(51):7626-7631. doi: 10.1016/j.vaccine.2023.11.021. Epub 2023 Nov 19. PMID: 37989611

Institutional trust is a distinct construct related to vaccine hesitancy and refusal.
Krastev S, Krajden O, Vang ZM, Juárez FP, Solomonova E, Goldenberg MJ, Weinstock D, Smith MJ, Dervis E, Pilat D, Gold I. BMC Public Health. 2023 Dec 12;23(1):2481. doi: 10.1186/s12889-023-17345-5. PMID: 38082287

Maternal Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department Visits in Infants.
Sahni LC, Olson SM, Halasa NB, Stewart LS, Michaels MG, Williams JV, Englund JA, Klein EJ, Staat MA, Schlaudecker EP, Selvarangan R, Schuster JE, Weinberg GA, Szilagyi PG, Boom JA, Patel MM, Muñoz FM; New Vaccine Surveillance Network Collaborators. JAMA Pediatr. 2023 Dec 18:e235639. doi: 10.1001/jamapediatrics.2023.5639. Online ahead of print. PMID: 38109102

Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
Jackson LA, Stapleton JT, Walter EB, Chen WH, Rouphael NG, Anderson EJ, Neuzil KM, Winokur PL, Smith MJ, Schmader KE, Swamy GK, Thompson AB, Mulligan MJ, Rostad CA, Cross K, Tsong R, Wegel A, Roberts PC. Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.12.001. Online ahead of print. PMID: 38105137

Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
Jiang W, Lu C, Yan X, Tucker JD, Lin L, Li J, Larson HJ, Gong W, Wu D. Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.11.046. Online ahead of print. PMID: 38103961

Extracting factors associated with vaccination from Twitter data and mapping to behavioral models.
Biswas MR, Shah Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2281729. doi: 10.1080/21645515.2023.2281729. Epub 2023 Nov 27. PMID: 38013461

Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects.
Kato H, Kurosawa T, Horikawa K, Kimura Y, Miyakawa K, Ryo A, Goto A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278376. doi: 10.1080/21645515.2023.2278376. Epub 2023 Nov 16. PMID: 37969091

Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond.
Hammershaimb EA, Berry AA. Expert Rev Vaccines. 2024 Jan-Dec;23(1):49-52. doi: 10.1080/14760584.2023.2292204. Epub 2023 Dec 14. PMID: 38095048

Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of Dabie Bandavirus in aged ferrets.
Kim D, Kim E, Kim S, Chung Y, Cho SD, Choi Y, Lai CJ, Dai X, Kang S, Kwak MJ, Cha I, Liu Z, Choi Y, Park SH, Choi YK, Jung JU. bioRxiv. 2023 Dec 12:2023.07.19.549761. doi: 10.1101/2023.07.19.549761. Preprint. PMID: 37503275

Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.
Pelton SI, Mould-Quevedo JF, Nguyen VH. Expert Rev Vaccines. 2024 Jan-Dec;23(1):82-87. doi: 10.1080/14760584.2023.2295014. Epub 2023 Dec 14. PMID: 38093415

Vaccines in long term care settings: a narrative review.
Frangos E, Barratt J, Michel JP, Ecarnot F. Gerontology. 2023 Dec 13. doi: 10.1159/000534998. Online ahead of print. PMID: 38091961

Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
Pichon S, Moureau A, Petit C, Kirstein JL, Sheldon E, Guinet-Morlot F, Minutello AM. Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.11.052. Online ahead of print. PMID: 38105138

In silico design of an epitope-based vaccine against PspC in Streptococcus pneumoniae using reverse vaccinology.
Nahian M, Shahab M, Mazumder L, Oliveira JIN, Banu TA, Sarkar MH, Goswami B, Habib A, Begum S, Akter S. J Genet Eng Biotechnol. 2023 Dec 12;21(1):166. doi: 10.1186/s43141-023-00604-8. PMID: 38085389

Acid hydrolysis conditions for quantification of meningococcal X polysaccharide in a pentavalent vaccine using HPAEC-PAD/ESI-MS.
Ghosh S, Pawar R, Kangralkar V, Mallya AD, Dhere RM, Bolgiano B, Ravenscroft N. Anal Biochem. 2023 Dec 15;683:115363. doi: 10.1016/j.ab.2023.115363. Epub 2023 Oct 20. PMID: 37866526

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children.
Chapman TJ, Olarte L, Dbaibo G, Houston AM, Tamms G, Lupinacci R, Feemster K, Buchwald UK, Banniettis N. Expert Rev Vaccines. 2024 Jan-Dec;23(1):137-147. doi: 10.1080/14760584.2023.2294153. Epub 2023 Dec 20. PMID: 38111990

Association between sex hormones and anti-S/RBD antibody responses to COVID-19 vaccines in healthcare workers.
Anticoli S, Dorrucci M, Iessi E, Chiarotti F, Di Prinzio RR, Vinci MR, Zaffina S, Puro V, Colavita F, Mizzoni K, Meschi S, Vonesch N, Albano C, Ortona E, Ruggieri A, Tomao P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2273697. doi: 10.1080/21645515.2023.2273697. Epub 2023 Nov 14. PMID: 37961893

Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination.
Suntronwong N, Kanokudom S, Thatsanathorn T, Thongmee T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2283916. doi: 10.1080/21645515.2023.2283916. Epub 2023 Nov 28. PMID: 38014687

The critical factors for COVID-19 vaccination uptake are perceived vaccine effectiveness and the desire to protect others.
Valinsky D, Heymann AD, Albukrek D, Tsamir J, Zacay G. Hum Vaccin Immunother. 2023 Dec 15;19(3):2265170. doi: 10.1080/21645515.2023.2265170. Epub 2023 Oct 17. PMID: 37846842

Barriers to and facilitators of human papillomavirus vaccination in an ethnically diverse group of migrant parents: A qualitative mixed methods study.
Khan A, Abonyi S, Neudorf C, Galea S, Ahmed S. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269721. doi: 10.1080/21645515.2023.2269721. Epub 2023 Oct 23. PMID: 37870066

A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults.
McMahon R, Fuchs U, Schneider M, Hadl S, Hochreiter R, Bitzer A, Kosulin K, Koren M, Mader R, Zoihsl O, Wressnigg N, Dubischar K, Buerger V, Eder-Lingelbach S, Jaramillo JC. J Travel Med. 2023 Dec 13:taad156. doi: 10.1093/jtm/taad156. Online ahead of print. PMID: 38091981

Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Jeantin L, Abdi B, Soulié C, Sterlin D, Maillart E, Beigneux Y, Hippolyte A, Belin L, Marcelin AG, Pourcher V, Louapre C. J Neurol Neurosurg Psychiatry. 2023 Dec 14;95(1):19-28. doi: 10.1136/jnnp-2023-331770. PMID: 37479463

Molecular assay for detecting MS-H vaccine strain and immune response mechanisms in chickens receiving one or two doses of live MS-H vaccine.
Limpavithayakul K, Charoenvisal N, Pakpinyo S. Avian Pathol. 2024 Feb;53(1):33-43. doi: 10.1080/03079457.2023.2267022. Epub 2023 Dec 19. PMID: 37791564

Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23.
Zeng X, Nong WX, Zou XQ, Li F, Ge YY, Zhang QM, Luo B, Huang W, Zou JX, Fan R, Xie XX. Hum Vaccin Immunother. 2023 Dec 15;19(3):2293299. doi: 10.1080/21645515.2023.2293299. Epub 2023 Dec 15. PMID: 38100550

Clinical, epidemiological, and molecular investigation of Kyasanur forest disease from Karnataka state, India during 2018-2019.
Munivenkatappa A, Yadav PD, Sahay RR, Sk K, Shete AM, Patil DY, Mohandas S, Jain R, Patil S, Sinha DP, Jayaswamy MM. Infect Dis (Lond). 2024 Feb;56(2):145-156. doi: 10.1080/23744235.2023.2282042. Epub 2023 Dec 18. PMID: 37966909

High genetic and haplotype diversity in vaccine candidate *Pfceltos* but not *Pfrh5* among malaria-infected children in Ibadan, Nigeria.
Oboh MA, Asmorom N, Falade C, Ojurongbe O, Thomas BN. PeerJ. 2023 Dec 11;11:e16519. doi: 10.7717/peerj.16519. eCollection 2023. PMID: 38099304

Cost-of-illness of gastroenteritis caused by rotavirus in Chinese children less than 5 years.
Fu XL, Ma Y, Li Z, Qi YY, Wang SJ, Fu LJ, Wang SM, von Seidlein L, Wang XY. Hum Vaccin Immunother. 2023 Dec 15;19(3):2276619. doi: 10.1080/21645515.2023.2276619. Epub 2023 Nov 27. PMID: 38013426

Humoral response against spike protein and fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects: What should be for the seventh dose?
Wiwanitkit S, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2295074. doi: 10.1080/21645515.2023.2295074. Epub 2023 Dec 18. PMID: 38111337

Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.

Morais S, Wissing MD, Khosrow-Khavar F, Burchell AN, Tellier PP, Coutlée F, Waterboer T, El-Zein M, Franco EL. Infect Dis (Lond). 2024 Jan;56(1):66-72. doi: 10.1080/23744235.2023.2277390. Epub 2023 Dec 18. PMID: 37994805

High Caregiver Adverse Childhood Experiences Are Associated With Pediatric Influenza and COVID-19 Vaccination Uptake.
Day ME, Sucharew H, Burkhardt MC, Reyner A, Giles D, Beck AF, Schlaudecker EP, Klein M. J Pediatric Infect Dis Soc. 2023 Dec 16;12(12):595-601. doi: 10.1093/jpids/piad090. PMID: 37846858

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens.
Zhang P, Luo S, Zou P, Deng Q, Wang C, Li J, Cai P, Zhang L, Li C, Li T. Microbiol Spectr. 2023 Dec 12;11(6):e0179423. doi: 10.1128/spectrum.01794-23. Epub 2023 Oct 25. PMID: 37877750

Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and Other Pediatric Vaccines.
Yonts AB, Gaviria-Agudelo C, Kimberlin DW, O'Leary ST, Paulsen GC. Pediatrics. 2023 Dec 14. doi: 10.1542/peds.2023-064990. Online ahead of print. PMID: 38095041

Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
F Schwarz T, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Maréchal C, Olivier A, Nakanwagi P, Lievens M, Hulstrøm V. J Infect Dis. 2023 Dec 14:jiad546. doi: 10.1093/infdis/jiad546. Online ahead of print. PMID: 38099559

Accessing health information during the COVID-19 pandemic: the experience of NHS maternity service users.
Ambihaipahan R, Chisnall G, Vindrola-Padros C, Irvine L. BMC Pregnancy Childbirth. 2023 Dec 11;23(1):851. doi: 10.1186/s12884-023-06160-w. PMID: 38082239

Comparing factors influencing seasonal influenza vaccine acceptance and intentions among Chinese university students residing in China and UK: A cross-sectional study.
Li L, Yang L, Wang Q, Wood CE, Kostkova P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2290798. doi: 10.1080/21645515.2023.2290798. Epub 2023 Dec 18. PMID: 38111087

Resilience of routine childhood immunization services in two counties in Kenya in the face of the COVID-19 pandemic.
Mirieri H, Nasimiyu C, Dawa J, Mburu C, Jalang'o R, Kamau P, Igboh L, Ebama M, Wainaina D, Gitonga J, Karanja J, Njenga E, Kariuki J, Machani J, Oginga P, Baraka I, Wamaru P, Muhula S, Ratemo P, Ayugi J, Kariuki Njenga M, Emukule GO, Osoro E, Otieno NA. Vaccine. 2023 Dec 18;41(52):7695-7704. doi: 10.1016/j.vaccine.2023.09.023. Epub 2023 Nov 25. PMID: 38008664

How enlightened self-interest guided global vaccine sharing benefits all: A modeling study.
Han Z, Chen L, Hao Q, He Q, Budeski K, Jin D, Xu F, Tang K, Li Y. J Glob Health. 2023 Dec 20;13:06038. doi: 10.7189/jogh.13.06038. PMID: 38115726

Co-administration of SARS-CoV-2 and influenza vaccines in healthcare workers: Results of two vaccination campaigns in a large teaching hospital in Rome.
Pascucci D, Lontano A, Regazzi L, Marziali E, Nurchis MC, Raponi M, Vetrugno G, Moscato U, Cadeddu C, Laurenti P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2287282. doi: 10.1080/21645515.2023.2287282. Epub 2023 Nov 28. PMID: 38016914

Gradient of vaccine hesitancy among French men having sex with men: An electronic cross-sectional survey in 2022.
Brosset E, Fressard L, Cogordan C, Bocquier A, Annequin M, Bourrelly M, Constance J, Michels D, Mora M, Morel S, Oliveri C, Maradan G, Berenger C, Spire B, Verger P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2293489. doi: 10.1080/21645515.2023.2293489. Epub 2023 Dec 14. PMID: 38093684

Strengthening immunization programs through innovative sub-national public-private partnerships in selected provinces in the Democratic Republic of the Congo.
Banza Mpiongo P, Kibanza J, Kambol Yav F, Nyombo D, Mwepu L, Basame D, Mpoyi R, Madika C, Hatton T, Mafuta E, Gascon O, Tschirhart K, Nkosi F, Lusamba P, Merritt S, Mwenda J, Tangney S, Hoff NA, Nkamba Mukadi D, Rimoin AW, Kaba D, El Mourid A, Senouci K, Ngoie Mwamba G, Mukamba Musenga E, Cikomola A. Vaccine. 2023 Dec 12;41(51):7598-7607. doi: 10.1016/j.vaccine.2023.11.029. Epub 2023 Nov 19. PMID: 37989612

Non-specific effects of Pneumococcal and Haemophilus vaccines in children aged 5 years and under: a systematic review.
Geraghty K, Rooney D, Watson C, Ledwidge MT, Glynn L, Gallagher J. BMJ Open. 2023 Dec 14;13(12):e077717. doi: 10.1136/bmjopen-2023-077717. PMID: 38101831

Views about vaccines and how views changed during the COVID-19 pandemic among a national sample of young gay, bisexual, and other men who have sex with men.
Marshall D, McRee AL, Gower AL, Reiter PL. Hum Vaccin Immunother. 2023 Dec 15;19(3):2281717. doi: 10.1080/21645515.2023.2281717. Epub 2023 Nov 15. PMID: 37965729

Stakeholders' perspectives on barriers to and facilitators of school-based HPV vaccination in the context of COVID-19 pandemic-related disruption: a qualitative mixed methods study.
Khan A, Abonyi S, Neudorf C, Galea S, Ahmed S. Int J Qual Stud Health Well-being. 2024 Dec;19(1):2295879. doi: 10.1080/17482631.2023.2295879. Epub 2023 Dec 20. PMID: 38118074

Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort.
Kirwan PD, Hall VJ, Foulkes S, Otter AD, Munro K, Sparkes D, Howells A, Platt N, Broad J, Crossman D, Norman C, Corrigan D, Jackson CH, Cole M, Brown CS, Atti A, Islam J; SIREN Study Group; Presanis AM, Charlett A, De Angelis D, Hopkins S. Lancet Reg Health Eur. 2023 Dec 14;36:100809. doi: 10.1016/j.lanepe.2023.100809. eCollection 2024 Jan. PMID: 38111727

Rapid Induction of Long-Lasting Systemic and Mucosal Immunity via Thermostable Microneedle-Mediated Chitosan Oligosaccharide-Encapsulated DNA Nanoparticles.
Li M, Yang L, Wang C, Cui M, Wen Z, Liao Z, Han Z, Zhao Y, Lang B, Chen H, Qian J, Shu Y, Zeng X, Sun C. ACS Nano. 2023 Dec 12;17(23):24200-24217. doi: 10.1021/acsnano.3c09521. Epub 2023 Nov 22. PMID: 37991848

Efficient cross-protection against serotype 4/8a fowl adenoviruses (FAdVs): recombinant FAdV-4 with FAdV-8a Fiber.
Lu Y, Yuan Y, Jiang H, Xu Z, Guo Y, Cao X, Li T, Wan Z, Shao H, Qin A, Xie Q, Ye J. Microbiol Spectr. 2023 Dec 12;11(6):e0246223. doi: 10.1128/spectrum.02462-23. Epub 2023 Nov 15. PMID: 37966208

Design and Implementation of a Federal Program to Engage Community Partners to Reduce Disparities in Adult COVID-19 Immunization Uptake, United States, 2021-2022.
Ashenafi SG, Martinez GM, Jatlaoui TC, Koppaka R, Byrne-Zaaloff M, Falcón AP, Frank A, Keitt SH, Matus K, Moss S, Ruddock C, Sun T, Waterman MB, Wu TY. Public Health Rep. 2023 Dec 18:333549231208642. doi: 10.1177/00333549231208642. Online ahead of print. PMID: 38111108

Acceptance of COVID-19 boosters among hypertensive patients in China: A multicenter cross-sectional study.
Yan Y, Chen Q, Nuermaimaiti A, Xiao Y, Chang L, Ji H, Sun H, Song Q, Gao Y, Xu J, Wang L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2283315. doi: 10.1080/21645515.2023.2283315. Epub 2023 Nov 20. PMID: 37982140

Missed opportunities for vaccination at point of care and their impact on coverage and urban-rural coverage inequity in the Gambia.
Sowe A, Namatovu F, Cham B, Gustafsson PE. Vaccine. 2023 Dec 18;41(52):7647-7654. doi: 10.1016/j.vaccine.2023.11.041. Epub 2023 Nov 22. PMID: 37996292

Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.
Elzouki AY, Elshafei MN, Aziz A, Elzouki I, Waheed MA, Farooqui K, Azad AM, Habas E, Danjuma MI. Qatar Med J. 2023 Dec 12;2023(3):21. doi: 10.5339/qmj.2023.21. eCollection 2023. PMID: 38089670

Human vaccines & immunotherapeutics: News November 2023.
Ellis R, Weiss A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2292940. doi: 10.1080/21645515.2023.2292940. Epub 2023 Dec 15. PMID: 38100575

Attitudes toward influenza vaccination in healthcare workers in Italy: A systematic review and meta-analysis.
Bianchi FP, Stefanizzi P, Di Lorenzo A, De Waure C, Boccia S, Daleno A, Migliore G, Tafuri S. Hum Vaccin Immunother. 2023 Dec 15;19(3):2265587. doi: 10.1080/21645515.2023.2265587. Epub 2023 Oct 17. PMID: 37849235

Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial.
Boulware DR, Atukunda M, Kagimu E, Musubire AK, Akampurira A, Tugume L, Ssebambulidde K, Kasibante J, Nsangi L, Mugabi T, Gakuru J, Kimuda S, Kasozi D, Namombwe S, Turyasingura I, Rutakingirwa MK, Mpoza E, Kigozi E, Muzoora C, Ellis J, Skipper CP, Matkovits T, Williamson PR, Williams DA, Fieberg A, Hullsiek KH, Abassi M, Dai B, Meya DB. Clin Infect Dis. 2023 Dec 15;77(12):1659-1667. doi: 10.1093/cid/ciad440. PMID: 37606364

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides.
Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, Zeng X, Wang J, Yang B, Zhang Y, Lao L, Chen J, Xin M, Nie Y, Saw PE, Su S, Song E. Nature. 2023 Dec 13. doi: 10.1038/s41586-023-06834-7. Online ahead of print. PMID: 38093017

Nonsecretor Phenotype Is Associated With Less Risk of Rotavirus-Associated Acute Gastroenteritis in a Vaccinated Nicaraguan Birth Cohort.
Reyes Y, St Jean DT, Bowman NM, González F, Mijatovic-Rustempasic S, Becker-Dreps S, Svensson L, Nordgren J, Bucardo F, Vielot NA. J Infect Dis. 2023 Dec 20;228(12):1739-1747. doi: 10.1093/infdis/jiad202. PMID: 37279878

Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries.
Arsenault C, Lewis TP, Kapoor NR, Okiro EA, Leslie HH, Armeni P, Jarhyan P, Doubova SV, Wright KD, Aryal A, Kounnavong S, Mohan S, Odipo E, Lee HY, Shin J, Ayele W, Medina-Ranilla J, Espinoza-Pajuelo L, Derseh Mebratie A, García Elorrio E, Mazzoni A, Oh J, SteelFisher GK, Tarricone R, Kruk ME. Lancet Glob Health. 2024 Jan;12(1):e156-e165. doi: 10.1016/S2214-109X(23)00490-4. Epub 2023 Dec 11. PMID: 38096888

Evaluating the accessibility and capacity of SARS-CoV-2 vaccination and analyzing convenience-related factors during the Omicron variant epidemic in Beijing, China.
Duan Y, Jiang M, Suo L, Xu M, Li X, Wang Q, Bai C, Wu J, Xu Z, Yang W, Feng L, Li J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2289250. doi: 10.1080/21645515.2023.2289250. Epub 2023 Dec 19. PMID: 38111955

Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice.
Liu J, Jaijyan DK, Chen Y, Feng C, Yang S, Xu Z, Zhan N, Hong C, Li S, Cheng T, Zhu H. Microbiol Spectr. 2023 Dec 12;11(6):e0246323. doi: 10.1128/spectrum.02463-23. Epub 2023 Nov 16. PMID: 37971259

Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice.
Wang Z, Jacobus EJ, Stirling DC, Krumm S, Flight KE, Cunliffe RF, Mottl J, Singh C, Mosscrop LG, Santiago LA, Vogel AB, Kariko K, Sahin U, Erbar S, Tregoning JS. Mol Ther Nucleic Acids. 2023 Oct 5;34:102045. doi: 10.1016/j.omtn.2023.102045. eCollection 2023 Dec 12. PMID: 37876532

Rational design of a multivalent vaccine targeting arthropod-borne viruses using reverse vaccinology strategies.
Dhanushkumar T, Selvam PK, M E S, Vasudevan K, C GPD, Zayed H, Kamaraj B. Int J Biol Macromol. 2023 Dec 15:128753. doi: 10.1016/j.ijbiomac.2023.128753. Online ahead of print. PMID: 38104690

A dual-antigen malaria vaccine targeting Pb22 and Pbg37 was able to induce robust transmission-blocking activity.
Gao W, Qiu Y, Zhu L, Yu X, Yang F, Chen M, He G, Liu Y, Cui L, Liu F, Zhu X, Cao Y. Parasit Vectors. 2023 Dec 14;16(1):455. doi: 10.1186/s13071-023-06071-x. PMID: 38098083

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression.
Shi X, Sun Y, Ding X. Clin Cosmet Investig Dermatol. 2023 Dec 15;16:3581-3587. doi: 10.2147/CCID.S439045. eCollection 2023. PMID: 38116145

A self-assembled graphene oxide adjuvant induces both enhanced humoral and cellular immune responses in influenza vaccine.
Huang S, Li Y, Zhang S, Chen Y, Su W, Sanchez DJ, Mai JDH, Zhi X, Chen H, Ding X. J Control Release. 2023 Dec 11;365:716-728. doi: 10.1016/j.jconrel.2023.11.047. Online ahead of print. PMID: 38036004

Genetic and potential antigenic evolution of influenza A(H1N1)pdm09 viruses circulating in Kenya during 2009-2018 influenza seasons.
Owuor DC, de Laurent ZR, Nyawanda BO, Emukule GO, Kondor R, Barnes JR, Nokes DJ, Agoti CN, Chaves SS. Sci Rep. 2023 Dec 15;13(1):22342. doi: 10.1038/s41598-023-49157-3. PMID: 38102198

Harnessing Nanovaccines for Effective Immunization—A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective.
Gholap AD, Gupta J, Kamandar P, Bhowmik DD, Rojekar S, Faiyazuddin M, Hatvate NT, Mohanto S, Ahmed MG, Subramaniyan V, Kumarasamy V. ACS Biomater Sci Eng. 2023 Dec 14. doi: 10.1021/acsbiomaterials.3c01247. Online ahead of print. PMID: 38096426

Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, Rosario N, Zhang Y, Mainou BA, Jimeno J, Aguirre G, Rüttimann R. Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00519-4. doi: 10.1016/S1473-3099(23)00519-4. Online ahead of print. PMID: 38109921

Comparative pathogenomic analysis reveals a highly tetanus toxin-producing clade of *Clostridium tetani* isolates in Japan.
Shitada C, Sekizuka T, Yamamoto A, Sakamoto C, Hashino M, Kuroda M, Takahashi M. mSphere. 2023 Dec 20;8(6):e0036923. doi: 10.1128/msphere.00369-23. Epub 2023 Nov 27. PMID: 38009947

A meta-analysis of immunogenicity and safety of two versus single-doses of influenza A (H1N1) vaccine in person living with HIV.
Zhang T, Geng J, Du Y, Yang H, Jin Y, Chen S, Duan G. Int J STD AIDS. 2023 Dec 12:9564624231220424. doi: 10.1177/09564624231220424. Online ahead of print. PMID: 38087772

Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants.
P KK, Chiteti SR, Aileni VK, Babji S (late), Blackwelder WC, Kumar A, Vagha J, Nayak U, Mitra M, D N, Kar S, Yadav S, Naidu S, Mahantshetti N, Khalatkar V, Mohapatra S, Purthi PK, Sharma P, Kannan A, Dhongade RK, Prasad SD, Ella R, Vadrevu KM. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278346. doi: 10.1080/21645515.2023.2278346. Epub 2023 Nov 15. PMID: 37968237

"Direct and indirect impacts of the COVID-19 pandemic on operational conduct of pediatric vaccine clinical trials".

McArthur MA, Bchir S, Dubois E, Gan L, Gerchman E, Gupta S, Liabis O, Perez L, Roche F, Vasquez G, Zambrano B, Gurunathan S, Dhingra MS. Hum Vaccin Immunother. 2023 Dec 15;19(3):2272535. doi: 10.1080/21645515.2023.2272535. Epub 2023 Nov 9. PMID: 37942563

Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany.
Joshi K, Scholz S, Maschio M, Kohli M, Lee A, Fust K, Ultsch B, Van de Velde N, Beck E. J Med Econ. 2024 Jan-Dec;27(1):39-50. doi: 10.1080/13696998.2023.2290388. Epub 2023 Dec 13. PMID: 38050685

Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
Larivière Y, Matuvanga TZ, Lemey G, Osang'ir BI, Vermeiren PP, Milolo S, Meta R, Kimbulu P, Esanga E, Matangila J, Van Geertruyden JP, Van Damme P, Maketa V, Muhindo-Mavoko H, Mitashi P. Vaccine. 2023 Dec 12;41(51):7587-7597. doi: 10.1016/j.vaccine.2023.11.030. Epub 2023 Nov 22. PMID: 37993355

Leveraging immunoinformatics for developing a multi-epitope subunit vaccine against *Helicobacter pylori* and *Fusobacterium nucleatum*.
Tamanna T, Rahman MS. J Biomol Struct Dyn. 2023 Dec 20:1-14. doi: 10.1080/07391102.2023.2292295. Online ahead of print. PMID: 38116749

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
Bhatla N, Muwonge R, Malvi SG, Joshi S, Poli URR, Lucas E, Esmy PO, Verma Y, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Vashist S, Mishra G, Jadhav R, Siddiqi M, Anantharaman D, Panicker G, Butt J, Sankaran S, Kannan TPRA, Varghese R, Kartha P, Pillai MR, Waterboer T, Müller M, Sehr P, Unger ER, Sankaranarayanan R, Basu P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2289242. doi: 10.1080/21645515.2023.2289242. Epub 2023 Dec 11. PMID: 38078840

Disease Flares Following COVID-19 Vaccination in Patients with Inflammatory Bowel Disease.
Yoshida Y, Fujioka S, Moriyama T, Umeno J, Kawasaki K, Fuyuno Y, Matsuno Y, Ihara Y, Torisu T, Kitazono T. Intern Med. 2023 Dec 15;62(24):3579-3584. doi: 10.2169/internalmedicine.2335-23. Epub 2023 Sep 29. PMID: 37779068

Examining vaccine hesitancy among a diverse sample of Canadian adults.
Burns KE, Dubé È, Godinho Nascimento H, Meyer SB. Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.12.030. Online ahead of print. PMID: 38103960

Plasmodium knowlesi in pig-tailed macaques: a potential new model for malaria vaccine research.
Shears MJ, Reynolds RA, Duncombe CJ, Watson FN, Staubus WJ, Chavtur C, Seilie AM, Tran TM, Chakravarty S, Hoffman SL, Murphy SC. Malar J. 2023 Dec 13;22(1):379. doi: 10.1186/s12936-023-04788-9. PMID: 38093306

Enhanced immunogenicity elicited by a novel DNA vaccine encoding the SARS-CoV-2 S1 protein fused to the optimized flagellin of *Salmonella typhimurium* in mice.
Song L, Wang Q, Wen Y, Tan R, Cui Y, Xiong D, Jiao X, Pan Z. Microbiol Spectr. 2023 Dec 12;11(6):e0254923. doi: 10.1128/spectrum.02549-23. Epub 2023 Nov 1. PMID: 37909745

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.
Boulton S, Poutou J, Gill R, Alluqmani N, He X, Singaravelu R, Crupi MJF, Petryk J, Austin B, Angka L, Taha Z, Teo I, Singh S, Jamil R, Marius R, Martin N, Jamieson T, Azad T, Diallo JS, Ilkow CS, Bell JC. Mol Ther Methods Clin Dev. 2023 Sep 16;31:101110. doi: 10.1016/j.omtm.2023.101110. eCollection 2023 Dec 14. PMID: 37822719

A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax.
Kunkeaw N, Nguitragool W, Takashima E, Kangwanrangsan N, Muramatsu H, Tachibana M, Ishino T, Lin PJC, Tam YK, Pichyangkul S, Tsuboi T, Pardi N, Sattabongkot J. NPJ Vaccines. 2023 Dec 14;8(1):187. doi: 10.1038/s41541-023-00786-9. PMID: 38092803

HIV vaccines induce CD8$^+$ T cells with low antigen receptor sensitivity.
Migueles SA, Nettere DM, Gavil NV, Wang LT, Toulmin SA, Kelly EP, Ward AJ, Lin S, Thompson SA, Peterson BA, Abdeen CS, Sclafani CR, Pryal PF, Leach BG, Ludwig AK, Rogan DC, Przygonska PA, Cattani A, Imamichi H, Sachs A, Cafri G, Huang NN, Patamawenu A, Liang CJ, Hallahan CW, Kambach DM, Han EX, Coupet T, Chen J, Moir SL, Chun TW, Coates EE, Ledgerwood J, Schmidt J, Taillandier-Coindard M, Michaux J, Pak H, Bassani-Sternberg M, Frahm N, McElrath MJ, Connors M. Science. 2023 Dec 15;382(6676):1270-1276. doi: 10.1126/science.adg0514. Epub 2023 Dec 14. PMID: 38096385

Dengue virus infection and neurological manifestations: an update.
Fong SL, Wong KT, Tan CT. Brain. 2023 Dec 11:awad415. doi: 10.1093/brain/awad415. Online ahead of print. PMID: 38079534

Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
Moita D, Nunes-Cabaço H, Rôla C, Franke-Fayard B, Janse CJ, Mendes AM, Prudêncio M. Vaccine. 2023 Dec 12;41(51):7618-7625. doi: 10.1016/j.vaccine.2023.11.023. Epub 2023 Nov 25. PMID: 38007342

Understanding Fc function for rational vaccine design against pathogens.
Bowman KA, Kaplonek P, McNamara RP. mBio. 2023 Dec 19:e0303623. doi: 10.1128/mbio.03036-23. Online ahead of print. PMID: 38112418

Lower rate of mpox vaccination hesitancy and medical consultation among Chinese men who have sex with men living with HIV in comparison with those living without HIV: A national observational study.
Zheng M, Du M, Yang G, Yao Y, Qian X, Zhi Y, Ma L, Tao R, Zhu Z, Zhou F, Dai S, Yang J, Liu M, Liu J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2290788. doi: 10.1080/21645515.2023.2290788. Epub 2023 Dec 6. PMID: 38054460

Dual analysis of wild-type and attenuated *Orf virus* and host cell transcriptomes revealed novel virus-host cell interactions.
Yao X, Jing T, Geng Q, Pang M, Zhao X, Li S, Chen D, Ma W. mSphere. 2023 Dec 20;8(6):e0039823. doi: 10.1128/msphere.00398-23. Epub 2023 Nov 20. PMID: 37982609

Integrating health belief model and theory of planned behavior to assess COVID-19 vaccine acceptance among urban slum people in Bangladesh.

Patwary MM, Disha AS, Hasan M, Bardhan M, Hasan M, Tuhi FI, Rahim SJ, Newaz MN, Imran SA, Haque MZ, Hossain MR, Kabir MP, Swed S. PLoS One. 2023 Dec 20;18(12):e0290412. doi: 10.1371/journal.pone.0290412. eCollection 2023. PMID: 38117841

Coated Porous Microneedles for Effective Intradermal Immunization with Split Influenza Vaccine.
Zhang L, Xiu X, Li Z, Su R, Li X, Ma S, Ma F. ACS Biomater Sci Eng. 2023 Dec 11;9(12):6880-6890. doi: 10.1021/acsbiomaterials.3c01212. Epub 2023 Nov 15. PMID: 37967566

Factors associated with the decision to receive bivalent COVID-19 booster vaccination among health care personnel.
Mohr NM, Plumb ID, Santos León E, Harland KK, Krishnadasan A, Nandi U, Hoth KF, Smithline HA, Talan DA. Hum Vaccin Immunother. 2023 Dec 15;19(3):2284471. doi: 10.1080/21645515.2023.2284471. Epub 2023 Nov 23. PMID: 37994545

Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
Payne AB, Ciesla AA, Rowley EAK, Weber ZA, Reese SE, Ong TC, Vazquez-Benitez G, Naleway AL, Klein NP, Embi PJ, Grannis SJ, Kharbanda AB, Gaglani M, Tenforde MW, Link-Gelles R; VISION Network. Vaccine. 2023 Dec 12;41(51):7581-7586. doi: 10.1016/j.vaccine.2023.11.025. Epub 2023 Nov 23. PMID: 38000964

A survey of potential acceptance of 9-valent HPV vaccine among Chinese male college students.
Jia S, Pan B, Hong D, Zhang Q, Jiang H, Hong Y, Hong J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2272533. doi: 10.1080/21645515.2023.2272533. Epub 2023 Nov 16. PMID: 37969075

Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase).
Lee MT, Lee JW, Lee HJ, Lee JM, Choi JC, Gu KM, Jung SY. BMJ Open Respir Res. 2023 Dec 11;10(1):e001992. doi: 10.1136/bmjresp-2023-001992. PMID: 38081769

Single-Component Multilayered Self-Assembling Protein Nanoparticles Displaying Extracellular Domains of Matrix Protein 2 as a Pan-influenza A Vaccine.
Braz Gomes K, Zhang YN, Lee YZ, Eldad M, Lim A, Ward G, Auclair S, He L, Zhu J. ACS Nano. 2023 Dec 12;17(23):23545-23567. doi: 10.1021/acsnano.3c06526. Epub 2023 Nov 21. PMID: 37988765

Insight into the invasion process and immune-protective evaluation of Tp0971, a membrane lipoprotein from *Treponema pallidum*.
Zhang X, Duan J, Wang Y, Xie B, Zhou J, Zhao S, Yin W, Liu P, Zhao F. Microbiol Spectr. 2023 Dec 12;11(6):e0004723. doi: 10.1128/spectrum.00047-23. Epub 2023 Oct 19. PMID: 37855609

H3K27M Vaccine Appears Safe and Immunogenic in Diffuse Midline Glioma.
[No authors listed] Cancer Discov. 2023 Dec 12;13(12):OF13. doi: 10.1158/2159-8290.CD-RW2023-155. PMID: 37772779

Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Systematic Review of Published Cases.

Clerici B, Pontisso E, Aloise C, Peroni B, Perricone R, Pisetta C, Scavone M, Birocchi S, Podda GM. Thromb Haemost. 2023 Dec 18. doi: 10.1055/s-0043-1777134. Online ahead of print. PMID: 38109906

An analysis of COVID-19 vaccination campaign in Ukraine.
Mamontova TV. Eur J Public Health. 2023 Dec 12:ckad201. doi: 10.1093/eurpub/ckad201. Online ahead of print. PMID: 38085983

A multi-epitope subunit vaccine based on CU/ZN-SOD, OMP31 and BP26 against Brucella melitensis infection in BALB/C mice.
Wang Y, Wu A, Xu Z, Zhang H, Li H, Fu S, Liu Y, Cui L, Miao Y, Wang Y, Zhumanov K, Xu Y, Sheng J, Yi J, Chen C. Int Immunopharmacol. 2023 Dec 18;127:111351. doi: 10.1016/j.intimp.2023.111351. Online ahead of print. PMID: 38113688

Immersion prime and oral boost vaccination with an inactivated Vibrio harveyi vaccine confers a specific immune response and protection in Asian seabass (Lates calcarifer).
Lan NGT, Dong HT, Vinh NT, Senapin S, Shinn AP, Salin KR, Rodkhum C. Fish Shellfish Immunol. 2023 Dec 15;144:109293. doi: 10.1016/j.fsi.2023.109293. Online ahead of print. PMID: 38104696

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.
Pichon S, Guinet-Morlot F, Saleh J, Essink B, Pineda-Peña AC, Moureau A, Petit C, Minutello AM. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275453. doi: 10.1080/21645515.2023.2275453. Epub 2023 Nov 3. PMID: 37921410

The association between influenza vaccination and the perception of COVID-19 as well as COVID-19 vaccination behavior among community residents in Anhui province, China.
Guo M, Li J, Wang Y, Chen G, Chen R, Wang L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275464. doi: 10.1080/21645515.2023.2275464. Epub 2023 Nov 8. PMID: 37941303

Probiotic *Enterococcus faecalis* surface-delivering key domain of EtMIC3 proteins: immunoprotective efficacies against *Eimeria tenella* infection in chickens.
Pan X, Kong R, Liu Q, Jia Z, Bai B, Chen H, Zhi W, Wang B, Ma C, Ma D. Microbiol Spectr. 2023 Dec 12;11(6):e0245523. doi: 10.1128/spectrum.02455-23. Epub 2023 Oct 19. PMID: 37855592

Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine.
Wijesundara DK, Yeow A, McMillan CLD, Choo JJY, Todorovic A, Mekonnen ZA, Masavuli MG, Young PR, Gowans EJ, Grubor-Bauk B, Muller DA. Mol Ther Nucleic Acids. 2023 Oct 16;34:102056. doi: 10.1016/j.omtn.2023.102056. eCollection 2023 Dec 12. PMID: 38028199

Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.
Rosa Duque JS, Cheng SMS, Cohen CA, Leung D, Wang X, Mu X, Chung Y, Lau TM, Wang M, Zhang W, Zhang Y, Wong HHW, Tsang LCH, Chaothai S, Kwan TC, Li JKC, Chan KCK, Luk LLH, Ho JCH, Li WY, Lee AMT, Lam JHY, Chan SM, Wong WHS, Tam IYS, Mori M, Valkenburg SA, Peiris M, Tu W, Lau YL. World J Pediatr. 2023 Dec 12. doi: 10.1007/s12519-023-00764-0. Online ahead of print. PMID: 38085470

Knowledge, attitudes, and practices towards human papillomavirus (HPV) and HPV vaccination among male nurses.
Sağtaş F, Gürsoy MY. Int J Nurs Pract. 2023 Dec 19:e13228. doi: 10.1111/ijn.13228. Online ahead of print. PMID: 38113644

[Why the regeneration of immunological tolerance by vaccination is difficult].
Radbruch A, Melchers F. Z Rheumatol. 2023 Dec 18. doi: 10.1007/s00393-023-01453-z. Online ahead of print. PMID: 38110746

Intention to receive the monkeypox vaccine and its psychological and sociodemographic predictors: a cross-sectional survey in the general population of Peru.
Caycho-Rodríguez T, Valencia PD, Ventura-León J, Carbajal-León C, Vilca LW, Gallegos M, Reyes-Bossio M, Noe-Grijalva M, Delgado-Campusano M, Del Carpio Toia ÁM, Torales J, Barria-Asenjo NA. Psicol Reflex Crit. 2023 Dec 18;36(1):39. doi: 10.1186/s41155-023-00281-z. PMID: 38108935

SARS-CoV-2 mRNA vaccination-induced immunological memory in human nonlymphoid and lymphoid tissues.
Proß V, Sattler A, Lukassen S, Tóth L, Thole LML, Siegle J, Stahl C, He A, Damm G, Seehofer D, Götz C, Bayerl C, Jäger P, Macke A, Eggeling S, Kirzinger B, Mayr T, Herbst H, Beyer K, Laue D, Krönke J, Braune J, Rosseck F, Kittner B, Friedersdorff F, Hubatsch M, Weinberger S, Lachmann N, Hofmann VM, Schrezenmeier E, Ludwig C, Schrezenmeier H, Jechow K, Conrad C, Kotsch K. J Clin Invest. 2023 Dec 15;133(24):e171797. doi: 10.1172/JCI171797. PMID: 37815874

Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
Lytras T, Di Gregorio AAA, Apostolopoulos D, Naziris D, Zingerle C, Heraclides A. Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.12.025. Online ahead of print. PMID: 38081753

Diverging humoral and cellular immune responses due to Omicron-a national study from the Faroe Islands.
Petersen MS, Pérez-Alós L, Í Kongsstovu SK, Eliasen EH, Hansen CB, Larsen S, Hansen JL, Bayarri-Olmos R, Fjallsbak JP, Weihe P, Garred P. Microbiol Spectr. 2023 Dec 12;11(6):e0086523. doi: 10.1128/spectrum.00865-23. Epub 2023 Nov 1. PMID: 37909772

Comparing the immune response and protective effect of COVID-19 vaccine under different vaccination strategies.
Zhao T, Huang X, Shu Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2273155. doi: 10.1080/21645515.2023.2273155. Epub 2023 Dec 19. PMID: 38111370

Research progress in the off-target effects of Bacille Calmette-Guérin vaccine.
Wu Y, Zhang X, Zhou L, Lu J, Zhu F, Li J. Chin Med J (Engl). 2023 Dec 13. doi: 10.1097/CM9.0000000000002890. Online ahead of print. PMID: 38092722

Addressing COVID-19 vaccine hesitancy in rural community pharmacies: a protocol for a stepped wedge randomized clinical trial.
Curran G, Mosley C, Gamble A, Painter J, Ounpraseuth S, Brewer NT, Teeter B, Smith M, Halladay J, Hughes T, Shepherd JG, Hastings T, Simpson K, Carpenter D. Implement Sci. 2023 Dec 18;18(1):72. doi: 10.1186/s13012-023-01327-7. PMID: 38110979

Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials.
Miao M, Yin J, Zhang L, Wang C, Qin C. Expert Rev Vaccines. 2023 Dec 19. doi: 10.1080/14760584.2023.2296937. Online ahead of print. PMID: 38112249

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
Nham E, Seong H, Hyun H, Yoon JG, Noh JY, Cheong HJ, Kim WJ, Kim E, Choi L, Lee JM, Song JY. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266233. doi: 10.1080/21645515.2023.2266233. Epub 2023 Nov 15. PMID: 37964587

Clinical course and management of COVID-19 in the era of widespread population immunity.
Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. Nat Rev Microbiol. 2023 Dec 19. doi: 10.1038/s41579-023-01001-1. Online ahead of print. PMID: 38114838

An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success.
Kumbhar PR, Kumar P, Lasure A, Velayutham R, Mandal D. Discov Nano. 2023 Dec 19;18(1):156. doi: 10.1186/s11671-023-03913-6. PMID: 38112935

Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
Ducasa N, Benencio P, Mauro E, Anders M, Mazzitelli B, Bleichmar L, Quiroga MF, Barbero M, Cairo F, Alter A, Etcheves P, Scarton G, Sobenko N, Biglione M, Mendizabal M. Vaccine. 2023 Dec 18;41(52):7663-7670. doi: 10.1016/j.vaccine.2023.11.039. Epub 2023 Nov 25. PMID: 38007341

Contents of antenatal care services in Afghanistan: findings from the national health survey 2018.
Stanikzai MH, Tawfiq E, Jafari M, Wasiq AW, Seddiq MK, Currie S, Sayam H, Baray AH, Saeedzai SA. BMC Public Health. 2023 Dec 11;23(1):2469. doi: 10.1186/s12889-023-17411-y. PMID: 38082286

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
McNeel DG, Emamekhoo H, Eickhoff JC, Kyriakopoulos CE, Wargowski E, Tonelli TP, Johnson LE, Liu G. J Immunother Cancer. 2023 Dec 14;11(12):e008067. doi: 10.1136/jitc-2023-008067. PMID: 38101860

The politics of COVID-19: Differences between U.S. red and blue states in COVID-19 regulations and deaths.
Dominik Güss C, Boyd L, Perniciaro K, Free DC, Free JR, Teresa Tuason M. Health Policy Open. 2023 Nov 11;5:100107. doi: 10.1016/j.hpopen.2023.100107. eCollection 2023 Dec 15. PMID: 38034472

What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
Ravlić S, Kurtović T, Cvetko Krajinović L, Hećimović A, Miloš M, Mateljak Lukačević S, Markotić A, Halassy B. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270310. doi: 10.1080/21645515.2023.2270310. Epub 2023 Oct 31. PMID: 37905722

The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study.
Le Saux N, Bettinger J, Shulha HP, Sadarangani M, Coyle D, Booth TF, Jadavji T, Halperin SA; For members of Immunization Monitoring Program Active. CMAJ Open. 2023 Dec 19;11(6):E1156-E1163. doi: 10.9778/cmajo.20220245. Print 2023 Nov-Dec. PMID: 38114258

SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.
Penetra SLS, Santos HFP, Resende PC, Bastos LS, da Silva MFB, Pina-Costa A, Lopes RS, Saboia-Vahia L, de Oliveira ACA, Pereira EC, Filho FM, Wakimoto MD, Calvet GA, Fuller TL, Whitworth J, Smith C, Nielsen-Saines K, Carvalho MS, Espíndola OM, Guaraldo L, Siqueira MM, Brasil P. J Infect Dis. 2023 Dec 20;228(12):1680-1689. doi: 10.1093/infdis/jiad336. PMID: 37571849

ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case-control study.
Ken-Dror G, Sharma P; international Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators and Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. J R Soc Med. 2023 Dec 12:1410768231214341. doi: 10.1177/01410768231214341. Online ahead of print. PMID: 38086410

A potent subset of Mycobacterium tuberculosis glycoproteins as relevant candidates for vaccine and therapeutic target.
Yari S, Afrough P, Yari F, Ghazanfari Jajin M, Fateh A, Hadizadeh Tasbiti A. Sci Rep. 2023 Dec 14;13(1):22194. doi: 10.1038/s41598-023-49665-2. PMID: 38092899

Lack of influence of social media on vaccine decision-making by university students in Ireland.
Moore LE, Vucen S, Moore AC. Hum Vaccin Immunother. 2023 Dec 15;19(3):2287279. doi: 10.1080/21645515.2023.2287279. Epub 2023 Dec 1. PMID: 38038598

Effectiveness of a Fourth COVID-19 mRNA Vaccine Dose Against the Omicron Variant in Solid Organ Transplant Recipients.
Naylor KL, Knoll GA, Smith G, McArthur E, Kwong JC, Dixon SN, Treleaven D, Kim SJ. Transplantation. 2024 Jan 1;108(1):294-302. doi: 10.1097/TP.0000000000004766. Epub 2023 Dec 13. PMID: 38098159

Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
Ryman J, Sachs JR, Yee KL, Banniettis N, Weaver J, Weiss T. Expert Rev Vaccines. 2024 Jan-Dec;23(1):60-68. doi: 10.1080/14760584.2023.2292773. Epub 2023 Dec 14. PMID: 38073483

Evaluating vaccine-elicited antibody activities against *Neisseria gonorrhoeae*: cross-protective responses elicited by the 4CMenB meningococcal vaccine.
Gray MC, Thomas KS, Lamb ER, Werner LM, Connolly KL, Jerse AE, Criss AK. Infect Immun. 2023 Dec 12;91(12):e0030923. doi: 10.1128/iai.00309-23. Epub 2023 Nov 22. PMID: 37991382

Human transcriptional signature of protection after *Plasmodium falciparum* immunization and infectious challenge *via* mosquito bites.

Mura M, Misganaw B, Gautam A, Robinson T, Chaudhury S, Bansal N, Martins AJ, Tsang J, Hammamieh R, Bergmann-Leitner E. Hum Vaccin Immunother. 2023 Dec 15;19(3):2282693. doi: 10.1080/21645515.2023.2282693. Epub 2023 Nov 27. PMID: 38010150

Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Nemoto T, Takeuchi JS, Li Y, Konishi M, Tsuchiya K, Gatanaga H, Oka S, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. J Infect Dis. 2023 Dec 20;228(12):1652-1661. doi: 10.1093/infdis/jiad317. PMID: 37756608

Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).
Hellfritzsch M, Christensen D, Foged C, Scherließ R, Thakur A. Int J Pharm. 2023 Dec 15;648:123581. doi: 10.1016/j.ijpharm.2023.123581. Epub 2023 Nov 4. PMID: 37931728

A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge.
Lin YL, Cheng PY, Chin CL, Chuang KT, Lin JY, Chang N, Pan CK, Lin CS, Pan SC, Chiang BL. J Biomed Sci. 2023 Dec 18;30(1):96. doi: 10.1186/s12929-023-00987-3. PMID: 38110940

Improving Program Outcomes Through Responsive Feedback: A Case Study of a Leadership Development Academy in Nigeria.
Aminu T, Otokpen O, Mmirikwe I, Adetunde O, Ajuwon I, Adelakun A, Salisu A, Shuaib F, Igbokwe U, Aina M. Glob Health Sci Pract. 2023 Dec 18;11(Suppl 2):e2200121. doi: 10.9745/GHSP-D-22-00121. Print 2023 Dec 18. PMID: 38110205

Age nine is possible: Improving age 9 HPV initiation through a national quality improvement initiative during the COVID-19 pandemic.
Isher-Witt J, Foley S, Hassan A, Sloan A, Nkonga J, Fisher-Borne M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2284359. doi: 10.1080/21645515.2023.2284359. Epub 2023 Nov 22. PMID: 37994120

Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in mice.
Rios LE, Lokugamage N, Choudhuri S, Chowdhury IH, Garg NJ. NPJ Vaccines. 2023 Dec 16;8(1):188. doi: 10.1038/s41541-023-00782-z. PMID: 38104118

A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in mice.
Zhao L, Wang X, Li Z. Int J Biol Macromol. 2023 Dec 14;258(Pt 1):128723. doi: 10.1016/j.ijbiomac.2023.128723. Online ahead of print. PMID: 38101679

RNA vaccines: A transformational advance.
Brown BD, Fauci AS, Belkaid Y, Merad M. Immunity. 2023 Dec 12;56(12):2665-2669. doi: 10.1016/j.immuni.2023.11.009. PMID: 38091944

RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
Wang Y, Hu Y, Ma Y, Li P, Zhou S, Xu M, He B, Liu S, Lv K, Liu S, Zhang Y, Zhou N, Chen S, Ye F, Chen YQ. Vaccine. 2023 Dec 18;41(52):7641-7646. doi: 10.1016/j.vaccine.2023.11.037. Epub 2023 Nov 27. PMID: 38016845

Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?
Potter GE, Callier V, Shrestha B, Joshi S, Dwivedi A, Silva JC, Laurens MB, Follmann DA, Deye GA. Malar J. 2023 Dec 19;22(1):383. doi: 10.1186/s12936-023-04802-0. PMID: 38115002

Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature.
Arya S, Norton N, Kaushik P, Brandtmüller A, Tsoumani E. Hum Vaccin Immunother. 2023 Dec 15;19(3):2279394. doi: 10.1080/21645515.2023.2279394. Epub 2023 Nov 28. PMID: 38014651

A review of foot-and-mouth disease in Ethiopia: epidemiological aspects, economic implications, and control strategies.
Zewdie G, Akalu M, Tolossa W, Belay H, Deresse G, Zekarias M, Tesfaye Y. Virol J. 2023 Dec 15;20(1):299. doi: 10.1186/s12985-023-02263-0. PMID: 38102688

Protective efficacy of multiepitope vaccines constructed from common antigens of Eimeria species in chickens.
Chen C, Su J, Lu M, Xu L, Yan R, Li X, Song X. Vet Res. 2023 Dec 13;54(1):119. doi: 10.1186/s13567-023-01253-y. PMID: 38093398

School-Located Vaccine Clinics: An Effective Strategy for Expanding Access to COVID-19 Vaccines in Los Angeles County.
Biederman CF, Pham MA, Jimoh L, Aguinaldo JL, Ramirez S, Alabadi-Bierman A, Yeganeh N. Public Health Rep. 2023 Dec 18:333549231214784. doi: 10.1177/00333549231214784. Online ahead of print. PMID: 38111103

Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
Ferroni E, Gennaro N, Maifredi G, Leoni O, Profili F, Stasi C, Cacciani L, Calandrini E, di Napoli A, Petrelli A, Zorzi M. Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.11.043. Online ahead of print. PMID: 38097455

Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate.
Thomson-Luque R, Stabler TC, Fürle K, Silva JC, Daubenberger C. Expert Rev Vaccines. 2023 Dec 15. doi: 10.1080/14760584.2023.2295430. Online ahead of print. PMID: 38100310

Genomic, transcriptomic, and phenotypic differences among archetype *Shigella flexneri* strains of serotypes 2a, 3a, and 6.
Gabor CE, Hazen TH, Delaine-Elias BC, Rasko DA, Barry EM. mSphere. 2023 Dec 20;8(6):e0040823. doi: 10.1128/msphere.00408-23. Epub 2023 Oct 13. PMID: 37830809

Poly(ethyl ethylene phosphate): Overcoming the "Polyethylene Glycol Dilemma" for Cancer Immunotherapy and mRNA Vaccination.
Yu X, Li H, Dong C, Qi S, Yang K, Bai B, Peng K, Buljan M, Lin X, Liu Z, Yu G. ACS Nano. 2023 Dec 12;17(23):23814-23828. doi: 10.1021/acsnano.3c07932. Epub 2023 Dec 1. PMID: 38038679

In vivo evaluation of new adjuvant systems based on combination of Salmonella Typhi porins with particulate systems: Liposomes versus polymeric particles.
Parmaksız S, Pekcan M, Özkul A, Türkmen E, Rivero-Arredondo V, Ontiveros-Padilla L, Forbes N, Perrie Y, López-Macías C, Şenel S. Int J Pharm. 2023 Dec 15;648:123568. doi: 10.1016/j.ijpharm.2023.123568. Epub 2023 Nov 2. PMID: 37925042

Characterizing Attitudes Toward Maternal RSV Vaccines Among Pregnant and Lactating Persons in Kenya: Key Considerations for Demand Generation Efforts for Vaccine Acceptance.
Limaye RJ, Sauer M, Njogu R, Singh P, Fesshaye B, Karron RA. J Pediatric Infect Dis Soc. 2023 Dec 16;12(12):638-641. doi: 10.1093/jpids/piad098. PMID: 37944043

Liver macrophages and sinusoidal endothelial cells execute vaccine-elicited capture of invasive bacteria.
Wang J, An H, Ding M, Liu Y, Wang S, Jin Q, Wu Q, Dong H, Guo Q, Tian X, Liu J, Zhang J, Zhu T, Li J, Shao Z, Briles DE, Veening JW, Zheng H, Zhang L, Zhang JR. Sci Transl Med. 2023 Dec 20;15(727):eade0054. doi: 10.1126/scitranslmed.ade0054. Epub 2023 Dec 20. PMID: 38117903

Determinants of parental self-reported uptake of influenza vaccination in preschool children during the COVID-19 pandemic.
Qu S, Yang M, He W, Xie H, Zhou M, Campy KS, Tao X. Hum Vaccin Immunother. 2023 Dec 15;19(3):2268392. doi: 10.1080/21645515.2023.2268392. Epub 2023 Nov 14. PMID: 37964617

The spectrum of side effects associated with COVID-19 vaccines in patients with inborn errors of immunity.
Özdemiral C, Cevik NN, Yavuz G, Gormez O, Zengin AB, Esenboga S, Karabulut E, Cagdas D. Clin Immunol. 2023 Dec 18:109878. doi: 10.1016/j.clim.2023.109878. Online ahead of print. PMID: 38122840

Bibliometric analysis of scientific papers on adverse reactions to COVID-19 vaccines published between 2019 and 2023.
Yang X, Chen M, Cao L, Zhao M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270194. doi: 10.1080/21645515.2023.2270194. Epub 2023 Oct 27. PMID: 37885372

[Research advances in the etiology and pathogenesis of immunoglobulin A vasculitis].
Jianati R, Liu XX, Zhu XJ. Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1287-1292. doi: 10.7499/j.issn.1008-8830.2307065. PMID: 38112149

Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.
Tayebi A, Samimisedeh P, Jafari Afshar E, Mahmoudnia S, Milan N, Ayati A, Madady A, Rastad H. BMC Neurol. 2023 Dec 11;23(1):437. doi: 10.1186/s12883-023-03486-y. PMID: 38082244

Pulmonary function assessment after COVID-19 in vaccinated healthcare workers.
Ippoliti L, Coppeta L, Somma G, Bizzarro G, Borelli F, Crispino T, Ferrari C, Iannuzzi I, Mazza A, Paolino A, Magrini A, Pietroiusti A. J Occup Med Toxicol. 2023 Dec 15;18(1):31. doi: 10.1186/s12995-023-00400-7. PMID: 38102626

Characterization of T-cell subsets in response to foot-and-mouth disease bivalent inactivated vaccine in Chinese Holstein cows.
Zhang Z, Wang D, Yao Y, Yang J, Yang Z, Yang Y. Microbiol Spectr. 2023 Dec 12;11(6):e0102923. doi: 10.1128/spectrum.01029-23. Epub 2023 Oct 10. PMID: 37815383

Testing novel facial recognition technology to identify dogs during vaccination campaigns.
Czupryna AM, Estepho M, Lugelo A, Bigambo M, Sambo M, Changalucha J, Lushasi KS, Rooyakkers P, Hampson K, Lankester F. Sci Rep. 2023 Dec 12;13(1):22025. doi: 10.1038/s41598-023-49522-2. PMID: 38086911

Despite Safe and Effective Vaccine, Measles Cases and Deaths Increased Worldwide From 2021 to 2022.
Rubin R. JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25527. Online ahead of print. PMID: 38117505

Correlation of Streptococcus agalactiae concentration on immune system and effective dose of inactivated vaccine for Chitralada 3 strain Nile tilapia (Oreochromis niloticus) in Thailand.
Khunrang T, Pooljun C, Wuthisuthimethavee S. BMC Vet Res. 2023 Dec 11;19(1):267. doi: 10.1186/s12917-023-03835-6. PMID: 38082432

The L-DBF vaccine cross protects mice against different *Shigella* serotypes after prior exposure to the pathogen.
Lu T, Howlader DR, Das S, Dietz ZK, Nagel AC, Whittier SK, Picking WD, Picking WL. Microbiol Spectr. 2023 Dec 12;11(6):e0006223. doi: 10.1128/spectrum.00062-23. Epub 2023 Oct 3. PMID: 37787548

Achieving measles elimination and emerging modified measles: Longitudinal measles epidemiology from 1982 to 2021 in Osaka Prefecture, Japan.
Kurata T, Kaida Y, Kanbayashi D, Motomura K. Vaccine. 2023 Dec 14:S0264-410X(23)01437-8. doi: 10.1016/j.vaccine.2023.12.004. Online ahead of print. PMID: 38097458

Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
Park SI, Park S, Lee K, Kwak HW, Kim YK, Park HJ, Bang YJ, Kim JY, Kim D, Seo KW, Lee SJ, Kim H, Kim Y, Kim DH, Park HJ, Jung SY, Ga E, Hwang J, Na W, Hong SH, Lee SM, Nam JH. Vaccine. 2023 Dec 14:S0264-410X(23)01444-5. doi: 10.1016/j.vaccine.2023.12.011. Online ahead of print. PMID: 38097457

Effect of the interval between birth and second dose of hepatitis B vaccine on perinatal transmission of hepatitis B virus.
Yang TU, Vargas-Zambrano JC, Park HA, Jung CW, Kim D, Jee Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278940. doi: 10.1080/21645515.2023.2278940. Epub 2023 Nov 13. PMID: 37955105

United States Influenza 2022-2023 Season Characteristics as Inferred from Wastewater Solids, Influenza Hospitalization, and Syndromic Data.

Schoen ME, Bidwell AL, Wolfe MK, Boehm AB. Environ Sci Technol. 2023 Dec 12;57(49):20542-20550. doi: 10.1021/acs.est.3c07526. Epub 2023 Nov 28. PMID: 38014848

Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain.
Picchio CA, Nomah DK, Rando-Segura A, Buti M, Lens S, Forns X, Tajes SR, Fernández E, Pamplona Portero J, Nuñez CL, van Selm L, MacKinnon M, Araujo SG, Martró E, Rodríguez-Frías F, Lazarus JV. Commun Med (Lond). 2023 Dec 14;3(1):182. doi: 10.1038/s43856-023-00420-8. PMID: 38097770

In silico analysis of HLA-1 and HLA-2 recognition of a designed recombinant human papillomavirus vaccine based on L1 protein HPV subtype 45.
Sulfianti A, Karimah N, Nurhasanah A. J Genet Eng Biotechnol. 2023 Dec 13;21(1):167. doi: 10.1186/s43141-023-00593-8. PMID: 38091180

Immunogenic dead cells engineered by the sequential treatment of ultraviolet irradiation/cryo-shocking for lung-targeting delivery and tumor vaccination.
Zang J, Zhang J, Mei Y, Xiong Y, Ci T, Feng N. Biomater Sci. 2023 Dec 19;12(1):164-175. doi: 10.1039/d3bm00854a. PMID: 37947455

Eosinophilic Granulomatosis With Polyangiitis Following COVID-19 Vaccination: A Case Report.
Hwang YK, Kwak HH, Yun JE, Kim SH, Chang YS. J Korean Med Sci. 2023 Dec 11;38(48):e382. doi: 10.3346/jkms.2023.38.e382. PMID: 38084026

Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
Law AW, Judy J, Atwell JE, Willis S, Shea KM. Vaccine. 2023 Dec 12;41(51):7632-7640. doi: 10.1016/j.vaccine.2023.11.009. Epub 2023 Nov 21. PMID: 37993354

Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism.
Palacpac NMQ, Ishii KJ, Arisue N, Tougan T, Horii T. Parasitol Int. 2023 Dec 13:102845. doi: 10.1016/j.parint.2023.102845. Online ahead of print. PMID: 38101534

It is worth a shot: vaccine uptake among an immunosuppressed dermatology cohort.
McFeely O, Blasco MC, Wolinska A, Andrawis M, Murphy L, Tobin AM. Clin Exp Dermatol. 2023 Dec 19;49(1):80. doi: 10.1093/ced/llad299. PMID: 37656030

Role of booster vaccines and hybrid immunity against severe COVID-19 outcomes during BA.5 omicron predominance in Thailand.
Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, Chotirosniramit N, Noppakun K, Khwanngern K, Teacharak W, Piamanant P, Chantaklang P, Khammawan P. Hum Vaccin Immunother. 2023 Dec 15;19(3):2291882. doi: 10.1080/21645515.2023.2291882. Epub 2023 Dec 11. PMID: 38083848

Temporal trends in 90-day survival of hospitalised individuals during two years of the COVID-19 pandemic in Denmark.
Leding C, Clausen CL, Roldgaard MS, Benfield T. Infect Dis (Lond). 2024 Jan;56(1):42-51. doi: 10.1080/23744235.2023.2267134. Epub 2023 Dec 18. PMID: 37819262

Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved *Neisseria gonorrhoeae* SliC antigen that blocks human lysozyme.
Martinez FG, Zielke RA, Fougeroux CE, Li L, Sander AF, Sikora AE. Infect Immun. 2023 Dec 12;91(12):e0024523. doi: 10.1128/iai.00245-23. Epub 2023 Nov 2. PMID: 37916806

Antigen spacing on protein nanoparticles influences antibody responses to vaccination.
Ellis D, Dosey A, Boyoglu-Barnum S, Park YJ, Gillespie R, Syeda H, Hutchinson GB, Tsybovsky Y, Murphy M, Pettie D, Matheson N, Chan S, Ueda G, Fallas JA, Carter L, Graham BS, Veesler D, Kanekiyo M, King NP. Cell Rep. 2023 Dec 13;42(12):113552. doi: 10.1016/j.celrep.2023.113552. Online ahead of print. PMID: 38096058

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.
Wu Q, Qian M, Welby S, Guignard A, Rosillon D, Gopala K, Xu Y, Liu K, He Y, Jiang N, Tan Q, Xie J, Zhu T, Wang Q, Pan Y, Zeng R, Yang J, Zhao X, Zhou M, Navarro-Torné A, Yu H, Borys D. Hum Vaccin Immunother. 2023 Dec 15;19(3):2283912. doi: 10.1080/21645515.2023.2283912. Epub 2023 Dec 1. PMID: 38038626

The rLVS Δ*capB*/*iglABC* vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent *Francisella tularensis* strains.
Mlynek KD, Cline CR, Biryukov SS, Toothman RG, Bachert BA, Klimko CP, Shoe JL, Hunter M, Hedrick ZM, Dankmeyer JL, Mou S, Fetterer DP, Qiu J, Lee ED, Cote CK, Jia Q, Horwitz MA, Bozue JA. Hum Vaccin Immunother. 2023 Dec 15;19(3):2277083. doi: 10.1080/21645515.2023.2277083. Epub 2023 Nov 17. PMID: 37975637

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, Cassaniti I. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288282. doi: 10.1080/21645515.2023.2288282. Epub 2023 Dec 1. PMID: 38037900

Outpatient respiratory syncytial virus infections and novel preventive interventions.
Hak SF, Venekamp RP, Wildenbeest JG, Bont LJ. Curr Opin Pediatr. 2023 Dec 13. doi: 10.1097/MOP.0000000000001323. Online ahead of print. PMID: 38085019

Preclinical assessment of an anti-HTLV-1 heterologous DNA/MVA vaccine protocol expressing a multiepitope HBZ protein.
Daian E Silva DSO, Cox LJ, Rocha AS, Lopes-Ribeiro Á, Souza JPC, Franco GM, Prado JLC, Pereira-Santos TA, Martins ML, Coelho-Dos-Reis JGA, Gomes-de-Pinho TM, Da Fonseca FG, Barbosa-Stancioli EF. Virol J. 2023 Dec 19;20(1):304. doi: 10.1186/s12985-023-02264-z. PMID: 38115107

Efficacy of recombinant H5 vaccines delivered in ovo or day of age in commercial broilers against the 2015 U.S. H5N2 clade 2.3.4.4c highly pathogenic avian Influenza virus.
Kapczynski DR, Chrzastek K, Shanmugasundaram R, Zsak A, Segovia K, Sellers H, Suarez DL. Virol J. 2023 Dec 15;20(1):298. doi: 10.1186/s12985-023-02254-1. PMID: 38102683

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.
Twumasi C, Moore S, Sadler R, Jeans S, Varghese S, Turner A, Agarwal G, Larham J, Gray N, Carty O, Barrett J, Bowcock S, Oppermann U, Gamble V, Cook G, Kyriakou C, Drayson M, Basu S, McDonald S, McKinley S, Gooding S, Javaid MK, Ramasamy K. Eur J Haematol. 2023 Dec 20. doi: 10.1111/ejh.14143. Online ahead of print. PMID: 38116695

The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells.
Zurlo M, Gasparello J, Verona M, Papi C, Cosenza LC, Finotti A, Marzaro G, Gambari R. Exp Cell Res. 2023 Dec 15;433(2):113853. doi: 10.1016/j.yexcr.2023.113853. Epub 2023 Nov 7. PMID: 37944576

Examining the effect of COVID-19 vaccines on the menstrual cycle: A study from Turkey.
Toktaş İ, Akelma H, Araç E. Medicine (Baltimore). 2023 Dec 15;102(50):e36638. doi: 10.1097/MD.0000000000036638. PMID: 38115291

Association Between Electronic Device Use at Bedtime and COVID-19 Vaccine-Related Adverse Events During the COVID-19 Pandemic in Korean Adults: A Nationwide Cross-Sectional Population-Based Study.
Kang KW, Kim J, Kim KT, Kim MK, Cho YW; Sleep Epidemiology Committee of the Korean Sleep Research Society. J Korean Med Sci. 2023 Dec 18;38(49):e413. doi: 10.3346/jkms.2023.38.e413. PMID: 38111283

A follow-up study: 6-year cART-free virologic control of rhesus macaques after PD-1-based DNA vaccination against pathogenic $SHIV_{SF162P3CN}$ challenge.
He X, Wong YC, Zhong M, Mo Y, Li B, Yim LY, Li X, Liu W, Du Y, Wang H, Zhang H, Chen Z. Microbiol Spectr. 2023 Dec 12;11(6):e0335023. doi: 10.1128/spectrum.03350-23. Epub 2023 Nov 3. PMID: 37921496

Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study.
Yamada N, Nakatsuka K, Tezuka M, Murata F, Maeda M, Akisue T, Fukuda H, Ono R. Vaccine. 2023 Dec 11:S0264-410X(23)01442-1. doi: 10.1016/j.vaccine.2023.12.009. Online ahead of print. PMID: 38087713

Potential determinants of parental hesitancy to vaccinate their children against COVID-19 infection: a cross-sectional investigation.
Rehman S, Rehman N, Li Z, Zhang Y. Sci Rep. 2023 Dec 13;13(1):22161. doi: 10.1038/s41598-023-47863-6. PMID: 38092826

Elizabethkingia anophelis outer membrane vesicles as a novel vaccine candidate against infection: insights into immune response and potential for passive immunity.
Yang Y-S, Chen H-J, Chen X-C, Tang H-J, Chang F-J, Huang Y-L, Pan Y-L, Kesavan DK, Chen H-Y, Shang H-S, Kuo S-C, Chen T-L, Chiang M-H. mSphere. 2023 Dec 20;8(6):e0040023. doi: 10.1128/msphere.00400-23. Epub 2023 Nov 28. PMID: 38014949

Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context.
Rhodes P, Parry P. Pathol Res Pract. 2023 Dec 12;253:155030. doi: 10.1016/j.prp.2023.155030. Online ahead of print. PMID: 38101158

Bayesian inference for prediction of survival probability in prime-boost vaccination regimes.
Lu Y, Carlin BP, Seaman JW Jr. Stat Med. 2023 Dec 18. doi: 10.1002/sim.9972. Online ahead of print. PMID: 38109707

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
Wolff M, Charpentier P, Canals A, Vial C, Hormazábal J, Cortés J, Silva M. Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.12.035. Online ahead of print. PMID: 38123398

Determinants of compliance to influenza and COVID-19 vaccination in a cohort of solid organ transplant patients in Puglia, Southern Italy (2017-2022).
Stefanizzi P, Bianchi FP, Moscara L, Martinelli A, Di Lorenzo A, Gesualdo L, Simone S, Rendina M, Tafuri S. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266932. doi: 10.1080/21645515.2023.2266932. Epub 2023 Oct 16. PMID: 37842986

Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study.
Ren N, Wang Z, Gao S. Viral Immunol. 2023 Dec 18. doi: 10.1089/vim.2023.0075. Online ahead of print. PMID: 38109058

New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study.
Carrión-Nessi FS, Ascanio LC, Pineda-Arapé AG, Omaña-Ávila ÓD, Mendoza-Millán DL, Romero SR, Almao-Rivero AB, Camejo-Ávila NA, Gebran-Chedid KJ, Rodriguez-Saavedra CM, Freitas-De Nobrega DC, Castañeda SA, Forero-Peña JL, Delgado-Noguera LA, Meneses-Ramírez LK, Cotuá JC, Rodriguez-Morales AJ, Forero-Peña DA, Paniz-Mondolfi AE. BMC Infect Dis. 2023 Dec 14;23(1):877. doi: 10.1186/s12879-023-08898-2. PMID: 38097988

Incidence of non-syndromic orofacial cleft during the COVID-19 pandemic in Saudi Arabia.
Sabbagh HJ, Alghamdi SM, Abdulhameed FD, Alhussain RM, Alrejaye NS, AlGudaibi LY, Sallout BI, Albaqawi BS, Alnamnakani EA, Brekeit LK, Alsharif MT, Alshaikh AB, Almalik MI, Aburiziza AJ, Al Soqih NS, Alqhtani FA, Alghamdi BM, Alraddadi AK, Aljohar AJ, Basri OA, Alamoudi RA. BMC Public Health. 2023 Dec 19;23(1):2538. doi: 10.1186/s12889-023-17270-7. PMID: 38114928

Spatiotemporal variability in socioeconomic inequalities in COVID-19 vaccination in Catalonia, Spain.
Barceló MA, Perafita X, Saez M. Public Health. 2023 Dec 14;227:9-15. doi: 10.1016/j.puhe.2023.11.024. Online ahead of print. PMID: 38101317

COVID-19 vaccine acceptance in the second wave of the pandemic among university students in Ethiopia: application of the health belief model.
Tilahun BD, Adane T, Fentanew M, Alene TD, Abebe GK, Ngusie HS. Ther Adv Infect Dis. 2023 Dec 13;10:20499361231213226. doi: 10.1177/20499361231213226. eCollection 2023 Jan-Dec. PMID: 38107553

SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City.

Soto-Nava M, Dávila-Conn V, Venancio-Rocha JP, García-Esparza P, Tapia-Trejo D, Hernández-Juan R, Zarza-Sánchez E, Murakami-Ogasawara A, Ávila-Ríos S. Virol J. 2023 Dec 15;20(1):300. doi: 10.1186/s12985-023-02261-2. PMID: 38102622

Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients.
Huh K, Kang M, Kim YE, Choi Y, An SJ, Seong J, Go MJ, Kang JM, Jung J. J Infect Dis. 2023 Dec 14:jiad501. doi: 10.1093/infdis/jiad501. Online ahead of print. PMID: 38097377

Computational design of experimentally validated multi-epitopes vaccine against hepatitis E virus: An immunological approach.
Anwar T, Ismail S, Parvaiz F, Abbasi SW, A Al-Abbasi F, M Alghamdi A, Al-Regaiey K, Ul-Haq A, Kaleem I, Bashir S, Waheed Y. PLoS One. 2023 Dec 14;18(12):e0294663. doi: 10.1371/journal.pone.0294663. eCollection 2023. PMID: 38096182

Learning to live with covid-19: testing, vaccination, and mask wearing still play a key part in managing the pandemic.
Arshad Z, Nazareth J, Pareek M. BMJ. 2023 Dec 14;383:2943. doi: 10.1136/bmj.p2943. PMID: 38097251

Who Australasians trusted during COVID-19: lessons from the pandemic response.
August R, Barrett-Young A, Guiney H, Hogan S, Ramrakha S, Poulton R. N Z Med J. 2023 Dec 15;136(1587):85-97. PMID: 38096438

A novel "prime and pull" strategy mediated by the combination of two dendritic cell-targeting designs induced protective lung tissue-resident memory T cells against H1N1 influenza virus challenge.
Wang Z, He Y, Wang W, Tian Y, Ge C, Jia F, Zhang T, Zhang G, Wang M, Gong J, Huang H, Wang J, Shi C, Yang W, Cao X, Zeng Y, Wang N, Qian A, Jiang Y, Yang G, Wang C. J Nanobiotechnology. 2023 Dec 13;21(1):479. doi: 10.1186/s12951-023-02229-y. PMID: 38093320

Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons in Italy.
Lapi F, Marconi E, Fallani E, Salvatore M, Cambiaggi M, Rossi A, Cricelli C. Expert Rev Vaccines. 2024 Jan-Dec;23(1):8-15. doi: 10.1080/14760584.2023.2291184. Epub 2023 Dec 11. PMID: 38078867

Commensal Neisseria cinerea outer membrane vesicles as a platform for the delivery of meningococcal and gonococcal antigens to the immune system.
Piliou S, Farman TA, Marini A, Manoharan S, Mastroeni P. Vaccine. 2023 Dec 18;41(52):7671-7681. doi: 10.1016/j.vaccine.2023.11.034. Epub 2023 Nov 25. PMID: 38008665

Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19.
Ameratunga R, Mears E, Leung E, Snell R, Woon ST, Kelton W, Medlicott N, Jordan A, Abbott W, Steele R, Rolleston W, Longhurst H, Lehnert K. Clin Exp Immunol. 2023 Dec 13;214(3):289-295. doi: 10.1093/cei/uxad096. PMID: 37565297

Tumor nano-lysate activates dendritic cells to evoke a preventative immune response.

Dombroski JA, Fabiano AR, Knoblauch SV, Rowland SJ, Gibson-Corley KN, King MR. J Immunol Methods. 2023 Dec 12;524:113601. doi: 10.1016/j.jim.2023.113601. Online ahead of print. PMID: 38092224

Effect of temperature on the protective efficacy of a live attenuated vaccine against herpesviral haematopoietic necrosis in goldfish.
Saito H, Minami S, Yuguchi M, Shitara A, Kondo H, Kato G, Sano M. J Fish Dis. 2023 Dec 19:e13906. doi: 10.1111/jfd.13906. Online ahead of print. PMID: 38115621

Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
Dawa J, Jalang'o R, Mirieri H, Kalani R, Marwanga D, Lafond KE, Muriuki MM, Ejoi J, Chiguba F, Patta S, Amoth P, Okunga E, Tabu C, Chaves SS, Ebama MS, Muthoka P, Njenga V, Kiptoo E, Jewa I, Mwanyamawi R, Bresee J, Njenga MK, Osoro E, Mecca L, Emukule GO. Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.11.036. Online ahead of print. PMID: 38105140

SARS-CoV-2 Vaccination- or Infection-related Trigeminal Neuralgia/Radiculitis.
Finsterer J. Intern Med. 2023 Dec 18. doi: 10.2169/internalmedicine.3152-23. Online ahead of print. PMID: 38104985

An antibody-free evaluation of an mRNA COVID-19 vaccine.
Branham PJ, Cooper HC, Williamson YM, Najjar FN, Sutton WJH, Pierce-Ruiz CL, Barr JR, Williams TL. Biologicals. 2023 Dec 13;85:101738. doi: 10.1016/j.biologicals.2023.101738. Online ahead of print. PMID: 38096736

Intraneural ganglion cyst of the peroneal nerve occurring after coronavirus disease-19 vaccination: A case report.
Kim N. Hum Vaccin Immunother. 2023 Dec 15;19(3):2265657. doi: 10.1080/21645515.2023.2265657. Epub 2023 Oct 11. PMID: 37818712

Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged ≥ 60 years and younger adults with chronic conditions.
van Roekel C, Labuschagne L, Pijpers J, van Roon A, Smagge B, Ferreira JA, Hahné S, de Melker H. Vaccine. 2023 Dec 14:S0264-410X(23)01471-8. doi: 10.1016/j.vaccine.2023.12.027. Online ahead of print. PMID: 38101955

COVID-19 and flu vaccinations among medical residents in a tertiary hospital in Italy: Correspondence.
Mungmunpuntipantip R, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2268397. doi: 10.1080/21645515.2023.2268397. Epub 2023 Oct 18. PMID: 37849321

Feeding with 4,4'-diaponeurosporene-producing Bacillus subtilis enhances the lactogenic immunity of sow.
Liu P, Zhang Q, Yang C, Wang X, Li Y, Li J, Yang Q. BMC Vet Res. 2023 Dec 19;19(1):280. doi: 10.1186/s12917-023-03846-3. PMID: 38115003

COVID-19 vaccination coverage in hypertensive patients with Omicron infection: Comments on factors.
Daungsupawong H, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285913. doi: 10.1080/21645515.2023.2285913. Epub 2023 Nov 22. PMID: 37991011

Absence of Myocardial Involvement After SARS-CoV-2 Vaccination in Asymptomatic Adolescents.
Párraga R, Real C, García-Lunar I, Pizarro G, Sánchez-González J, Diaz-Munoz R, González-Calvo E, Fernandez-Alvira JM, Martínez-Gómez J, Fernández-Jiménez R. J Cardiovasc Transl Res. 2023 Dec 19. doi: 10.1007/s12265-023-10455-w. Online ahead of print. PMID: 38112908

Protective efficacy of a candidate live attenuated vaccine derived from the SD-R strain of lineage 1 porcine reproductive and respiratory syndrome virus against a lethal challenge with HP-PRRSV HuN4 in piglets.
Zhang H, Li C, Xu H, Gong B, Li W, Guo Z, Xiang L, Sun Q, Zhao J, Peng J, Wang Q, Zhou G, Tang Y-D, An T, Cai X-H, Tian Z-J. Microbiol Spectr. 2023 Dec 12;11(6):e0198423. doi: 10.1128/spectrum.01984-23. Epub 2023 Oct 11. PMID: 37819126

Socioeconomic inequalities in vaccine uptake: A global umbrella review.
Sacre A, Bambra C, Wildman JM, Thomson K, Bennett N, Sowden S, Todd A. PLoS One. 2023 Dec 13;18(12):e0294688. doi: 10.1371/journal.pone.0294688. eCollection 2023. PMID: 38091273

Attitudes and perceptions about COVID-19 vaccination in the population with chronic HIV infection: A systematic review.
Shirley EAL, Francisco JD, Elisabet DS, Teresa GVC, María BM. Health Sci Rep. 2023 Dec 13;6(12):e1653. doi: 10.1002/hsr2.1653. eCollection 2023 Dec. PMID: 38098974

Is BCG vaccination of possums the solution to the Buruli ulcer epidemic in south-eastern Australia?
O'Brien DP, Blasdell K, Muhi S, Marais BJ, Buddle B, McNamara B, Athan E. Med J Aust. 2023 Dec 11;219(11):520-522. doi: 10.5694/mja2.52096. Epub 2023 Sep 7. PMID: 37679050

Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
Portnoy A, Pedersen K, Sy S, Tropé A, Engesaeter B, Kim JJ, Burger EA. Int J Cancer. 2023 Dec 13. doi: 10.1002/ijc.34804. Online ahead of print. PMID: 38088449

Incidence of Omicron Variant Reinfection and Reduction of Reinfection Risk After Coronavirus Disease 2019 Vaccination in Children.
Ikuse T, Aizawa Y, Hasegawa S, Takahashi M, Hayashi T, Kon M, Tamura T, Matsumoto H, Saitoh A. J Pediatric Infect Dis Soc. 2023 Dec 16;12(12):634-637. doi: 10.1093/jpids/piad093. PMID: 37936292

Adjuvant effects of novel water/oil emulsion formulations on immune responses against infectious bronchitis (IB) vaccine in mice.
Alsakini KAMH, Çöven FO, Nalbantsoy A. Biologicals. 2023 Dec 14;85:101736. doi: 10.1016/j.biologicals.2023.101736. Online ahead of print. PMID: 38101004

Intraneural ganglion cyst of the peroneal nerve and coronavirus disease-19 vaccination: Relationship and possible mechanism.
Wiwanitkit S, Wiwanitkit V. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278357. doi: 10.1080/21645515.2023.2278357. Epub 2023 Nov 8. PMID: 37941376

A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.

Ratishvili T, Quach HQ, Haralambieva IH, Suryawanshi YR, Ovsyannikova IG, Kennedy RB, Poland GA. Vaccine. 2023 Dec 16:S0264-410X(23)01468-8. doi: 10.1016/j.vaccine.2023.12.024. Online ahead of print. PMID: 38105139

COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
Arashiro T, Miwa M, Nakagawa H, Takamatsu J, Oba K, Fujimi S, Kikuchi H, Iwasawa T, Kanbe F, Oyama K, Kanai M, Ogata Y, Asakura T, Asami T, Mizuno K, Sugita M, Jinta T, Nishida Y, Kato H, Atagi K, Higaki T, Nakano Y, Tsutsumi T, Doi K, Okugawa S, Ueda A, Nakamura A, Yoshida T, Shimada-Sammori K, Shimizu K, Fujita Y, Okochi Y, Tochitani K, Nakanishi A, Rinka H, Taniyama D, Yamaguchi A, Uchikura T, Matsunaga M, Aono H, Hamaguchi M, Motoda K, Nakayama S, Yamamoto K, Oka H, Tanaka K, Inoue T, Kobayashi M, Fujitani S, Tsukahara M, Takeda S, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Fujino Y, Arima Y, Takeda S, Hashimoto S, Suzuki M. Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.12.033. Online ahead of print. PMID: 38114409

Epidemiological and clinical features of SARS-CoV-2 Omicron variant infection in Quanzhou, Fujian province: a retrospective study.
Zhang H, Weng Z, Zheng Y, Zheng M, Chen W, He H, Ye X, Zheng Y, Xie J, Zheng K, Zhang J, Zhuang X, Su Z, Zhou Y, Yu X. Sci Rep. 2023 Dec 13;13(1):22152. doi: 10.1038/s41598-023-49098-x. PMID: 38092887

Analysis of the yearly transition function in measles disease modeling.
Davila-Payan CS, Hill A, Kayembe L, Alexander JP, Lynch M, Pallas SW. Stat Med. 2023 Dec 15. doi: 10.1002/sim.9951. Online ahead of print. PMID: 38100282

Assessing vaccine-induced immunity against pneumococcus, hepatitis A and B over a 9-year follow-up in pediatric liver transplant recipients: a nationwide retrospective study.
Gold T, Gualtieri R, Posfay-Barbe K, Wildhaber BE, McLin V, Blanchard-Rohner G. Am J Transplant. 2023 Dec 14:S1600-6135(23)00911-5. doi: 10.1016/j.ajt.2023.12.011. Online ahead of print. PMID: 38103788

The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population.
Pires Farias J, Andreata-Santos R, Dalety da Silva Brito R, Silva Souza M, Moreira Costa Fogaça M, Ramos Pinheiro J, Ferreira da Cruz E, Liang W, Simões RdC, Barros Luiz W, Birbrair A, Oliveira Vidal P, Terzi Maricato J, Torres Braconi C, Ferreira LCdS, Ramos Janini LM, Amorim JH. Microbiol Spectr. 2023 Dec 12;11(6):e0285723. doi: 10.1128/spectrum.02857-23. Epub 2023 Nov 1. PMID: 37909777

Enhanced protective immunity against Baylisascaris schroederi infection in mice through a multi-antigen cocktail vaccine approach.
Xiong L, Chen Y, Chen L, Hua R, Shen N, Yang G. Parasitol Res. 2023 Dec 11;123(1):20. doi: 10.1007/s00436-023-08016-w. PMID: 38072876

Comparative protective efficacy of a newly generated live recombinant thermostable highly attenuated vaccine rK148/GVII-F using a single regimen against lethal NDV GVII.1.1.
Abdallah Mouhamed A, Lee J, Kim DH, Song CS. Avian Pathol. 2024 Feb;53(1):14-32. doi: 10.1080/03079457.2023.2263395. Epub 2023 Dec 19. PMID: 38009206

Comprehensive Bibliometric Analysis of Research Articles on Post-Herpetic Neuralgia and Varicella-Zoster Virus: A 20-Year Review(2003-2022).
Zhang H, Zhao Y. J Pain Res. 2023 Dec 11;16:4267-4279. doi: 10.2147/JPR.S432485. eCollection 2023. PMID: 38107370

The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
Wang E, Hagberg O, Malmström PU. PLoS One. 2023 Dec 14;18(12):e0292174. doi: 10.1371/journal.pone.0292174. eCollection 2023. PMID: 38096211

Interpersonal distance perception during the normalization of an pandemic situation: Effects of mask-wearing and vaccination.
Yu X, Chen CH, Xia Z, Wang C, Xiong W. Psych J. 2023 Dec 17. doi: 10.1002/pchj.719. Online ahead of print. PMID: 38105590

Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines.
Faghfuri E. Per Med. 2023 Dec 13. doi: 10.2217/pme-2023-0054. Online ahead of print. PMID: 38088165

COVID-19 vaccination effectiveness in the population of Friuli Venezia Giulia, North-East Italy. Control of bias associated with divergent compliance to policies in a test-negative case-control study.
Rosolen V, Turoldo F, Zamaro G, Del Bianco F, Pezzotti P, Castriotta L, Barbone F. BMC Public Health. 2023 Dec 11;23(1):2476. doi: 10.1186/s12889-023-17244-9. PMID: 38082276

Knowledge and attitudes of community pharmacists on vaccination, barriers and willingness to implement community pharmacy-based vaccination services in Ethiopia.
Tadele S, Demissie BN, Tamiru MT, Tadesse TA. Hum Vaccin Immunother. 2023 Dec 15;19(3):2291243. doi: 10.1080/21645515.2023.2291243. Epub 2023 Dec 18. PMID: 38111325

New-onset Immune-mediated Necrotizing Myopathy and Trigeminal Neuropathy after SARS-CoV-2 mRNA Vaccination in a Patient with Rheumatoid Arthritis and Sjögren's Syndrome.
Tsuzuki Wada T, Yokota K, Inayoshi F, Sakai S, Okumura N, Matsuda M, Osawa I, Araki Y, Funakubo Asanuma Y, Akiyama Y, Mimura T. Intern Med. 2023 Dec 15;62(24):3699-3706. doi: 10.2169/internalmedicine.2551-23. Epub 2023 Oct 13. PMID: 37839879

COVID-19 vaccination of children with refugee backgrounds in Western Australia: a retrospective observational study.
Volkman T, Clarke R, Anstey J, Cherian S. Med J Aust. 2023 Dec 11;219(11):549-550. doi: 10.5694/mja2.52131. Epub 2023 Oct 24. PMID: 37875281

Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).
Efron A, Biolchi A, Sorhouet Pereira C, Tomei S, Campos J, De Belder D, Moscoloni MA, Santos M, Vidal G, Nocita F, Vizzotti C, Pizza M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288389. doi: 10.1080/21645515.2023.2288389. Epub 2023 Dec 18. PMID: 38111094

CpG ODN enhances the efficacy of F protein vaccine against respiratory syncytial virus infection in the upper respiratory tract via CD4$^+$ T cells.

Kawahara E, Yamamoto S, Shibata T, Hirai T, Yoshioka Y. Biochem Biophys Res Commun. 2023 Dec 17;686:149143. doi: 10.1016/j.bbrc.2023.149143. Epub 2023 Oct 26. PMID: 37926041

Use of recombinant malate dehydrogenase (MDH) and superoxide dismutase (SOD) [CuZn] as antigens in indirect ELISA for diagnosis of bovine brucellosis.
Andrade RS, Faria AR, de Andrade HM, de Sousa Bueno Filho JS, Mansur HS, Mansur AAP, Lage AP, Dorneles EMS. J Microbiol Methods. 2023 Dec 13:106874. doi: 10.1016/j.mimet.2023.106874. Online ahead of print. PMID: 38101579

An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
Opriessnig T, Gauger PC, Filippsen Favaro P, Rawal G, Magstadt DR, Digard P, Lee HM, Halbur PG. Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.12.012. Online ahead of print. PMID: 38087714

End stage renal disease in patient with microscopic polyangiitis and atypical hemolytic-uremic syndrome arose 3 weeks after the third dose of anti-SARS-CoV2 vaccine mRNA-1273: A case report with literature revision.
Moronti V, Carubbi F, Sollima L, Piscitani L, Ferri C. Medicine (Baltimore). 2023 Dec 15;102(50):e36560. doi: 10.1097/MD.0000000000036560. PMID: 38115241

SARS-CoV-2 vaccination uptake in six ethnic groups living in Amsterdam, the Netherlands: A registry-based study within the HELIUS cohort.
Campman SL, Boyd A, Coyer L, Schinkel J, Agyemang C, Galenkamp H, Koopman ADM, Chilunga FP, Schim van der Loeff MF, van Houtum L, Leenstra T, Stronks K, Prins M. Prev Med. 2023 Dec 14;178:107822. doi: 10.1016/j.ypmed.2023.107822. Online ahead of print. PMID: 38103796

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine.
Wan Shuaib WMA, Badaruddin IA, Mansor M, Salleh SA, Hassan MR, Lindong S, Samad SN, Othman H. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266931. doi: 10.1080/21645515.2023.2266931. Epub 2023 Oct 13. PMID: 37828861

Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients.
Dalu D, Tarkowski M, Ruggieri L, Cona MS, Gabrieli A, De Francesco D, Fasola C, Ferrario S, Gambaro A, Masedu E, Parma G, Rulli E, De Stradis C, Mavilio D, Calcaterra F, Manoni F, Riva A, La Verde N. Int J Cancer. 2023 Dec 15. doi: 10.1002/ijc.34817. Online ahead of print. PMID: 38100252

Empowering our First Nations workforce: evaluation of a First Nations COVID-19 vaccination training program.
Cowley S, Baigrie K, Panaretto K, Trudgen K, Clements V, Whitehead O, Lacey R. Aust J Prim Health. 2023 Dec 18. doi: 10.1071/PY23027. Online ahead of print. PMID: 38104344

Pharmaceutical and non-pharmaceutical interventions for controlling the COVID-19 pandemic.
Molla J, Farhang-Sardroodi S, Moyles IR, Heffernan JM. R Soc Open Sci. 2023 Dec 20;10(12):230621. doi: 10.1098/rsos.230621. eCollection 2023 Dec. PMID: 38126062

Looking beyond vaccines: Cultural tightness-looseness moderates the relationship between immunization coverage and disease prevention vigilance.
Ma MZ, Chen SX, Wang X. Appl Psychol Health Well Being. 2023 Dec 17. doi: 10.1111/aphw.12519. Online ahead of print. PMID: 38105555

Expression of water-soluble nucleocapsid protein of SARS-CoV-2 and analysis of its immunogenicity.
Wang YB, Wang SW, Jin QY, Chen LP, Zhang FQ, Shi JJ, Yin Y, Fan ZX, Liu XY, Wang LP, Li P. Pol J Vet Sci. 2023 Dec 12;26(4):571-579. doi: 10.24425/pjvs.2023.148277. PMID: 38088301

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. PMID: 38101861

Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects.
Chen J, Xu Y, Zhou M, Xu S, Varley AJ, Golubovic A, Lu RXZ, Wang KC, Yeganeh M, Vosoughi D, Li B. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2309472120. doi: 10.1073/pnas.2309472120. Epub 2023 Dec 7. PMID: 38060560

Endoplasmic Reticulum-Targeting AIE Photosensitizers to Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma.
Miao Z, Li J, Zeng S, Lv Y, Jia S, Ding D, Li W, Liu Q. ACS Appl Mater Interfaces. 2023 Dec 19. doi: 10.1021/acsami.3c14068. Online ahead of print. PMID: 38113527

Impact of COVID-19 on HPV Vaccination Rates in New York City and Long Island.
Bower M, Kothari U, Akerman M, Krilov LR, Fiorito TM. Pediatr Infect Dis J. 2024 Jan 1;43(1):84-87. doi: 10.1097/INF.0000000000004149. Epub 2023 Dec 19. PMID: 37963272

"The needle is already ready to go": communities' and health care professionals' perceptions of routine vaccination in Nunavik, Canada.
Dubé E, Renaud MP, Lyonnais MC, Pelletier C, Fletcher C. Int J Circumpolar Health. 2024 Dec;83(1):2295042. doi: 10.1080/22423982.2023.2295042. Epub 2023 Dec 17. PMID: 38105644

Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, Miyashita A, Okumura K, Nishiyama D, Hirakawa K, Shimura K, Kaneko H, Kiyota M, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03680-1. Online ahead of print. PMID: 38082201

Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore.

Thakkar K, Spinardi J, Kyaw MH, Yang J, Mendoza CF, Ozbilgili E, Taysi B, Dodd J, Yarnoff B, Oh HM. Expert Rev Vaccines. 2024 Jan-Dec;23(1):16-26. doi: 10.1080/14760584.2023.2290931. Epub 2023 Dec 12. PMID: 38047434

SARS-CoV-2 neutralizing antibody titers in maternal blood, umbilical cord blood, and breast milk.
Khalifeh M, Rubin LG, Dayya D, Cerise J, Skinner K, Maloney M, Walworth C, Petropoulos CJ, Wrin T, Chun K, Weinberger B. J Perinatol. 2023 Dec 13. doi: 10.1038/s41372-023-01843-w. Online ahead of print. PMID: 38092879

Viral Respiratory Epidemic Modeling of Societal Segregation Based on Vaccination Status.
Hickey J, Rancourt DG. Cureus. 2023 Dec 14;15(12):e50520. doi: 10.7759/cureus.50520. eCollection 2023 Dec. PMID: 38098739

From admission to vaccination: COVID vaccination patterns and their relationship with hospitalization in trauma patients.
Rafaqat W, Abiad M, Lagazzi E, Argandykov D, Velmahos GC, Hwabejire JO, Parks JJ, Luckhurst CM, Kaafarani HMA, DeWane MP. Surgery. 2023 Dec 18:S0039-6060(23)00890-5. doi: 10.1016/j.surg.2023.11.025. Online ahead of print. PMID: 38114393

The Impact of a Student-Led Health Education Clinic on the Health Literacy and Behaviors of a Rural Community in the State of Pennsylvania, USA.
Short HB, Guare EG, Spanos K, Karakoleva EV, Patel D, Truong N, Huang M, Lehman E, Mendez-Miller M. J Community Health. 2023 Dec 14. doi: 10.1007/s10900-023-01306-5. Online ahead of print. PMID: 38095814

Trends of measles in Tanzania: a five-year review of case-based surveillance data, 2018-2022.
Michael F, Mirambo MM, Misinzo G, Minzi O, Beyanga M, Mujuni D, Kalabamu FS, Nyanda EN, Mwanyika-Sando M, Ndiyo D, Kasonogo R, Ismail A, Bahati A, Hassan F, Kaale E, Chai JJ, Kinyunyi P, Kyesi F, Tinuga F, Mongi D, Salehe A, Muhindi B, Mdachi J, Magodi R, Mwenesi M, Nyaki H, Katembo B, Tenga K, Kasya M, Mwengee W, Mshana SE. Int J Infect Dis. 2023 Dec 18:S1201-9712(23)00809-3. doi: 10.1016/j.ijid.2023.12.007. Online ahead of print. PMID: 38122965

Heteromultimeric sarbecovirus receptor binding domain immunogens primarily generate variant-specific neutralizing antibodies.
Zang T, Osei Kuffour E, Baharani VA, Canis M, Schmidt F, Da Silva J, Lercher A, Chaudhary P, Hoffmann HH, Gazumyan A, Miranda IC, MacDonald MR, Rice CM, Nussenzweig MC, Hatziioannou T, Bieniasz PD. Proc Natl Acad Sci U S A. 2023 Dec 19;120(51):e2317367120. doi: 10.1073/pnas.2317367120. Epub 2023 Dec 14. PMID: 38096415

Targeted mutagenesis of the β-strand DNA binding region of African swine fever virus histone-like protein (pA104R) impairs DNA-binding activity and antibody recognition.
Urbano AC, Ferreira N, Jordão N, Boinas F, Martins C, Ferreira F. Antiviral Res. 2023 Dec 14:105784. doi: 10.1016/j.antiviral.2023.105784. Online ahead of print. PMID: 38103699

Disseminated Bacillus Calmette-Guérin Infection with Rhabdomyolysis, Acute Kidney Injury, and Interstitial Pneumonia after Bacillus Calmette-Guérin Intravesical Instillation Therapy.

Sakurai Y, Furuto Y, Saito T, Namikawa A, Takahashi H, Shibuya Y. Intern Med. 2023 Dec 15;62(24):3707-3712. doi: 10.2169/internalmedicine.1413-22. Epub 2023 May 10. PMID: 37164678

Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an *ad hoc* Italian expert panel.
Girmenia C, Ciceri F, Corradini P, Cuneo A, D'Ancona F, Musto P, Risitano AM, Voso MT, Venditti A, Barosi G. Haematologica. 2023 Dec 14. doi: 10.3324/haematol.2023.284417. Online ahead of print. PMID: 38105723

Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study.
Halford F, Yates K, Clare T, Lopez-Bernal J, Kall M, Allen H. J R Soc Med. 2023 Dec 14:1410768231216332. doi: 10.1177/01410768231216332. Online ahead of print. PMID: 38096898

'Vaccines are for children only'? Some institutional roots of popular scepticism about vaccines for COVID-19 in Sierra Leone.
Mokuwa EY. J Biosoc Sci. 2023 Dec 20:1-19. doi: 10.1017/S0021932023000287. Online ahead of print. PMID: 38116731

Animal-to-Human Dose Translation of ANTHRASIL for Treatment of Inhalational Anthrax in Healthy Adults, Obese Adults, and Pediatric Subjects.
Beliveau M, Rubets I, Bojan D, Hall C, Toth D, Kodihalli S, Kammanadiminti S. Clin Pharmacol Ther. 2023 Dec 11. doi: 10.1002/cpt.3097. Online ahead of print. PMID: 38082506

Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study.
Chen Z, Tang W, Feng N, Lv M, Meng F, Wu H, Zhao Y, Xu H, Dai Y, Xue J, Wang J, Xu A, Zhang B, Chu D, Li Y, Wu D, Dong L, Zhang S, Xue R. EBioMedicine. 2023 Dec 13;99:104912. doi: 10.1016/j.ebiom.2023.104912. Online ahead of print. PMID: 38096688

HPV vaccines induce trained immunity and modulate pro-inflammatory cytokine expression in response to secondary Toll-like receptor stimulations.
Yamaguchi M, Mtali YS, Sonokawa H, Takashima K, Fukushima Y, Kouwaki T, Oshiumi H. Microbiol Immunol. 2023 Dec 17. doi: 10.1111/1348-0421.13108. Online ahead of print. PMID: 38105559

Potential motivators affecting parental intention in COVID-19 vaccination for children aged 6 months to 4 years: Implications for targeted vaccine interventions in Japan.
Kato Y, Shinozaki T, Sugiyama D, Taguchi A, Nagata S. Hum Vaccin Immunother. 2023 Dec 15;19(3):2296737. doi: 10.1080/21645515.2023.2296737. Epub 2023 Dec 19. PMID: 38112133

Effect of influenza vaccination on resting metabolic rate and c-reactive protein concentrations in healthy young adults.
Parker CH, Sadhir S, Swanson Z, McGrosky A, Hinz E, Urlacher SS, Pontzer H. PLoS One. 2023 Dec 15;18(12):e0295540. doi: 10.1371/journal.pone.0295540. eCollection 2023. PMID: 38100425

Antigenic similarities and clinical cross-protection between variant- and classic non-viscous strains of Moritella viscosa in Atlantic salmon in Norway.
Tingbø MG, Haugen Tunheim S, Klevan A, Kamisinska A, Behzaad H, Sandtrø A, Furevik A. Fish Shellfish Immunol. 2023 Dec 18:109306. doi: 10.1016/j.fsi.2023.109306. Online ahead of print. PMID: 38122955

Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern.
O'Neill A, Mantri CK, Tan CW, Saron WAA, Nagaraj SK, Kala MP, Joy CM, Rathore APS, Tripathi S, Wang LF, St John AL. EBioMedicine. 2023 Dec 18;99:104924. doi: 10.1016/j.ebiom.2023.104924. Online ahead of print. PMID: 38113758

Response to Letter to the Editor by Amnuay Kleebayoon, Viroj Wiwanitkit titled: Hesitancy toward vaccination against COVID-19.
Alam Z, Mohamed S, Nauman J, Al-Rifai RH, Ahmed LA, Elbarazi I. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270847. doi: 10.1080/21645515.2023.2270847. Epub 2023 Oct 18. PMID: 37853518

Public perceptions of Ebola vaccines and confidence in health services to treat Ebola, malaria, and tuberculosis: Findings from a cross-sectional household survey in Uganda, 2020.
Koyuncu A, Carter RJ, Musaazi J, Namageyo-Funa A, Carter VM, Lamorde M, Prybylski D, Apondi R, Bakyaita T, Boore AL, Homsy J, Brown VR, Kigozi J, Nabaggala MS, Nakate V, Nkurunziza E, Stowell DF, Walwema R, Olowo A, Jalloh MF. PLOS Glob Public Health. 2023 Dec 19;3(12):e0001884. doi: 10.1371/journal.pgph.0001884. eCollection 2023. PMID: 38113241

COVID-19 vaccination strategies in settings with limited rollout capacity: a mathematical modelling case study in Sierra Leone.
Bilgin GM, Lokuge K, Jabbie E, Munira SL, Glass K. BMC Public Health. 2023 Dec 11;23(1):2466. doi: 10.1186/s12889-023-17374-0. PMID: 38082260

Prolongation of the Menstrual Cycle After Receipt of the Primary Series and Booster Doses of mRNA Coronavirus Disease 2019 (COVID-19) Vaccination.
Hosoya S, Piedvache A, Nakamura A, Nasu R, Hine M, Itoi S, Yokomizo R, Umezawa A, Hiraike O, Koga K, Osuga Y, Narumi S, Morisaki N. Obstet Gynecol. 2023 Dec 14. doi: 10.1097/AOG.0000000000005476. Online ahead of print. PMID: 38061045

[Expert consensus on the management of interstitial lung disease during the COVID-19 epidemic].
Respiratory Council of Chinese Research Hospital Association. Zhonghua Jie He He Hu Xi Za Zhi. 2023 Dec 12;46(12):1204-1218. doi: 10.3760/cma.j.cn112147-20230922-00187. PMID: 38044048

Neutralization Testing-based Immunogenicity Analysis of Recent Prevalent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Sublineages.
Lee EJ, Lee H, O SW, Rhee JE, Kim JM, Kim DJ, Kim IH, No JS, Park AK, Kim JA, Lee CY, Choi YK, Kim EJ. Ann Lab Med. 2023 Dec 13. doi: 10.3343/alm.2023.0256. Online ahead of print. PMID: 38087945

Acute Myocarditis Following COVID-19 Vaccination in a Young Adult.
Singh PV, Izquierdo SA, Ekasi S, Schnepp T, Rabanal C, Olimba LJA, Dickinson M. Cureus. 2023 Dec 15;15(12):e50592. doi: 10.7759/cureus.50592. eCollection 2023 Dec. PMID: 38107210

Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.
Henning L, Anderson M, Triplett C, Smith T, Boyce K, Hendey L, Ridenour A, Eng J, Schaeufele D, Wilson E, Sabourin CL, Adams LE, Babas T, Parish L, Wolfe D. Hum Vaccin Immunother. 2023 Dec 15;19(3):2290345. doi: 10.1080/21645515.2023.2290345. Epub 2023 Dec 19. PMID: 38115181

Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge.
Bartalucci C, Limongelli A, Nicolini LA, Ponzano M, Tigano S, Farinella ST, Carrega G, Malerba G, Magnè F, Balletto E, Giacobbe DR, Riccio G, Cenderello G, Taramasso L, Bruzzone B, Vena A, Di Biagio A, Mikulska M, De Maria A, Dentone C, Bassetti M. J Chemother. 2023 Dec 14:1-8. doi: 10.1080/1120009X.2023.2289269. Online ahead of print. PMID: 38095569

Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.
Tadesse BT, Keddy KH, Rickett NY, Zhusupbekova A, Poudyal N, Lawley T, Osman M, Dougan G, Kim JH, Lee JS, Jeon HJ, Marks F. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S597-S607. doi: 10.1093/cid/ciad562. PMID: 38118013

How to increase COVID-19 vaccination among a population with persistently suboptimal vaccine uptake? Evidence from the North Macedonia mobile vaccination and public health advice caravan.
Serrano-Alarcón M, Mckee M, Palumbo L, Salvi C, Johansen A, Stuckler D. Health Policy. 2023 Dec 12;139:104966. doi: 10.1016/j.healthpol.2023.104966. Online ahead of print. PMID: 38101148

SARS-CoV-2 Exposures at a Large Gathering Event and Acquisition of COVID-19 in the Post-Vaccination Era: A Randomized Trial Is Possible During the Pandemic.
Conly JM, Loeb M. Clin Infect Dis. 2023 Dec 15;77(12):1656-1658. doi: 10.1093/cid/ciad609. PMID: 37797309

The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
O'Neil SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, Sivasankaran A. Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.12.016. Online ahead of print. PMID: 38092610

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
Zhan XY, Chen Y, Zhang X, Shi Q, Chen K, Zeng C, Zhang Y, Liang Y, Li W, Li M, Peng Q, Qin C, Liu T, Xu H, Yuan D, Ye Z, Yan L, Cheng S, Zhang Y, Xu Y, Chen Y, Chen M, Li K, Ke C, Zhu Y, Huang B. Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.12.021. Online ahead of print. PMID: 38103966

The impact of comorbidities and sociodemographic predictors on pneumococcal vaccination coverage in adults with coronary heart disease.
Allihien SM, Ibrahim S, Markson F, Agyeman WY, Fugar S, Kesiena O. Future Cardiol. 2023 Dec 19. doi: 10.2217/fca-2023-0095. Online ahead of print. PMID: 38112281

Mothers' intention to vaccinate their daughters against human papillomavirus in NorthWest Ethiopia, using the theory of planned behavior.

Tilahun S, Wondiye H, Anteneh Yigzaw Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288390. doi: 10.1080/21645515.2023.2288390. Epub 2023 Dec 18. PMID: 38111322

Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model.
Fang C, Fu W, Liu N, Zhao H, Zhao C, Yu K, Liu C, Yin Z, Xu L, Xia N, Wang W, Cheng T. Antiviral Res. 2023 Dec 12;221:105781. doi: 10.1016/j.antiviral.2023.105781. Online ahead of print. PMID: 38097049

"A Friendly Conversation." Developing an eHealth Intervention to Increase COVID-19 Testing and Vaccination Literacy Among Women with Criminal and Legal System Involvement.
Geana MV, Liu P, Pei J, Anderson S, Ramaswamy M. J Health Commun. 2023 Dec 18:1-12. doi: 10.1080/10810730.2023.2293094. Online ahead of print. PMID: 38111197

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models.
Zhang Y, Sun J, Zheng J, Li S, Rao H, Dai J, Zhang Z, Wang Y, Liu D, Chen Z, Ran W, Zhu A, Li F, Yan Q, Wang Y, Yu K, Zhang S, Wang D, Tang Y, Liu B, Cheng L, Huo J, Perlman S, Zhao J, Zhao J. Adv Sci (Weinh). 2023 Dec 17:e2303366. doi: 10.1002/advs.202303366. Online ahead of print. PMID: 38105421

Response to Dr. Somovilla del Saz's letter to the editor regarding "Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies".
Marchand GJ, Masoud A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2264599. doi: 10.1080/21645515.2023.2264599. Epub 2023 Oct 8. PMID: 37806668

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine: Correspondence.
Pan W, Yu D, Shi N, Bao Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2286117. doi: 10.1080/21645515.2023.2286117. Epub 2023 Nov 22. PMID: 37992397

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, McQuarrie LJ, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. J Infect Dis. 2023 Dec 20;228(12):1662-1666. doi: 10.1093/infdis/jiad323. PMID: 37561027

A secreted form of chorismate mutase (Rv1885c) in Mycobacterium bovis BCG contributes to pathogenesis by inhibiting mitochondria-mediated apoptotic cell death of macrophages.
Lee MH, Kim HL, Seo H, Jung S, Kim BJ. J Biomed Sci. 2023 Dec 18;30(1):95. doi: 10.1186/s12929-023-00988-2. PMID: 38110948

Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
Dong C, Ma Y, Zhu W, Wang Y, Kim J, Wei L, Gill HS, Kang SM, Wang BZ. Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.12.039. Online ahead of print. PMID: 38097456

Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses.
Wan J, Wang Z, Wang L, Wu L, Zhang C, Zhou M, Fu ZF, Zhao L. mBio. 2023 Dec 11:e0177523. doi: 10.1128/mbio.01775-23. Online ahead of print. PMID: 38078742

[After the COVID-19 pandemic-Which new vaccinations for adults are available or coming soon?].
Kwetkat A, Leischker A, Endres AS, Heppner HJ. Inn Med (Heidelb). 2023 Dec 18. doi: 10.1007/s00108-023-01640-9. Online ahead of print. PMID: 38108878

Identification of T cell and linear B cell epitopes on African horse sickness virus serotype 4 proteins VP1-1, VP2, VP4, VP7 and NS3.
Faber E, van Schalkwyk A, Ivy Tshilwane S, Van Kleef M, Pretorius A. Vaccine. 2023 Dec 13:S0264-410X(23)01474-3. doi: 10.1016/j.vaccine.2023.12.028. Online ahead of print. PMID: 38097459

Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
Watanabe S, Yoshikawa T, Kaku Y, Kurosu T, Fukushi S, Sugimoto S, Nishisaka Y, Fuji H, Marsh G, Maeda K, Ebihara H, Morikawa S, Shimojima M, Saijo M. PLoS Negl Trop Dis. 2023 Dec 15;17(12):e0011851. doi: 10.1371/journal.pntd.0011851. Online ahead of print. PMID: 38100536

Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery.
Li X, Xiu X, Su R, Ma S, Li Z, Zhang L, Wang Z, Zhu Y, Ma F. Nanotechnology. 2023 Dec 15. doi: 10.1088/1361-6528/ad1644. Online ahead of print. PMID: 38100843

Hopes for bovine TB vaccination in UK.
Loeb J. Vet Rec. 2023 Dec 16;193(12):466. doi: 10.1002/vetr.3767. PMID: 38100700

Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
Cao Z, Yu R, Yuan Q, Ji W, Li X, Gao P, Miao L, Wen X, Suo L. Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.12.014. Online ahead of print. PMID: 38097454

A systematic review reveals that African children of 15-17 years demonstrate low hepatitis B vaccine seroprotection rates.
Muwanda F, Sendagire H, Mboowa G, Kateete DP, Achan B, Mupere E, Kafeero HM, Bagaya BS. Sci Rep. 2023 Dec 13;13(1):22182. doi: 10.1038/s41598-023-49674-1. PMID: 38092870

9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
Stumpf J, Anders L, Siepmann T, Schwöbel J, Karger C, Lindner T, Faulhaber-Walter R, Langer T, Escher K, Anding-Rost K, Seidel H, Hüther J, Pistrosch F, Martin H, Schewe J, Stehr T, Meistring F, Paliege A, Schneider D, Bast I, Steglich A, Gembardt F, Kessel F, Kröger H, Arndt P, Sradnick J, Frank K, Skrzypczyk S, Anft M, Klimova A, Mauer R, Roeder I, Tonn T, Babel N, Hugo C. Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.12.034. Online ahead of print. PMID: 38114410

The clinical features and impact of SARS-CoV-2/COVID-19 infection in children with Cystic Fibrosis (CF): A Qatari experience.

Hamad SG, Kammouh H, Alamri M, Zahraldin K. Qatar Med J. 2023 Dec 12;2023(3):19. doi: 10.5339/qmj.2023.19. eCollection 2023. PMID: 38089672

Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates.
Wu Y, Wu N, Jia X, Wu Y, Zhang X, Liu Y, Hou Y, Shen Y, Li E, Wang W, Wang Y, Chiu S. MedComm (2020). 2023 Dec 15;4(6):e460. doi: 10.1002/mco2.460. eCollection 2023 Dec. PMID: 38107058

MHC-Fine: Fine-tuned AlphaFold for Precise MHC-Peptide Complex Prediction.
Glukhov E, Kalitin D, Stepanenko D, Zhu Y, Nguyen T, Jones G, Simmerling C, Mitchell JC, Vajda S, Dill KA, Padhorny D, Kozakov D. bioRxiv. 2023 Dec 14:2023.11.29.569310. doi: 10.1101/2023.11.29.569310. Preprint. PMID: 38077000

Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine.
Hu X, Xian MY, Wang XF, Zou GQ, Luo R, Peng H, Liu Z. ACS Med Chem Lett. 2023 Nov 20;14(12):1647-1655. doi: 10.1021/acsmedchemlett.3c00154. eCollection 2023 Dec 14. PMID: 38116441

Hybrid use of Raman spectroscopy and artificial neural networks to discriminate Mycobacterium bovis BCG and other Mycobacteriales.
Macgregor-Fairlie M, De Gomes P, Weston D, Rickard JJS, Goldberg Oppenheimer P. PLoS One. 2023 Dec 11;18(12):e0293093. doi: 10.1371/journal.pone.0293093. eCollection 2023. PMID: 38079400

Exploring the reasons behind low COVID-19 vaccination coverage in ethnic minorities-A qualitative study among Arabic-speaking public in Denmark.
Al-Saudi G, Thabit AK, Jose J, Badr AF, Jad L, Kaae S, Jacobsen R. Health Policy. 2023 Dec 13;139:104965. doi: 10.1016/j.healthpol.2023.104965. Online ahead of print. PMID: 38104373

Fast and sensitive differential diagnosis of pseudorabies virus-infected versus pseudorabies virus-vaccinated swine using CRISPR-Cas12a.
Wang H, Li H, Tang B, Ye C, Han M, Teng L, Yue M, Li Y. Microbiol Spectr. 2023 Dec 11:e0261723. doi: 10.1128/spectrum.02617-23. Online ahead of print. PMID: 38078715

Elbow septic arthritis in an infant: an unusual presentation of invasive pneumococcal disease.
Santos P, Gouveia C, Ovídio J, Ribeiro C. BMJ Case Rep. 2023 Dec 12;16(12):e256888. doi: 10.1136/bcr-2023-256888. PMID: 38086576

Case of Exacerbation of Psoriasis Following COVID-19 Vaccination During Treatment with Brodalumab, Which Resulted in Secondary Failure.
Tokuyama M, Mabuchi T. Tokai J Exp Clin Med. 2023 Dec 20;48(4):136-138. PMID: 37981850

SARS-CoV-2 vaccination may improve anxious, insomnia and depressive symptoms among Chinese population aged 18-75 years during the COVID-19 pandemic.
Zhang X, Yue Q, Li M, Wu C, Zhou L, Cai Y, Xu J. Sci Rep. 2023 Dec 12;13(1):22029. doi: 10.1038/s41598-023-48977-7. PMID: 38087031

The "3 Ps" of EmPowerment, Partnership and Protection - Stakeholder Perceptions of Beneficial Outcomes of Engagement in HIV Prevention Trials.
Wilkinson A, Thabethe S, Salzwedel J, Slack C. J Empir Res Hum Res Ethics. 2023 Dec 17:15562646231221259. doi: 10.1177/15562646231221259. Online ahead of print. PMID: 38105464

Elimination of Mother-to-Child Transmission of Hepatitis B Virus in Gulf Cooperation Council Countries: Current Status and Future Prospects.
Al Awaidy S, Tohme RA, Al Romaihi HE, Ezzikouri S, Mahomed O. Am J Trop Med Hyg. 2023 Dec 11:tpmd230587. doi: 10.4269/ajtmh.23-0587. Online ahead of print. PMID: 38081049

Fusion of PspA to detoxified pneumolysin enhances pneumococcal vaccine coverage.
Milani B, Dos Santos TW, Guerra MES, Oliveira S, Goulart C, André GO, Leite LCC, Converso TR, Darrieux M. PLoS One. 2023 Dec 14;18(12):e0291203. doi: 10.1371/journal.pone.0291203. eCollection 2023. PMID: 38096222

Inactivated whole virion vaccine protects K18-hACE2 Tg mice against Omicron SARS-CoV-2 variant via cross-reactive T cells and non-neutralizing antibody responses.
Kruglov AA, Bondareva MA, Gogoleva VS, Semin IK, Astrakhantseva IV, Zvartsev R, Lunin AS, Apolokhov VD, Shustova EY, Volok VP, Ustyugov AA, Ishmukhametov AA, Nedospasov SA, Kozlovskaya LI, Drutskaya MS. Eur J Immunol. 2023 Dec 13:e2350664. doi: 10.1002/eji.202350664. Online ahead of print. PMID: 38088236

SARS-CoV-2 infection in healthcare workers during the first two years of the pandemic at a cancer hospital in Mexico.
Ibanes-Gutierrez C, Martínez-Rivera N, Martin-Onraet A, Rivera-Buendia F, Piñeirua-Menendez A, Villaseñor-Echavarri R, Serrano-Ortega J, Vilar-Compte D. Am J Infect Control. 2023 Dec 14:S0196-6553(23)00834-9. doi: 10.1016/j.ajic.2023.12.004. Online ahead of print. PMID: 38103647

Development of recombinant rotavirus carrying herpes simplex virus 2 glycoprotein D gene based on reverse genetics technology.
Kawamura Y, Komoto S, Fukuda S, Kugita M, Tang S, Patel A, Pieknik JR, Nagao S, Taniguchi K, Krause PR, Yoshikawa T. Microbiol Immunol. 2023 Dec 14. doi: 10.1111/1348-0421.13107. Online ahead of print. PMID: 38098134

Development of a quantum dot-based lateral flow immunoassay strip for rapid and sensitive detection of SARS-CoV-2 neutralizing antibodies.
Wang X, Shao S, Ye H, Li S, Gu B, Tang B. Sci Rep. 2023 Dec 14;13(1):22253. doi: 10.1038/s41598-023-49244-5. PMID: 38097611

Adverse event following immunization or vaccination in children in Minas Gerais: 2015 to 2020.
Camargos SM, Oliveira MLS, Luvisaro BMO, Silva TPRD, Souza JFA, Vimieiro AM, Silva TMRD, Matozinhos FP. Rev Bras Epidemiol. 2023 Dec 11;26:e230056. doi: 10.1590/1980-549720230056. eCollection 2023. PMID: 38088715

Is the level of varicella-zoster virus IgG associated with symptomatic status of genital herpes simplex virus infection? A case-control study.

Palmer BS, Tang A, Winchester S, Atkins M, Barton S, Kelleher P. Int J STD AIDS. 2023 Dec 13:9564624231221172. doi: 10.1177/09564624231221172. Online ahead of print. PMID: 38093464

Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
Vukovich MJ, Raju N, Kgagudi P, Manamela NP, Abu-Shmais AA, Gripenstraw KR, Wasdin PT, Shen X, Dwyer B, Akoad J, Lynch RM, Montefiori DC, Richardson SI, Moore PL, Georgiev IS. J Virol. 2023 Dec 12:e0147823. doi: 10.1128/jvi.01478-23. Online ahead of print. PMID: 38085509

Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X, Zhao R, Tong Z, Guo S, Peng W, Liu K, Li S, Wu L, Tong J, Chai Y, Han P, Wang F, Jia P, Li Z, Zhao X, Li D, Zhang R, Zhang X, Zou W, Li W, Wang Q, Gao GF, Wu Y, Dai L, Gao F. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2314193120. doi: 10.1073/pnas.2314193120. Epub 2023 Dec 18. PMID: 38109549

Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity.
Lineburg KE, Crooks P, Raju J, Le Texier L, Khaledi P, Berry K, Swaminathan S, Panikkar A, Rehan S, Guppy-Coles K, Neller MA, Khanna R, Smith C. iScience. 2023 Nov 14;26(12):108474. doi: 10.1016/j.isci.2023.108474. eCollection 2023 Dec 15. PMID: 38077128

Transcriptomic analysis reveals impact of gE/gI/TK deletions on host response to PRV infection.
Wang X, Li Y, Dong S, Wang C, Wang Y, Zhang H. Virol J. 2023 Dec 19;20(1):303. doi: 10.1186/s12985-023-02265-y. PMID: 38115115

Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV.
Ray S, Narayanan A, Vesterbacka J, Blennow O, Chen P, Gao Y, Gabarrini G, Ljunggren HG, Buggert M, Manoharan L, Chen MS, Aleman S, Sönnerborg A, Nowak P. NPJ Biofilms Microbiomes. 2023 Dec 20;9(1):104. doi: 10.1038/s41522-023-00461-w. PMID: 38123600

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China.
Zhang YY, Xu JW, Liu Y, Qiu W, Bai PN, Zeng Y, Wang Q. Hum Vaccin Immunother. 2023 Dec 15;19(3):2281700. doi: 10.1080/21645515.2023.2281700. Epub 2023 Dec 19. PMID: 38112061

Immunogenic Extracellular Vesicles Derived from Endoplasmic Reticulum-Stressed Tumor Cells: Implications as the Therapeutic Cancer Vaccine.
Han KH, Kim CH, Kim SH, Lee CH, Park M, Bui VD, Duong VH, Kwon S, Ha M, Kang H, Park JH. ACS Nano. 2023 Dec 18. doi: 10.1021/acsnano.3c05645. Online ahead of print. PMID: 38109681

Cationic micelle delivery of a multi-epitope vaccine candidate derived from tumor-associated antigens, causing regression in established CT26 colorectal tumors in mice.
Sabzehei F, Taromchi AH, Ramazani A, Nedaei K, Feizi A, Arsang-Jang S, Danafar H. J Biomed Mater Res A. 2023 Dec 13. doi: 10.1002/jbm.a.37654. Online ahead of print. PMID: 38088136

Evaluate the potential use of TonB-dependent receptor protein as a subunit vaccine against Aeromonas veronii infection in Nile tilapia (Oreochromis niloticus).
Saichuer P, Khrisanapant P, Senapin S, Rattanarojpong T, Somsoros W, Khunrae P, Sangsuriya P. Protein Expr Purif. 2023 Dec 15:106412. doi: 10.1016/j.pep.2023.106412. Online ahead of print. PMID: 38104792

Utilization of Immunization Information Systems (IIS) among independently owned community pharmacies: A national survey.
Meininger C, Ezeala O, McCormick N, Fish H, Beckner J, Ha D, Westrick SC. Vaccine. 2023 Dec 15:S0264-410X(23)01486-X. doi: 10.1016/j.vaccine.2023.12.040. Online ahead of print. PMID: 38103965

Errors and issues in risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
Black T, Meyerowitz-Katz G, Owusu-Boaitey N, Oliver S. Hum Vaccin Immunother. 2023 Dec 15;19(3):2290173. doi: 10.1080/21645515.2023.2290173. Epub 2023 Dec 10. PMID: 38073041

Potential contribution of vaccination uptake to occupational differences in risk of SARS-CoV-2: analysis of the ONS COVID-19 Infection Survey.
Rhodes S, Demou E, Wilkinson J, Cherrie M, Edge R, Gittins M, Katikireddi SV, Kromydas T, Mueller W, Pearce N, van Tongeren M. Occup Environ Med. 2023 Dec 12:oemed-2023-108931. doi: 10.1136/oemed-2023-108931. Online ahead of print. PMID: 38124150

Rate and Cause of Sudden Cardiac Death in the Young During the COVID-19 Pandemic and Vaccination.
De Gaspari M, Fedeli U, Saia M, Carturan E, Pilichou K, Corrado D, Thiene G, Rizzo S, Basso C. Circulation. 2023 Dec 19;148(25):2069-2071. doi: 10.1161/CIRCULATIONAHA.123.066270. Epub 2023 Dec 18. PMID: 38109343

Hollow metal-organic framework-based, stimulator of interferon genes pathway-activating nanovaccines for tumor immunotherapy.
Zhao Y, Song R, Zhang Z, Hu H, Ning W, Duan X, Jiao J, Fu X, Zhang G. Nanoscale Adv. 2023 Dec 8;6(1):72-78. doi: 10.1039/d3na00867c. eCollection 2023 Dec 19. PMID: 38125595

SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: The COmmunity Cohort Study.
Bachelet VC, Silva-Ayarza I, Navarrete MS. Medwave. 2023 Dec 20;23(11):e2787. doi: 10.5867/medwave.2023.11.2787. PMID: 38117982

Oral tolerance to systemic vaccination remains intact without RORγt expression in regulatory T cells.
Potchen NB, Johnson AMF, Hager K, Graham J, Van P, Lyn-Kew KH, Warrier L, Talavera IC, Lund JM, Kublin JG. iScience. 2023 Nov 22;26(12):108504. doi: 10.1016/j.isci.2023.108504. eCollection 2023 Dec 15. PMID: 38125026

Effective measures to improve influenza vaccination coverage among healthcare workers during and after COVID-19.
Jia W, Zhang X, Sun R, Li P, Wang D, Song C. Hum Vaccin Immunother. 2023 Dec 15;19(3):2289243. doi: 10.1080/21645515.2023.2289243. Epub 2023 Dec 6. PMID: 38053367

Painful proctitis associated with anorectal mpox, syphilis, HSV, LGV, gonorrhoea and *Mycoplasma genitalium* in a person living with virologically suppressed HIV and vaccinated against mpox.
Huang ZY, Cornelisse VJ, Burdon RM. Sex Transm Infect. 2023 Dec 14:sextrans-2023-056033. doi: 10.1136/sextrans-2023-056033. Online ahead of print. PMID: 38124214

Response to Letters regarding "Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis".
Kitano T, Dudley MZ, Engineer L, Thompson DA, Salmon DA. Am J Epidemiol. 2023 Dec 19:kwad243. doi: 10.1093/aje/kwad243. Online ahead of print. PMID: 38115177

Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform.
Park J, Champion JA. ACS Nano. 2023 Dec 12. doi: 10.1021/acsnano.3c07669. Online ahead of print. PMID: 38084728

Re-Routing Persuasion: How Conversion Messages Boost Attitudes and Reduce Resistance Among Holdouts Unvaccinated for COVID-19.
Conlin J, Kumble S, Baker M, Shen F. Health Commun. 2023 Dec 11:1-16. doi: 10.1080/10410236.2023.2289280. Online ahead of print. PMID: 38083877

Successful management of severe generalized tetanus in a 23-year man with phenobarbital adjuvant: A case report.
Ahmadi A, Karimpour-Razkenari E, Ansari R, Marashi M, Sharifnia H, Najafi A, Mojtahedzadeh M. Clin Case Rep. 2023 Dec 15;11(12):e8286. doi: 10.1002/ccr3.8286. eCollection 2023 Dec. PMID: 38107081

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series.
Thomas B, Moskow J, Garza M, Warren B, Abraham B, Glassner K. ACG Case Rep J. 2023 Dec 15;10(12):e01221. doi: 10.14309/crj.0000000000001221. eCollection 2023 Dec. PMID: 38107605

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Ratcliffe H, Tiley KS, Longet S, Tonry C, Roarty C, Watson C, Amirthalingam G, Vichos I, Morey E, Douglas NL, Marinou S, Plested E, Aley PK, Galiza E, Faust SN, Hughes S, Murray C, Roderick MR, Shackley F, Oddie S, Lee TWR, Turner DPJ, Raman M, Owens S, Turner PJ, Cockerill H, Lopez Bernal J, Ijaz S, Poh J, Shute J, Linley E, Borrow R, Hoschler K, Brown KE, Carroll MW, Klenerman P, Dunachie SJ, Ramsay M, Voysey M, Waterfield T, Snape MD. iScience. 2023 Nov 21;26(12):108500. doi: 10.1016/j.isci.2023.108500. eCollection 2023 Dec 15. PMID: 38089581

Popular Among Distrustful Youth? Social Media Influencers' Communication About COVID-19 and Young People's Risk Perceptions and Vaccination Intentions.
Schmuck D, Harff D. Health Commun. 2023 Dec 15:1-14. doi: 10.1080/10410236.2023.2286408. Online ahead of print. PMID: 38099315

Paediatric COVID-19 vaccination and parental decision: Arising issue for discussion.
Kleebayoon A, Wiwanitkit V. Child Care Health Dev. 2023 Dec 12. doi: 10.1111/cch.13215. Online ahead of print. PMID: 38085125

Establishment of serological neutralizing tests using pseudotyped viruses for comprehensive detection of antibodies against all 18 lyssaviruses.
Inoue Y, Kaku Y, Harada M, Ishijima K, Kuroda Y, Tatemoto K, Virhuez-Mendoza M, Nishino A, Yamamoto T, Park ES, Inoue S, Matsuu A, Maeda K. J Vet Med Sci. 2023 Dec 12. doi: 10.1292/jvms.23-0463. Online ahead of print. PMID: 38092389

A case of vitiligo after COVID-19 vaccination: a possible role of thymic dysfunction.
Kuznetsov D, Kalyuzhin O, Mironov A, Neschisliaev V, Kuznetsova A. J Zhejiang Univ Sci B. 2023 Dec 15;24(12):1141-1150. doi: 10.1631/jzus.B2300025. PMID: 38057270

COVID-19 Vaccination in Patients Receiving Dialysis: Does Vaccine Dose Matter?
Singh N, Argyropoulos CP. Clin J Am Soc Nephrol. 2023 Dec 19. doi: 10.2215/CJN.0000000000000386. Online ahead of print. PMID: 38113178

Influenza Vaccination in Pregnancy-Rolling Up Sleeves for Pregnant Persons and Infants.
Zuber MJ, Miller A, Poehling KA. JAMA Pediatr. 2023 Dec 18. doi: 10.1001/jamapediatrics.2023.5630. Online ahead of print. PMID: 38109106

Extending the Knowledge Gap Hypothesis to Narrative Persuasion: Parents' Information-Seeking Intention and Learning About Adolescent Children's Covid-19 Vaccination.
Lee TK, Kim HK. Health Educ Behav. 2023 Dec 11:10901981231216742. doi: 10.1177/10901981231216742. Online ahead of print. PMID: 38078454

Pfs230 Domain 7 is targeted by a potent malaria transmission-blocking monoclonal antibody.
Inklaar MR, de Jong RM, Bekkering ET, Nagaoka H, Fennemann FL, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Stoter R, King CR, Proellochs NI, Bousema T, Takashima E, Tsuboi T, Jore MM. NPJ Vaccines. 2023 Dec 12;8(1):186. doi: 10.1038/s41541-023-00784-x. PMID: 38086855

Vaccines reduce the risk of long COVID in children.
Hall S. Nature. 2023 Dec 20. doi: 10.1038/d41586-023-04032-z. Online ahead of print. PMID: 38114835

The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all *Orthocoronavirinae* genera.
Singh G, Abbad A, Kleiner G, Srivastava K, Gleason C; PARIS Study Group; Carreño JM, Simon V, Krammer F. mBio. 2023 Dec 19:e0225023. doi: 10.1128/mbio.02250-23. Online ahead of print. PMID: 38112467

Ocular Adverse Events After Influenza Vaccination in Older Adults: Self-Controlled Case Series Using a Large Database in Japan.
Hashimoto Y, Iwagami M, Yamana H, Ono S, Takeuchi Y, Michihata N, Uemura K, Aihara M, Yasunaga H. Ophthalmic Epidemiol. 2023 Dec 12:1-6. doi: 10.1080/09286586.2023.2289990. Online ahead of print. PMID: 38085757

Structural Diversity of Tick-Borne Encephalitis Virus Particles in the Inactivated Vaccine Based on Strain Sofjin.

Moiseenko A, Zhang Y, Vorovitch MF, Ivanova AL, Liu Z, Osolodkin DI, Egorov AM, Ishmukhametov AA, Sokolova OS. Emerg Microbes Infect. 2023 Dec 11:2290833. doi: 10.1080/22221751.2023.2290833. Online ahead of print. PMID: 38073510

Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles.
Shafieichaharberoud F, Lang S, Whalen C, Rivera Quiles C, Purcell L, Talbot C, Wang P, Norton EB, Mazei-Robison M, Sulima A, Jacobson AE, Rice KC, Matyas GR, Huang X. Bioconjug Chem. 2023 Dec 19. doi: 10.1021/acs.bioconjchem.3c00415. Online ahead of print. PMID: 38113481

Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study.
Millán-Pascual J, Valero-López G, Iniesta-Martinez F, Hellin-Gil MF, Jimenez-Veiga J, López-Tovar IA, Morales-Ortiz A, Meca-Lallana JE. Neurol Ther. 2023 Dec 14. doi: 10.1007/s40120-023-00572-8. Online ahead of print. PMID: 38097868

Special focus on the association between COVID-19 vaccination and Raynaud's phenomenon in autoimmune disease.
Bao Z, Liu J, Yu D. Hum Vaccin Immunother. 2023 Dec 15;19(3):2295077. doi: 10.1080/21645515.2023.2295077. Epub 2023 Dec 18. PMID: 38109761

Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan.
Namba M, Kaneda Y, Iida M. Ther Adv Vaccines Immunother. 2023 Dec 11;11:25151355231216408. doi: 10.1177/25151355231216408. eCollection 2023. PMID: 38090642

Milestone in infant health: unveiling the RSV vaccine's shielding effect for newborns.
Nazir Z, Habib A, Ali T, Singh A, Zulfiqar E, Haque MA. Int J Surg. 2023 Dec 14. doi: 10.1097/JS9.0000000000001002. Online ahead of print. PMID: 38100625

Inhaled COVID vaccines stop infection in its tracks in monkey trials.
Callaway E. Nature. 2023 Dec 19. doi: 10.1038/d41586-023-04003-4. Online ahead of print. PMID: 38114832

Trends in HPV Vaccination Before Age 13 Years in the US National Immunization Survey-Teen.
White JL, Grabowski MK, Quinn TC, Tobian AAR, Patel EU. JAMA Pediatr. 2023 Dec 18:e235238. doi: 10.1001/jamapediatrics.2023.5238. Online ahead of print. PMID: 38109082

Barriers to human papilloma virus Vaccination for Patients With Sickle Cell Disease and Childhood Cancer Survivors: Comment.
Daungsupawong H, Wiwanitkit V. J Pediatr Hematol Oncol. 2023 Dec 18. doi: 10.1097/MPH.0000000000002799. Online ahead of print. PMID: 38113268

Correction: *Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases.*
[No authors listed] J Neurointerv Surg. 2023 Dec 19;16(1):e4. doi: 10.1136/neurintsurg-2021-018238corr1. PMID: 38114330

COVID-19 breakthrough infections and sleep disorders: A population-based propensity matched analysis.

Punj M, Desai A, Hashash JG, Farraye FA, Castillo PR. Sleep Med X. 2023 Oct 12;6:100089. doi: 10.1016/j.sleepx.2023.100089. eCollection 2023 Dec 15. PMID: 37881352

U.S. Vietnamese parents' trusted sources of information and preferences for intervention messaging about HPV vaccination: A mixed methods study.
Vu M, Berg CJ, Pham NT, Tiro JA, Escoffery C, Spring B, Bednarczyk RA, Ta D, Kandula NR. PEC Innov. 2023 Jul 6;3:100189. doi: 10.1016/j.pecinn.2023.100189. eCollection 2023 Dec 15. PMID: 37521956

In silico design of a trivalent multi-epitope global-coverage vaccine-candidate protein against influenza viruses: evaluation by molecular dynamics and immune system simulation.
Jalalvand A, Fotouhi F, Bahramali G, Bambai B, Farahmand B. J Biomol Struct Dyn. 2023 Dec 13:1-17. doi: 10.1080/07391102.2023.2292293. Online ahead of print. PMID: 38088331

Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach.
Choi MJ, Na Y, Hyun HJ, Nham E, Yoon JG, Seong H, Seo YB, Choi WS, Song JY, Kim DW, Kim YE, Jung J, Cheong HJ. Clin Microbiol Infect. 2023 Dec 13:S1198-743X(23)00600-6. doi: 10.1016/j.cmi.2023.12.010. Online ahead of print. PMID: 38101473

Health-care policies during the COVID-19 pandemic in Mexico: A continuous case of heterogeneous, reactive, and unequal response.
Bautista-Reyes D, Werner-Sunderland J, Aragón-Gama AC, Duran JRC, Medina KDC, Urbina-Fuentes M, Bautista-González E. Health Policy Open. 2023 Aug 2;5:100100. doi: 10.1016/j.hpopen.2023.100100. eCollection 2023 Dec 15. PMID: 37662095

The first autopsy case of Epstein-Barr virus-positive marginal zone lymphoma that deteriorated after COVID-19 vaccination.
Wang Z, Muto R, Miyoshi H, Aoki M, Uesugi N, Murayama H, Masutani K, Hamasaki M. Pathol Int. 2023 Dec 20. doi: 10.1111/pin.13398. Online ahead of print. PMID: 38116849

Childhood community-acquired pneumonia.
Meyer Sauteur PM. Eur J Pediatr. 2023 Dec 19. doi: 10.1007/s00431-023-05366-6. Online ahead of print. PMID: 38112800

Managing acute COVID-19 in immunocompromised pediatric patients.
Mercolini F, Abram N, Cesaro S. Expert Rev Clin Immunol. 2023 Dec 15. doi: 10.1080/1744666X.2023.2295982. Online ahead of print. PMID: 38099388

Comparison of the test-negative design and cohort design with explicit target trial emulation for evaluating Covid-19 vaccine effectiveness.
Li G, Gerlovin H, Figueroa Muñiz MJ, Wise JK, Madenci AL, Robins JM, Aslan M, Cho K, Gaziano JM, Lipsitch M, Casas JP, Hernán MA, Dickerman BA. Epidemiology. 2023 Dec 18. doi: 10.1097/EDE.0000000000001709. Online ahead of print. PMID: 38109485

Beyond the waves: Unraveling pandemic outcomes with genomic insights and immunity analysis - Evidence from 14 countries.

Jang YA, Wu HY, Hsu YT, Chen YK, Chiou HY, Sytwu HK, Chen WJ, Tsou HH. Prev Med. 2023 Dec 11:107820. doi: 10.1016/j.ypmed.2023.107820. Online ahead of print. PMID: 38092329

Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
Yildirim I, Lapidot R, Shaik-Dasthagirisaheb YB, Hinderstein S, Lee H, Klevens M, Grant L, Arguedas Mohs AG, Cane A, Madoff L, Johnson H, Ivanof C, Burns M, Pelton S. Pediatrics. 2023 Dec 13:e2023063039. doi: 10.1542/peds.2023-063039. Online ahead of print. PMID: 38087952

An epitope encoded by uORF of *RNF10* elicits a therapeutic anti-tumor immune response.
Zeng L, Zheng W, Zhang J, Wang J, Ji Q, Wu X, Meng Y, Zhu X. Mol Ther Oncolytics. 2023 Oct 19;31:100737. doi: 10.1016/j.omto.2023.100737. eCollection 2023 Dec 19. PMID: 38020063

Phospholipid scramblase 1 is involved in immunogenic cell death and contributes to dendritic cell-based vaccine efficiency to elicit antitumor immune response in vitro.
Montico B, Nigro A, Lamberti MJ, Martorelli D, Mastorci K, Ravo M, Giurato G, Steffan A, Dolcetti R, Casolaro V, Dal Col J. Cytotherapy. 2023 Dec 14:S1465-3249(23)01127-1. doi: 10.1016/j.jcyt.2023.11.014. Online ahead of print. PMID: 38099895

TLR4 sensing of IsdB of *Staphylococcus aureus* induces a proinflammatory cytokine response via the NLRP3-caspase-1 inflammasome cascade.
Gonzalez JJl, Hossain MF, Neef J, Zwack EE, Tsai C-M, Raafat D, Fechtner K, Herzog L, Kohler TP, Schlüter R, Reder A, Holtfreter S, Liu GY, Hammerschmidt S, Völker U, Torres VJ, van Dijl JM, Lillig CH, Bröker BM, Darisipudi MN. mBio. 2023 Dec 19:e0022523. doi: 10.1128/mbio.00225-23. Online ahead of print. PMID: 38112465

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
Wynne C, Balgos A, Li J, Hamilton P, Tirador L, Jaen AM, Mo C, Yue Z, Ma Y, Wang Q, Wen R, Yao Z, Yu J, Yao W, Zhang J, Zheng H, Hong K, Zhu F, Liu Y. Infect Dis Ther. 2023 Dec 16. doi: 10.1007/s40121-023-00896-w. Online ahead of print. PMID: 38103161

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.
Narayanasamy S, Curtis LH, Hernandez AF, Woods CW, Moody MA, Sulkowski M, Turbett SE, Baden LR, Gulick RM, Pau AK, Adam SJ, Marks P, Stockbridge NL, Dobbins JR, Krofah E, Leav B, Pang P, Roessig L, Vedin O, Waldstreicher J, Berman SC, Cremisi H, Schofield L, Gandhi RT, Naggie S. Clin Infect Dis. 2023 Dec 15;77(12):1635-1643. doi: 10.1093/cid/ciad418. PMID: 37435958

Honduras HIV cohort: HLA class I and CCR5-Δ32 profiles and their associations with HIV disease outcome.
Valenzuela-Ponce H, Carbajal C, Soto-Nava M, Tapia-Trejo D, García-Morales C, Murillo W, Lorenzana I, Reyes-Terán G, Ávila-Ríos S. Microbiol Spectr. 2023 Dec 12;11(6):e0161323. doi: 10.1128/spectrum.01613-23. Epub 2023 Nov 14. PMID: 37962394

Wealth-based inequity in full child vaccination coverage: An experience from Mali, Bangladesh, and South Africa. A multilevel poison regression.
Birhanu F, Yitbarek K. PLoS One. 2023 Dec 20;18(12):e0293522. doi: 10.1371/journal.pone.0293522. eCollection 2023. PMID: 38117824

Risk of stroke within 3, 7, 14, 21 and 30 days after influenza vaccination in Alberta, Canada: A population-based study.
Tanaka K, Demchuk AM, Malo S, Hill MD, Holodinsky JK. Eur J Neurol. 2023 Dec 20. doi: 10.1111/ene.16172. Online ahead of print. PMID: 38117538

Connecting the dots: Human papillomavirus vaccination gaps and the upsurge of oral human papillomavirus infection in United States of America.
Farhan K, Imam SI, Tariq MB, Ahmed A, Suheb MK, Akilimali A. Int J Gynaecol Obstet. 2023 Dec 12. doi: 10.1002/ijgo.15306. Online ahead of print. PMID: 38084756

A data-driven epidemic model with human mobility and vaccination protection for COVID-19 prediction.
Li R, Song Y, Qu H, Li M, Jiang GP. J Biomed Inform. 2023 Dec 12;149:104571. doi: 10.1016/j.jbi.2023.104571. Online ahead of print. PMID: 38092247

[Postexposure prophylaxis after bite of a broad-winged bat with evidence of European bat lyssavirus 1 (EBLV-1)].
Fasse J, Trawinski H, Hardt M, Lübbert C. Inn Med (Heidelb). 2023 Dec 15. doi: 10.1007/s00108-023-01638-3. Online ahead of print. PMID: 38100072

Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses.
Dosey A, Ellis D, Boyoglu-Barnum S, Syeda H, Saunders M, Watson MJ, Kraft JC, Pham MN, Guttman M, Lee KK, Kanekiyo M, King NP. Cell Rep. 2023 Dec 13;42(12):113553. doi: 10.1016/j.celrep.2023.113553. Online ahead of print. PMID: 38096052

Pediatric Diabetes Mellitus Hospitalizations and COVID-19 Pandemic Response Measures.
Shimony H, Miller L, Reich P, Banull NR, Burch M, Bryan M, María Arbeláez A. Diabetes Res Clin Pract. 2023 Dec 16:111060. doi: 10.1016/j.diabres.2023.111060. Online ahead of print. PMID: 38110121

Cost-effectiveness of HEV vaccination strategy.
Kato H. Hepatol Res. 2023 Dec 13. doi: 10.1111/hepr.14000. Online ahead of print. PMID: 38091250

MS2 Virus-like Particles as a Versatile Peptide Presentation Platform: Insights into the Deterministic Abilities for Accommodating Heterologous Peptide Lengths.
Dang M, Wu LJ, Zhang SR, Zhu JR, Hu YZ, Yang CX, Zhang XY. ACS Synth Biol. 2023 Dec 15;12(12):3704-3715. doi: 10.1021/acssynbio.3c00503. Epub 2023 Nov 9. PMID: 37946498

Optimizing environmental viral surveillance: bovine serum albumin increases RT-qPCR sensitivity for high pathogenicity avian influenza H5Nx virus detection from dust samples.
Bessière P, Hayes B, Filaire F, Lèbre L, Vergne T, Pinson M, Croville G, Guérin J-L. Microbiol Spectr. 2023 Dec 12;11(6):e0305523. doi: 10.1128/spectrum.03055-23. Epub 2023 Nov 20. PMID: 37982626

A *Salmonella* Pullorum outbreak with neurological signs in adult layers and outbreak investigation using whole genome sequencing.
Molenaar RJ, Dijkman R, Ter Veen C, Heuvelink A, van Kaam F, Augustijn M, Feberwee A. Avian Pathol. 2024 Feb;53(1):44-55. doi: 10.1080/03079457.2023.2268027. Epub 2023 Dec 19. PMID: 37800359

Expanded vaccination practice in 2-year-old children and maternal knowledge on expanded vaccination in Tien Giang, Vietnam.
Nguyen GLN, Nguyen GVT, Nguyen MTN, Nguyen DV, Phan NTT, Tran V, Pham TT, Le MH, Nguyen DT, Pham TT. Ann Ig. 2023 Dec 14. doi: 10.7416/ai.2023.2590. Online ahead of print. PMID: 38085560

Anticipatory declarations for vaccination of the newborn.
Wheeler R. Arch Dis Child. 2023 Dec 13:archdischild-2023-326329. doi: 10.1136/archdischild-2023-326329. Online ahead of print. PMID: 38123942

[Congenital malformations of the brain misinterpreted as sequelae of poliomyelitis].
Djukic M, Eiffert H, Gossner J, Nau R. Z Gerontol Geriatr. 2023 Dec 18. doi: 10.1007/s00391-023-02264-2. Online ahead of print. PMID: 38108898

MBPCA-OS: an exploratory multiblock method for variables of different measurement levels. Application to study the immune response to SARS-CoV-2 infection and vaccination.
Paries M, Vigneau E, Huneau A, Lantz O, Bougeard S. Int J Biostat. 2023 Dec 13. doi: 10.1515/ijb-2023-0062. Online ahead of print. PMID: 38083810

Correction to: Vaccines and variants: an update on cardiopulmonary assessment prior to return to high-hazard occupations following COVID-19.
[No authors listed] Eur J Prev Cardiol. 2023 Dec 13:zwad382. doi: 10.1093/eurjpc/zwad382. Online ahead of print. PMID: 38092465

A thorny case of spastic paralysis.
Lines T, Ashok A, Khan SF, Loftus MJ. Med J Aust. 2023 Dec 11;219(11):526-527. doi: 10.5694/mja2.52164. Epub 2023 Nov 12. PMID: 37952612

Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis.
Niu J, Jiang W, Fan D, Li X, Zhou W, Zhang H. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269794. doi: 10.1080/21645515.2023.2269794. Epub 2023 Oct 26. PMID: 37885280

[Anogenital warts-An update].
Chromy D, Silling S, Wieland U, Kreuter A. Dermatologie (Heidelb). 2023 Dec 18. doi: 10.1007/s00105-023-05282-8. Online ahead of print. PMID: 38108864

Vaccine appointments and records will be available through NHS app, says NHS England.
Mahase E. BMJ. 2023 Dec 14;383:2945. doi: 10.1136/bmj.p2945. PMID: 38097257

Healthcare Workers' Vulnerability to SARS-CoV-2 in Western Romania: A Study on Incidence and Risk Factors for Non-Vaccination and Reinfection [Letter].
Fikri E. Int J Gen Med. 2023 Dec 11;16:5799-5800. doi: 10.2147/IJGM.S452489. eCollection 2023. PMID: 38106973

Top five unanswered questions in fungal cell surface research.
Gow NAR, Casadevall A, Fang W. Cell Surf. 2023 Nov 3;10:100114. doi: 10.1016/j.tcsw.2023.100114. eCollection 2023 Dec 15. PMID: 38024560

NK cells propagate T cell immunity following in situ tumor vaccination.
Jin WJ, Jagodinsky JC, Vera JM, Clark PA, Zuleger CL, Erbe AK, Ong IM, Le T, Tetreault K, Berg T, Rakhmilevich AL, Kim K, Newton MA, Albertini MR, Sondel PM, Morris ZS. Cell Rep. 2023 Dec 13;42(12):113556. doi: 10.1016/j.celrep.2023.113556. Online ahead of print. PMID: 38096050

Erythema nodosum after COVID-19 vaccine associated with varicella-zoster virus reactivation.
Kobayashi E, Ohyama M, Yamazaki Y, Mizukawa Y. Int J Dermatol. 2023 Dec 13. doi: 10.1111/ijd.16974. Online ahead of print. PMID: 38093470

Combined Osteopontin Blockade and Type 2 Classical Dendritic Cell Vaccination as Effective Synergetic Therapy for Conjunctival Melanoma.
Peil J, Vossen C, Bock F, Clahsen T, Schiller P, Heindl LM, Bosch JJ, Wunderlich FT, Cursiefen C, Schlereth SL. J Immunol. 2023 Dec 15:ji2300063. doi: 10.4049/jimmunol.2300063. Online ahead of print. PMID: 38099710

Association of a coronavirus disease 2019 (COVID-19) vaccine booster with control of a COVID-19 outbreak in a long-term care facility in Switzerland, November to December 2021.
Leiblein TW, Winistörfer A, Seiler K, Hauri R, Sommerstein R. Infect Control Hosp Epidemiol. 2023 Dec 13:1-3. doi: 10.1017/ice.2023.240. Online ahead of print. PMID: 38086644

Damage-associated cellular markers in the clinical and pathogenic profile of Vaccine-induced Immune Thrombotic Thrombocytopenia.
Abrams ST, Du M, Shaw RJ, Johnson C, McGuinness D, Schofield J, Yong J, Turtle L, Nicolson PL, Moxon C, Wang G, Toh CH. J Thromb Haemost. 2023 Dec 14:S1538-7836(23)00873-5. doi: 10.1016/j.jtha.2023.12.008. Online ahead of print. PMID: 38103733

Revisiting a risk benefit analysis of mRNA COVID-19 vaccines during the omicron era.
Lataster R. Am J Epidemiol. 2023 Dec 13:kwad242. doi: 10.1093/aje/kwad242. Online ahead of print. PMID: 38100362

Prevalence, predictors and reasons for COVID-19 vaccine hesitancy: Comment.
Daungsupawong H, Wiwanitkit V. Health Policy. 2023 Dec 11;139:104964. doi: 10.1016/j.healthpol.2023.104964. Online ahead of print. PMID: 38113539

A penile edema induced by mRNA SARS-CoV-2 vaccine.
Russo G, Laffitte E. Ital J Dermatol Venerol. 2023 Dec 12. doi: 10.23736/S2784-8671.23.07693-4. Online ahead of print. PMID: 38088125

Single and repeat-dose toxicity and local tolerance assessment of newly developed oil emulsion adjuvant formulations for veterinary purposes.
Alsakini KAMH, Sanci E, Buhur A, Yavasoglu A, Karabay Yavasoglu NÜ, Nalbantsoy A. Drug Chem Toxicol. 2023 Dec 13:1-12. doi: 10.1080/01480545.2023.2291985. Online ahead of print. PMID: 38093608

Molecular epidemiology of infectious bursal disease virus in the Near East and Persian Gulf regions.
Legnardi M, Poletto F, Alam S, Cherfane A, Le-Tallec B, Franzo G, Tucciarone CM, Lupini C, Pasotto D, Cecchinato M. Avian Pathol. 2024 Feb;53(1):56-67. doi: 10.1080/03079457.2023.2270531. Epub 2023 Dec 19. PMID: 37823857

Intramuscular but not nebulized administration of a mRNA vaccine against Rhodococcus equi stimulated humoral immune responses in neonatal foals.
Legere RM, Poveda C, Ott JA, Bray JM, Villafone EG, Silveira BPD, Kahn SK, Martin CL, Mancino C, Taraballi F, Criscitiello MF, Berghman L, Bordin AI, Pollet J, Cohen ND. Am J Vet Res. 2023 Dec 11:1-12. doi: 10.2460/ajvr.23.09.0208. Online ahead of print. PMID: 38056076

Monoclonal antibodies for the prevention of *Plasmodium falciparum* malaria: a multi-target approach?
Lampejo T. Infect Dis (Lond). 2024 Jan;56(1):73-77. doi: 10.1080/23744235.2023.2274897. Epub 2023 Dec 18. PMID: 37921336

Recording and Reporting of Antimicrobial Resistance (AMR) Priority Variables and Its Implication on Expanding Surveillance Sites in Nepal: A CAPTURA Experience.
Maharjan S, Gallagher P, Gautam M, Joh HS, Sujan MJ, Aboushady AT, Kwon SY, Gautam S, Upadhyaya MK, Jha R, Acharya J, MacWright WR, Marks F, Stelling J, Poudyal N. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S560-S568. doi: 10.1093/cid/ciad581. PMID: 38118014

Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.
Lakerveld AJ, Gelderloos AT, Schepp RM, de Haan CAM, van Binnendijk RS, Rots NY, van Beek J, van Els CACM, van Kasteren PB. Clin Exp Immunol. 2023 Dec 11;214(1):79-93. doi: 10.1093/cei/uxad101. PMID: 37605554

Identification of dynamical changes of rabies transmission under quarantine: Community-based measures towards rabies elimination.
Rysava K, Tildesley MJ. PLoS Comput Biol. 2023 Dec 15;19(12):e1011187. doi: 10.1371/journal.pcbi.1011187. Online ahead of print. PMID: 38100528

Hepatitis C virus modified $sE2_{F442NYT}$ as an antigen in candidate vaccine facilitates human immune cell activation.
Haga Y, Meyer K, Sung MMH, Reagan EK, Weissman D, Ray R. J Virol. 2023 Dec 12:e0180923. doi: 10.1128/jvi.01809-23. Online ahead of print. PMID: 38084956

Nobel-Honored mRNA Tech Advancing Cancer Therapy.
[No authors listed] Cancer Discov. 2023 Dec 12;13(12):OF2. doi: 10.1158/2159-8290.CD-NB2023-0073. PMID: 37787498

Immunotherapy: Constructive Approach for Breast Cancer Treatment.
Anayyat U, Ahad F, Muluh TA, Zaidi SAA, Usmani F, Yang H, Li M, Hassan HA, Wang X. Breast Cancer (Dove Med Press). 2023 Dec 15;15:925-951. doi: 10.2147/BCTT.S424624. eCollection 2023. PMID: 38116189

Global health economics: The Equitable Impact Sensitive Tool (EQUIST) - development, validation, implementation and evaluation of impact (2011 to 2022).
Chopra M, Balaji LN, Campbell H, Rudan I. J Glob Health. 2023 Dec 15;13:04183. doi: 10.7189/jogh.13.04183. PMID: 38095507

Outcomes and Management following COVID-19 Critical Illness.
Cagino L, Seagly K, Noyes E, Prescott H, Valley T, Eaton T, McSparron JI. Chest. 2023 Dec 15:S0012-3692(23)05854-3. doi: 10.1016/j.chest.2023.11.044. Online ahead of print. PMID: 38104961

Comparative evolution of influenza A virus H1 and H3 head and stalk domains across host species.
Trovão NS, Khan SM, Lemey P, Nelson MI, Cherry JL. mBio. 2023 Dec 11:e0264923. doi: 10.1128/mbio.02649-23. Online ahead of print. PMID: 38078770

Engineering carrier nanoparticles with biomimetic moieties for improved intracellular targeted delivery of mRNA therapeutics and vaccines.
Puccetti M, Pariano M, Schoubben A, Ricci M, Giovagnoli S. J Pharm Pharmacol. 2023 Dec 13:rgad089. doi: 10.1093/jpp/rgad089. Online ahead of print. PMID: 38092697

Association between having a primary care physician and health behavioral intention in Japan: results from a nationwide survey.
Sugiyama K, Oshio T, Kuwahara S, Kimura H. BMC Prim Care. 2023 Dec 19;24(1):280. doi: 10.1186/s12875-023-02238-8. PMID: 38114896

Toxigenic cutaneous diphtheria without recent travel, Sydney, Australia, 2022.
Swift C, Katelaris AL, Tiqui TB, Smith J, Papa T, Janz-Robinson E, Nguyen T, Wang Q, Draper J, Sintchenko V, Marriott DJ, Sheppeard V. Med J Aust. 2023 Dec 18. doi: 10.5694/mja2.52190. Online ahead of print. PMID: 38111182

Estimation of foot-and-mouth disease virus sero-prevalence rates using novel computational approach for the susceptible bovine population in India during the period 2008-2021.
Das S, Pal S, Rautaray SS, Mohapatra JK, Subramaniam S, Rout M, Rai SN, Singh RP. Sci Rep. 2023 Dec 19;13(1):22583. doi: 10.1038/s41598-023-48459-w. PMID: 38114542

Effective Stakeholder Engagement for Collation, Analysis and Expansion of Antimicrobial Resistance (AMR) Data: A CAPTURA Experience.
Poudyal N, Holm M, Joh HS, Gautam S, Sujan MJ, Kwon SY, Sahikh A, Shaw A, Gallagher P, Prifti K, Cho A, Chi KK, Aboushady AT, MacWright WR, Stelling J, Marks F. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S519-S527. doi: 10.1093/cid/ciad585. PMID: 38118005

Novel oral polio vaccine for serotype 2: new hope.
Mathur P, Kottilil S. Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00549-2. doi: 10.1016/S1473-3099(23)00549-2. Online ahead of print. PMID: 38109920

Key Recommendations for Antimicrobial Resistance Surveillance: Takeaways From the CAPTURA Project.
Aboushady AT, Sujan MJ, Pham K, Clark A, Marks F, Holm M, Joh HS, Poudyal N, Stelling J. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S581-S587. doi: 10.1093/cid/ciad487. PMID: 38118016

Author Correction: Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge.

Eckhardt E, Schinköthe J, Gischke M, Sehl-Ewert J, Corleis B, Dorhoi A, Teifke J, Albrecht D, Geluk A, Gilleron M, Bastian M. Sci Rep. 2023 Dec 18;13(1):22614. doi: 10.1038/s41598-023-49215-w. PMID: 38114538

Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines.
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Nat Rev Drug Discov. 2023 Dec 12. doi: 10.1038/s41573-023-00873-5. Online ahead of print. PMID: 38086950

Risk of anaphylaxis after COVID-19 vaccination in South Korea: A nationwide self-controlled case series analysis.
Yoon D, Kim JH, Jeong HE, Ko HY, Kim SR, Shin JY; CoVaSC Investigators. Allergy. 2023 Dec 12. doi: 10.1111/all.15975. Online ahead of print. PMID: 38084802

Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity.
Papadas A, Huang Y, Cicala A, Dou Y, Fields M, Gibbons A, Hong D, Lagal DJ, Quintana V, Rizo A, Zomalan B, Asimakopoulos F. Biochem Soc Trans. 2023 Dec 20;51(6):2017-2028. doi: 10.1042/BST20221083. PMID: 38031753

Altered Transcriptome Response in PBMCs of Czech Adults Linked to Multiple PFAS Exposure: B Cell Development as a Target of PFAS Immunotoxicity.
Rudzanová B, Thon V, Vespalcová H, Martyniuk CJ, Piler P, Zvonař M, Klánová J, Bláha L, Adamovsky O. Environ Sci Technol. 2023 Dec 19. doi: 10.1021/acs.est.3c05109. Online ahead of print. PMID: 38112183

SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
Smeets JJH, van Malenstein H, van der Merwe S, Nevens F, Verbeek J. J Hepatol. 2023 Dec 16:S0168-8278(23)05362-X. doi: 10.1016/j.jhep.2023.12.008. Online ahead of print. PMID: 38110008

Correction: mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company.
Killeen T, Kermer V, Troxler Saxer R. J Pharm Policy Pract. 2023 Dec 11;16(1):167. doi: 10.1186/s40545-023-00677-3. PMID: 38082358

Chemical Synthesis Creates Single Glycoforms of the Ectodomain of Herpes Simplex Virus-1 Glycoprotein D.
Zhao J, Liu X, Liu J, Ye F, Wei B, Deng M, Li T, Huang P, Wang P. J Am Chem Soc. 2023 Dec 20. doi: 10.1021/jacs.3c11543. Online ahead of print. PMID: 38117537

"Stronger than I thought I was": Older Adults' Coping across Two Years of the COVID-19 Pandemic.
Fuller HR, Huseth-Zosel A, Kinkade E, Van Vleet B, Hajdar M. Gerontologist. 2023 Dec 18:gnad164. doi: 10.1093/geront/gnad164. Online ahead of print. PMID: 38109780

Soybean Oil-Derived Lipids for Efficient Mrna Delivery.
Tang Z, Yu F, Hsu JC, Shi J, Cai W. Adv Mater. 2023 Dec 19:e2302901. doi: 10.1002/adma.202302901. Online ahead of print. PMID: 38113460

SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode.
Goike J, Hsieh CL, Horton AP, Gardner EC, Zhou L, Bartzoka F, Wang N, Javanmardi K, Herbert A, Abbassi S, Xie X, Xia H, Shi PY, Renberg R, Segall-Shapiro TH, Terrace CI, Wu W, Shroff R, Byrom M, Ellington AD, Marcotte EM, Musser JM, Kuchipudi SV, Kapur V, Georgiou G, Weaver SC, Dye JM, Boutz DR, McLellan JS, Gollihar JD. Commun Biol. 2023 Dec 11;6(1):1250. doi: 10.1038/s42003-023-05649-6. PMID: 38082099

Building safety into CAR-T therapy.
Peters DT, Savoldo B, Grover NS. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275457. doi: 10.1080/21645515.2023.2275457. Epub 2023 Nov 15. PMID: 37968136

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
Li H, Huang Q, Zhang Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2291900. doi: 10.1080/21645515.2023.2291900. Epub 2023 Dec 19. PMID: 38112002

Optimization of a foot-and-mouth disease virus Southern African Territories-specific solid-phase competitive ELISA for small ruminant serum samples.
Seoke L, Fosgate GT, Opperman PA, Malesa RP, Lazarus DD, Sirdar MM, Heath L. J Vet Diagn Invest. 2023 Dec 18:10406387231218202. doi: 10.1177/10406387231218202. Online ahead of print. PMID: 38111309

SARS-CoV-2 specific sIgA in saliva increases after disease-related video stimulation.
Keller JK, Dulovic A, Gruber J, Griesbaum J, Schneiderhan-Marra N, Wülfing C, Kruse J, Hartmann A, Diekhof EK. Sci Rep. 2023 Dec 20;13(1):22631. doi: 10.1038/s41598-023-47798-y. PMID: 38123577

Assessment of knowledge and practices of exclusive breastfeeding among rural women during the COVID-19 pandemic in Egypt: a cross sectional study.
El-Gamel N, El-Nemer A. BMC Womens Health. 2023 Dec 18;23(1):673. doi: 10.1186/s12905-023-02831-0. PMID: 38110927

Bibliometric analysis of monoclonal antibodies for atherosclerosis.
Ma J, Zhao K, Zhu Y, Xu W, Huang J, Wei X, Zhao Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266926. doi: 10.1080/21645515.2023.2266926. Epub 2023 Oct 31. PMID: 37905896

Knowledge-map analysis of bladder cancer immunotherapy.
Lv Z, Hou J, Wang Y, Wang X, Wang Y, Wang K. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267301. doi: 10.1080/21645515.2023.2267301. Epub 2023 Oct 30. PMID: 37903500

Targeted amplification and genetic sequencing of the severe acute respiratory syndrome coronavirus 2 surface glycoprotein.
Keller MW, Keong LM, Rambo-Martin BL, Hassell N, Lacek KA, Wilson MM, Kirby MK, Liddell J, Owuor DC, Sheth M, Madden J, Lee JS, Kondor RJ, Wentworth DE, Barnes JR. Microbiol Spectr. 2023 Dec 12:e0298223. doi: 10.1128/spectrum.02982-23. Online ahead of print. PMID: 38084972

Gut microbiota and immunotherapy of renal cell carcinoma.
Bibbò S, Porcari S, Del Vecchio LE, Severino A, Mullish BH, Ianiro G, Gasbarrini A, Cammarota G. Hum Vaccin Immunother. 2023 Dec 15;19(3):2268982. doi: 10.1080/21645515.2023.2268982. Epub 2023 Nov 13. PMID: 37955340

Knowledge mapping of B cell and atherosclerosis over the past 20 years: A bibliometric analysis.
Cheng T, You Y, Jia B, Wang H, Lv M, Zhu X, Hu Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2277567. doi: 10.1080/21645515.2023.2277567. Epub 2023 Nov 12. PMID: 37953301

Chickenpox Outbreaks in Three Refugee Camps on Mainland Greece, 2016-2017: A Retrospective Study.
Scales SE, Park JW, Nixon R, Guha-Sapir D, Horney JA. Prehosp Disaster Med. 2023 Dec 18:1-10. doi: 10.1017/S1049023X23006702. Online ahead of print. PMID: 38108128

[End of the use of masks in public spaces during the COVID-19 pandemic: impact on the mental health of pregnant women].
Muñoz-Vela FJ, Gómez-Salgado J, Fernández-Carrasco FJ, Allande Cussó R, Vázquez-Lara JM, García Iglesias JJ, Rodríguez-Díaz L. Rev Esp Salud Publica. 2023 Dec 12;97:e202312109. PMID: 38087961

Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic.
Elfström M, Gray PG, Dillner J. Elife. 2023 Dec 12;12:e80905. doi: 10.7554/eLife.80905. PMID: 38085566

Integrated Immunization Information System in Indonesia: Prototype Design Using Quantitative and Qualitative Data.
Rahmadhan MAWP, Handayani PW. JMIR Form Res. 2023 Dec 14;7:e53132. doi: 10.2196/53132. PMID: 38096005

A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein.
Ballegeer M, van Scherpenzeel RC, Delgado T, Iglesias-Caballero M, García Barreno B, Pandey S, Rush SA, Kolkman JA, Mas V, McLellan JS, Saelens X. mBio. 2023 Dec 20:e0212223. doi: 10.1128/mbio.02122-23. Online ahead of print. PMID: 38117059

Serum stabilities and antiviral activities of chemically modified peptides against dengue serotypes 1-4.
Lee MF, Anasir MI, Poh CL. J Pharm Sci. 2023 Dec 14:S0022-3549(23)00535-X. doi: 10.1016/j.xphs.2023.12.009. Online ahead of print. PMID: 38103687

The effects of industrial chemicals bonded to plastic materials in newborns: A systematic review.
Laccetta G, Di Chiara M, Cardillo A, De Nardo MC, Terrin G. Environ Res. 2023 Dec 15;239(Pt 1):117298. doi: 10.1016/j.envres.2023.117298. Epub 2023 Oct 9. PMID: 37821060

CAPTURA Regional Workshop Proceedings (28-30 June 2022, Virtual).
Joh HS, Dolabella B, Early E, Stelling J, Ak G, Upadhyaya MK, Rahman A, Chuki P, MacWright WR, Ondoa P, Sarkar S, Moore C, Holm M, Leslie T, Zellweger RM, Paing G, Kwon SY, Marks F, Poudyal N. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S536-S542. doi: 10.1093/cid/ciad568. PMID: 38118006

The Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019 (COVID-19): Molecular Diagnostic Testing.

Hayden MK, Hanson KE, Englund JA, Lee MJ, Loeb M, Lee F, Morgan DJ, Patel R, El Mikati IK, Iqneibi S, Alabed F, Amarin JZ, Mansour R, Patel P, Falck-Ytter Y, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. Clin Infect Dis. 2023 Dec 19:ciad646. doi: 10.1093/cid/ciad646. Online ahead of print. PMID: 38112284

Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer.
Wei F, Sasada T. Genes Immun. 2023 Dec 14. doi: 10.1038/s41435-023-00236-5. Online ahead of print. PMID: 38097745

Biophysical Interaction Landscape of Mycobacterial Mycolic Acids and Phenolic Glycolipids with Host Macrophage Membranes.
Srivatsav AT, Kapoor S. ACS Appl Bio Mater. 2023 Dec 18;6(12):5555-5562. doi: 10.1021/acsabm.3c00748. Epub 2023 Nov 28. PMID: 38015441

COVID-19-Related School Closures, United States, July 27, 2020-June 30, 2022.
Zviedrite N, Jahan F, Moreland S, Ahmed F, Uzicanin A. Emerg Infect Dis. 2024 Jan;30(1):58-69. doi: 10.3201/eid3001.231215. Epub 2023 Dec 12. PMID: 38086396

Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy.
Dang BN, Kwon TK, Lee S, Jeong JH, Yook S. J Control Release. 2023 Dec 14;365:773-800. doi: 10.1016/j.jconrel.2023.12.007. Online ahead of print. PMID: 38081328

O-acetyl-homoserine sulfhydrylase deficient Streptococcus suis serotype 2 strain SC19 becomes an avirulent strain and provides immune protection against homotype infection in mice.
Wu T, Jiang H, Li F, Jiang X, Wang J, Wei S, Sun Y, Tian Y, Chu H, Shi Y, Zhang N, Li N, Lei L. Vet Microbiol. 2023 Dec 14;288:109943. doi: 10.1016/j.vetmic.2023.109943. Online ahead of print. PMID: 38113574

Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida N, Gkolfinopoulou K, Kostaki EG, Loukides S, Kotanidou A, Skoutelis A, Thiraios E, Saroglou G, Zografopoulos D, Filippou D, Mossialos E, Zaoutis T, Gaga M, Tsiodras S, Antoniadou A. J Infect Dis. 2023 Dec 20;228(12):1667-1674. doi: 10.1093/infdis/jiad324. PMID: 37565522

The functionality of a therapeutic antibody candidate restored by a single mutation from proline to threonine in the variable region.
Hautiere M, Maffucci I, Costa N, Herbet A, Essono S, Padiolleau-Lefevre S, Boquet D. Hum Vaccin Immunother. 2023 Dec 15;19(3):2279867. doi: 10.1080/21645515.2023.2279867. Epub 2023 Nov 27. PMID: 38012091

Treatment-prognostication-adjustment a new therapeutic idea by analyzing T cell immune checkpoint in tumor microenvironment by algorithm: A bibliometric analysis.
Ma S, Wu X, Wu Z, Zhao Q. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269788. doi: 10.1080/21645515.2023.2269788. Epub 2023 Oct 31. PMID: 37905399

The PfRCR complex bridges malaria parasite and erythrocyte during invasion.
Farrell B, Alam N, Hart MN, Jamwal A, Ragotte RJ, Walters-Morgan H, Draper SJ, Knuepfer E, Higgins MK. Nature. 2023 Dec 20. doi: 10.1038/s41586-023-06856-1. Online ahead of print. PMID: 38123677

Analysis of global research hotspots and trends in immune cells in intervertebral disc degeneration: A bibliometric study.
Wang N, Mi Z, Chen S, Fang X, Xi Z, Xu W, Xie L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2274220. doi: 10.1080/21645515.2023.2274220. Epub 2023 Nov 9. PMID: 37941392

Toxicokinetics of a humanized anti-cocaine monoclonal antibody in male and female rats and lack of cross-reactivity.
Webster RP, Marckel JA, Norman AB. Hum Vaccin Immunother. 2023 Dec 15;19(3):2274222. doi: 10.1080/21645515.2023.2274222. Epub 2023 Nov 8. PMID: 37936497

An outbreak of SARS-CoV-2 in a public-facing office in England.
Nicholls G, Atkinson B, van Veldhoven K, Nicholls I, Coldwell M, Clarke A, Atchison CJ, Raja AI, Bennett AM, Morgan D, Pearce N, Fletcher T, Brickley EB, Chen Y. Occup Med (Lond). 2023 Dec 11:kqad100. doi: 10.1093/occmed/kqad100. Online ahead of print. PMID: 38078549

Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India.
Misra P, Singh AK, Mishra B, Behera B, Patro BK, Medigeshi GR, Joshi HS, Ahmad M, Chaturvedi PK, Chinnakali P, Haldar P, Bairwa M, Kharya P, Dhodapkar R, Rath R, Guleria R, Rai SK, Kar SS, Kant S, Sarkar S, Baidya S, Meena S, Mandal S, Kishore S, Majumder T, Hada V. PLoS One. 2023 Dec 11;18(12):e0287807. doi: 10.1371/journal.pone.0287807. eCollection 2023. PMID: 38079384

Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA).
Holm M, MacWright WR, Poudyal N, Shaw AG, Joh HS, Gallagher PF, Kim JH, Shaikh AT, Seo HJ, Kwon SY, Prifti K, Dolabella B, Taylor BEW, Yeats C, Aanensen DM, Stelling J, Marks F. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S500-S506. doi: 10.1093/cid/ciad567. PMID: 38118015

Predicting the impact of COVID-19 non-pharmaceutical intervention on short- and medium-term dynamics of enterovirus D68 in the US.
Park SW, Messacar K, Douek DC, Spaulding AB, Metcalf CJE, Grenfell BT. Epidemics. 2023 Dec 18;46:100736. doi: 10.1016/j.epidem.2023.100736. Online ahead of print. PMID: 38118274

Advances in brain epitranscriptomics research and translational opportunities.
Zhang F, Ignatova VV, Ming GL, Song H. Mol Psychiatry. 2023 Dec 20. doi: 10.1038/s41380-023-02339-x. Online ahead of print. PMID: 38123727

Collecting Multi-country Retrospective Antimicrobial Consumption and Use Data: Challenges and Experience.
Prifti K, Chi KK, Eraly E, Joh HS, Sujan MJ, Poudyal N, Marks F, Holm M. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S528-S535. doi: 10.1093/cid/ciad667. PMID: 38118011

Identification, classification, and characterization of alpha and beta subunits of LVP1 protein from the venom gland of four Iranian scorpion species.

Salabi F, Vazirianzadeh B, Baradaran M. Sci Rep. 2023 Dec 14;13(1):22277. doi: 10.1038/s41598-023-49556-6. PMID: 38097679

Methodological Approach to Identify and Expand the Volume of Antimicrobial Resistance (AMR) Data in the Human Health Sector in Low- and Middle-Income Countries in Asia: Implications for Local and Regional AMR Surveillance Systems Strengthening.
Joh HS, Yeats C, Shaw A, Poudyal N, Gallagher P, Kim JH, Shaikh A, Seo HJ, Chi KK, Prifti K, Cho A, Sujan MJ, Eraly E, Pham KD, Shrestha S, Aboushady AT, Pak G, Jang G, Park EL, Seo HW, Abudahab K, Taylor BEW, Clark A, Dolabella B, Yoon H, Han J, Kwon SY, Marks F, Stelling J, Aanensen DM, MacWright WR, Holm M. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S507-S518. doi: 10.1093/cid/ciad634. PMID: 38118007

Identification of key residues of B cell epitopes in hemagglutinin of H6 influenza A virus.
Wan Z, Gong J, Sang J, Jiang W, Zhao Z, Tang T, Li Y, Zhao Y, Kan Q, Xie Q, Li T, Shao H, Gao W, Qin A, Ye J. Microbiol Spectr. 2023 Dec 12;11(6):e0205923. doi: 10.1128/spectrum.02059-23. Epub 2023 Oct 26. PMID: 37882566

Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis.
Ou L, Su C, Liang L, Duan Q, Li Y, Zang H, He Y, Zeng R, Li Y, Zhou H, Xiao L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267865. doi: 10.1080/21645515.2023.2267865. Epub 2023 Oct 16. PMID: 37846106

Poly(I:C) induces anti-inflammatory response against secondary LPS challenge in zebrafish larvae.
Wang Z, You X, Zhang Y, Liu Q, Yang D. Fish Shellfish Immunol. 2023 Dec 12;144:109285. doi: 10.1016/j.fsi.2023.109285. Online ahead of print. PMID: 38092095

The association between antibody responses and prolonged viable SARS-CoV-2 shedding in immunocompromised patients: a prospective cohort study.
Lim SY, Kim JW, Kim JY, Kang SW, Jang CY, Chang E, Yang JS, Kim KC, Jang HC, Kim DS, Shin Y, Lee JY, Kim SH. J Infect Dis. 2023 Dec 19:jiad579. doi: 10.1093/infdis/jiad579. Online ahead of print. PMID: 38114088

Same yet different - how lymph node heterogeneity affects immune responses.
Cruz de Casas P, Knöpper K, Dey Sarkar R, Kastenmüller W. Nat Rev Immunol. 2023 Dec 14. doi: 10.1038/s41577-023-00965-8. Online ahead of print. PMID: 38097778

tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2.
Bernauer H, Schlör A, Maier J, Bannert N, Hanack K, Ivanusic D. Biol Methods Protoc. 2023 Dec 12;8(1):bpad030. doi: 10.1093/biomethods/bpad030. eCollection 2023. PMID: 38090673

Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.
Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, Völkl S, Mackensen A, Schett G, Basu S. Mol Ther Methods Clin Dev. 2023 Sep 1;31:101104. doi: 10.1016/j.omtm.2023.08.023. eCollection 2023 Dec 14. PMID: 37744005

Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
Shi M, Sun D, Ma X, Liu J, Zhang Y, Liu T, Chen X, Mo S, Zhao Y, Zhang L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2294579. doi: 10.1080/21645515.2023.2294579. Epub 2023 Dec 18. PMID: 38111107

Nanoparticle formulation for the development of a dog nanovaccine against Cystic Echinococcosis.
Silvarrey C, Alvite G, Esteves A. Biologicals. 2023 Dec 14;85:101737. doi: 10.1016/j.biologicals.2023.101737. Online ahead of print. PMID: 38101003

Impact of the COVID-19 Pandemic on Health Care Utilization in the Vaccine Safety Datalink: Retrospective Cohort Study.
Qian L, Sy LS, Hong V, Glenn SC, Ryan DS, Nelson JC, Hambidge SJ, Crane B, Zerbo O, DeSilva MB, Glanz JM, Donahue JG, Liles E, Duffy J, Xu S. JMIR Public Health Surveill. 2023 Dec 12. doi: 10.2196/48159. Online ahead of print. PMID: 38091476

Addressing disparities in funding for robust cancer research.
Cordero DA Jr. Ther Adv Vaccines Immunother. 2023 Dec 15;11:25151355231219083. doi: 10.1177/25151355231219083. eCollection 2023. PMID: 38107389

Breaching the blood-brain barrier: AAV triggers dose-dependent toxicity in the brain.
Stone D, Aubert M, Jerome KR. Mol Ther Methods Clin Dev. 2023 Sep 20;31:101105. doi: 10.1016/j.omtm.2023.09.001. eCollection 2023 Dec 14. PMID: 37753219

Molecular docking and ADMET studies of halogenated metabolites from marine sponges as inhibitors of wild-type and mutants PBP2 in *Neisseria gonorrhoeae*.
Alanzi AR, Alajmi MF, Alqahtani MJ. J Biomol Struct Dyn. 2023 Dec 13:1-13. doi: 10.1080/07391102.2023.2292291. Online ahead of print. PMID: 38088353

Characteristic analysis of China's actions against the COVID-19 in schools and comparison with other countries.
Li N, Yu X. Public Health Nurs. 2023 Dec 18. doi: 10.1111/phn.13275. Online ahead of print. PMID: 38111269

Effect of SARS-CoV-2 incidence and immunisation rates on sporadic Creutzfeldt-Jakob disease incidence.
Hermann P, Böhnke J, Bunck T, Goebel S, Jaeger VK, Karch A, Zerr I. Neuroepidemiology. 2023 Dec 12. doi: 10.1159/000535112. Online ahead of print. PMID: 38086343

Correction: Activation and induction of antigen-specific T follicular helper cells play a critical role in recombinant SARS-CoV-2 RBD vaccine-induced humoral responses.
Yang S, Duan L, Wang C, Zhang C, Hou S, Wang H, Song J, Zhang T, Li Z, Wang M, Tang J, Zheng Q, Wang H, Wang Q, Zhao W. Mol Biomed. 2023 Dec 18;4(1):50. doi: 10.1186/s43556-023-00152-0. PMID: 38109019

A structural foundation for studying chlamydial polymorphic membrane proteins.
Debrine AM, Karplus PA, Rockey DD. Microbiol Spectr. 2023 Dec 12;11(6):e0324223. doi: 10.1128/spectrum.03242-23. Epub 2023 Oct 26. PMID: 37882824

A systemic approach to identify non-abundant immunogenic proteins in Lyme disease pathogens.
Yaş OB, Coleman AS, Lipman RM, Sharma K, Raghunandanan S, Alanazi F, Rana VS, Kitsou C, Yang X, Pal U. mSystems. 2023 Dec 11:e0108723. doi: 10.1128/msystems.01087-23. Online ahead of print. PMID: 38078774

Viral Persistence in the Gut-Associated Lymphoid Tissue and Barriers to HIV Cure.
Cossarini F, Aberg JA, Chen BK, Mehandru S. AIDS Res Hum Retroviruses. 2023 Dec 13. doi: 10.1089/AID.2022.0180. Online ahead of print. PMID: 37450338

Human fetal tissue is critical for biomedical research.
Brumbaugh J, Aguado BA, Lysaght T, Goldstein LSB. Stem Cell Reports. 2023 Dec 12;18(12):2300-2312. doi: 10.1016/j.stemcr.2023.10.008. Epub 2023 Nov 16. PMID: 37977142

A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.
Adams LJ, VanBlargan LA, Liu Z, Gilchuk P, Zhao H, Chen RE, Raju S, Chong Z, Whitener BM, Shrihari S, Jethva PN, Gross ML, Crowe JE Jr, Whelan SPJ, Diamond MS, Fremont DH. Cell Rep Med. 2023 Dec 19;4(12):101305. doi: 10.1016/j.xcrm.2023.101305. Epub 2023 Nov 30. PMID: 38039973

Meningitis in critically ill patients admitted to intensive care unit for severe community-acquired pneumococcal pneumonia.
Jaubert P, Charpentier J, Benghanem S, Cariou A, Pène F, Mira JP, Jozwiak M. Ann Intensive Care. 2023 Dec 18;13(1):129. doi: 10.1186/s13613-023-01211-z. PMID: 38108904

Redeveloping antigen detection kits for the diagnosis of rat hepatitis E virus.
Chen Z, Li G, Situ J, Li Z, Guo S, Huang Y, Wu S, Tang Z, Wen G, Wang S, Fang M, Wang Y, Yu H, Sridhar S, Zheng Z, Xia N. J Clin Microbiol. 2023 Dec 19;61(12):e0071023. doi: 10.1128/jcm.00710-23. Epub 2023 Dec 1. PMID: 38038482

Tissue-Resident Memory T Cell: Ontogenetic Cellular Mechanism and Clinical Translation.
Xu H, Zhou R, Chen Z. Clin Exp Immunol. 2023 Dec 13;214(3):249-259. doi: 10.1093/cei/uxad090. PMID: 37586053

Molecular dynamics simulations show how antibodies may rescue HIV-1 mutants incapable of infecting host cells.
Rajendra D, Maroli N, Dixit NM, Maiti PK. J Biomol Struct Dyn. 2023 Dec 18:1-11. doi: 10.1080/07391102.2023.2294835. Online ahead of print. PMID: 38111161

Uncommon Hematogenous Metastasis: Orbital Involvement in Uterine Cervical Cancer.
Yamaguchi S, Koizumi M, Kakuda M, Yamamoto T. Am J Case Rep. 2023 Dec 14;24:e941076. doi: 10.12659/AJCR.941076. PMID: 38096131

An interaction network approach predicts protein cage architectures in bionanotechnology.
Fatehi F, Twarock R. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2303580120. doi: 10.1073/pnas.2303580120. Epub 2023 Dec 7. PMID: 38060565

'You just emotionally break': understanding COVID-19 narratives through public health humanities.
Saffran L, Doobay-Persaud A. Med Humanit. 2023 Dec 19;49(4):537-544. doi: 10.1136/medhum-2022-012607. PMID: 37419677

Considerations for Expanding Antimicrobial Resistance Surveillance Networks.
Gallagher P, Shaw A, Bhandari A, Poudyal N, Holm M, MacWright WR. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S578-S580. doi: 10.1093/cid/ciad548. PMID: 38118012

Hybrid grey assisted whale optimization based machine learning for the COVID-19 prediction.
Shyamala A, Murugeswari S, Mahendran G, Jothi Chitra R. Comput Methods Biomech Biomed Engin. 2023 Dec 19:1-10. doi: 10.1080/10255842.2023.2292008. Online ahead of print. PMID: 38112339

Correction to: Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics.
Haltaufderhyde K, Roberts BJ, Khan S, Terry F, Boyle CM, McAllister M, Martin W, Rosenberg A, De Groot AS. AAPS J. 2023 Dec 19;26(1):6. doi: 10.1208/s12248-023-00868-5. PMID: 38114731

Increase in iGAS incidence: a call to action for effective prevention and treatment.
Gibney KB, Bowen AC. Lancet Child Adolesc Health. 2023 Dec 13:S2352-4642(23)00320-6. doi: 10.1016/S2352-4642(23)00320-6. Online ahead of print. PMID: 38103565

Viral platform engineering for targeted gene delivery to human hematopoietic stem cells.
Del Veliz S, Coughlan L. Mol Ther. 2023 Dec 11:S1525-0016(23)00658-5. doi: 10.1016/j.ymthe.2023.11.025. Online ahead of print. PMID: 38086382

Multipass high-dimensional flow cytometry.
Lugli E, Roederer M, Sottile R. Nat Biomed Eng. 2023 Dec 20. doi: 10.1038/s41551-023-01165-4. Online ahead of print. PMID: 38123663

AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H, Yu W, Li Y, Bao X, Ni Y, Chen X, Sun Y, Chen A, Zhou W, Li J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269790. doi: 10.1080/21645515.2023.2269790. Epub 2023 Oct 25. PMID: 37877820

Autologous engineered T cell receptor therapy in advanced cancer.
Tsimberidou AM, Baysal MA, Chakraborty A, Andersson BS. Hum Vaccin Immunother. 2023 Dec 15;19(3):2290356. doi: 10.1080/21645515.2023.2290356. Epub 2023 Dec 19. PMID: 38114231

Onconephrology: mitigation of renal injury in chemotherapy administration.
Selamet U, Ahdoot RS, Salasnek R, Abdelnour L, Hanna RM. Curr Opin Nephrol Hypertens. 2023 Dec 15. doi: 10.1097/MNH.0000000000000960. Online ahead of print. PMID: 38095483

Unveiling P. vivax invasion pathways in Duffy-negative individuals.
Bouyssou I, El Hoss S, Doderer-Lang C, Schoenhals M, Rasoloharimanana LT, Vigan-Womas I, Ratsimbasoa A, Abate A, Golassa L, Mabilotte S, Kessler P, Guillotte-Blisnick M, Martinez FJ, Chitnis CE, Strouboulis J, Ménard D. Cell Host Microbe. 2023 Dec 13;31(12):2080-2092.e5. doi: 10.1016/j.chom.2023.11.007. Epub 2023 Dec 5. PMID: 38056460

H3 K27M-altered Glioma and Diffuse Intrinsic Pontine Glioma: Semi-systematic Review of Treatment Landscape and Future Directions.
van den Bent M, Saratsis AM, Geurts M, Franceschi E. Neuro Oncol. 2023 Dec 15:noad220. doi: 10.1093/neuonc/noad220. Online ahead of print. PMID: 38102230

Epidemiology and clinical manifestations of reported Lyme disease cases: Data from the Canadian Lyme disease enhanced surveillance system.
Murison K, Wilson CH, Clow KM, Gasmi S, Hatchette TF, Bourgeois AC, Evans GA, Koffi JK. PLoS One. 2023 Dec 15;18(12):e0295909. doi: 10.1371/journal.pone.0295909. eCollection 2023. PMID: 38100405

Progressive pulmonary fibrosis: where are we now?
Kang HK, Song JW. Tuberc Respir Dis (Seoul). 2023 Dec 18. doi: 10.4046/trd.2023.0119. Online ahead of print. PMID: 38111100

Atypical B cells consist of subsets with distinct functional profiles.
Reyes RA, Batugedara G, Dutta P, Reers AB, Garza R, Ssewanyana I, Jagannathan P, Feeney ME, Greenhouse B, Bol S, Ay F, Bunnik EM. iScience. 2023 Nov 20;26(12):108496. doi: 10.1016/j.isci.2023.108496. eCollection 2023 Dec 15. PMID: 38098745

Myocarditis in Athletes: Risk Factors and Relationship with Strenuous Exercise.
Terry KJ, Narducci D, Moran B, Chang P, Orlando D, Bindas B, Botto E, Retzloff A, Esan D, Coris E. Sports Med. 2023 Dec 11. doi: 10.1007/s40279-023-01969-z. Online ahead of print. PMID: 38079080

A longitudinal transition imputation model for categorical data applied to a large registry dataset.
Mamouris P, Nassiri V, Verbeke G, Janssens A, Vaes B, Molenberghs G. Stat Med. 2023 Dec 20;42(29):5405-5418. doi: 10.1002/sim.9919. Epub 2023 Sep 27. PMID: 37752860

Viral Hepatitis Necessitating Liver Transplantation in Children.
Valamparampil J, Kelly D. Transplantation. 2024 Jan 1;108(1):127-136. doi: 10.1097/TP.0000000000004641. Epub 2023 Dec 13. PMID: 37221640

Genomic and transcriptomic analysis of *Ligilactobacillus salivarius* IBB3154-in search of new promoters for vaccine construction.
Kobierecka P, Wyszyńska A, Aleksandrzak-Piekarczyk T, Sałańska A, Gawor J, Bardowski J, Jagusztyn Krynicka KE. Microbiol Spectr. 2023 Dec 12;11(6):e0284423. doi: 10.1128/spectrum.02844-23. Epub 2023 Nov 20. PMID: 37982628

Dissecting components of the *Campylobacter jejuni fetMP-fetABCDEF* gene cluster under iron limitation.
Richardson-Sanchez T, Chan ACK, Sabatino B, Lin H, Gaynor EC, Murphy MEP. Microbiol Spectr. 2023 Dec 14:e0314823. doi: 10.1128/spectrum.03148-23. Online ahead of print. PMID: 38096459

Mucosal and systemic antigen-specific antibody responses correlate with protection against active tuberculosis in nonhuman primates.
Ishida E, Corrigan DT, Chen T, Liu Y, Kim RS, Song L, Rutledge TM, Magee DM, LaBaer J, Lowary TL, Lin PL, Achkar JM. EBioMedicine. 2023 Dec 13;99:104897. doi: 10.1016/j.ebiom.2023.104897. Online ahead of print. PMID: 38096687

A survey of the impact of COVID-19 on the management of animal experiments and laboratory animal facilities in Korea.
Ahn N, Park J, Ihm J, Roh S. Exp Anim. 2023 Dec 15. doi: 10.1538/expanim.23-0145. Online ahead of print. PMID: 38105004

L-glutamine protects against enterohemorrhagic *Escherichia coli* infection by inhibiting bacterial virulence and enhancing host defense concurrently.
Fang F, Xue Y, Xu X, Fang D, Liu W, Zhong Y, Han J, Li Y, Tao Q, Lu R, Ma C, Kumar A, Wang D. Microbiol Spectr. 2023 Dec 12;11(6):e0097523. doi: 10.1128/spectrum.00975-23. Epub 2023 Oct 10. PMID: 37815335

Genetic diversity and relatedness of feline parvovirus in Vietnam and its potential implications for canine-feline transmission.
Minh H, Son NV, Duc HM, Lin CN, Tyan YC, Chuang KP. Arch Virol. 2023 Dec 15;169(1):11. doi: 10.1007/s00705-023-05946-9. PMID: 38102389

Progress of SARS-CoV-2 Main protease peptide-like inhibitors.
Liu X, Ren X, Hua M, Liu F, Ren X, Sui C, Li Q, Luo F, Jiang Z, Xia Z, Chen J, Yang B. Chem Biol Drug Des. 2023 Dec 11:e14425. doi: 10.1111/cbdd.14425. Online ahead of print. PMID: 38082476

Advances and challenges in clinical applications of tumor cell-derived extracellular vesicles.
Yu L, Zeng X, Hu X, Wen Q, Chen P. Colloids Surf B Biointerfaces. 2023 Dec 11;234:113704. doi: 10.1016/j.colsurfb.2023.113704. Online ahead of print. PMID: 38113751

Utilizing non-human primate models to combat recent COVID-19/SARS-CoV-2 and viral infectious disease outbreaks.
Kwon T. J Med Primatol. 2023 Dec 11:e12689. doi: 10.1111/jmp.12689. Online ahead of print. PMID: 38084001

Metagenomic and Molecular Detection of Novel Fecal Viruses in Free-Ranging Agile Wallabies.
Okoh GR, Ariel E, Whitmore D, Horwood PF. Ecohealth. 2023 Dec 13. doi: 10.1007/s10393-023-01659-2. Online ahead of print. PMID: 38091182

Musculoskeletal manifestations of COVID-19.
da Silva LNM, Filho AGO, Guimarães JB. Skeletal Radiol. 2023 Dec 20. doi: 10.1007/s00256-023-04549-4. Online ahead of print. PMID: 38117308

Dynamic transmission modeling of COVID-19 to support decision-making in Brazil: A scoping review in the pre-vaccine era.
Berg de Almeida G, Mendes Simon L, Maria Bagattini Â, Quarti Machado da Rosa M, Borges ME, Felizola Diniz Filho JA, de Souza Kuchenbecker R, Kraenkel RA, Pio Ferreira C, Alves Camey S, Castelo Branco Fortaleza CM, Toscano CM. PLOS Glob Public Health. 2023 Dec 13;3(12):e0002679. doi: 10.1371/journal.pgph.0002679. eCollection 2023. PMID: 38091336

The Association Between Black vs. White Race and 30-Day Hospitalization Among People Diagnosed with COVID-19 Within an Integrated Care Setting: a Cohort Study.

Harding JL, Doucet N, Patel SA, Davis T, McDonald B, Goldberg B, Patzer RE, Walker-Williams D, Jagannathan R, Teunis L, Gander JC. J Racial Ethn Health Disparities. 2023 Dec 18. doi: 10.1007/s40615-023-01894-x. Online ahead of print. PMID: 38110800

Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice.
Wei T, Li Y, Li B, Xie Q, Huang Y, Wu Z, Chen H, Meng Y, Liang L, Wang M, Geng J, Lei M, Shang J, Guo S, Yang Z, Jia H, Ren F, Zhao T. Int Immunopharmacol. 2023 Dec 15;127:111362. doi: 10.1016/j.intimp.2023.111362. Online ahead of print. PMID: 38103411

Global Remodeling of Host Proteome in Response to *Leishmania* Infection.
Reyaz E, Puri N, Selvapandiyan A. ACS Infect Dis. 2023 Dec 12. doi: 10.1021/acsinfecdis.3c00492. Online ahead of print. PMID: 38084821

Application of PAT Probes in Aluminum Phosphate Adjuvant Manufacturing.
Kowal P, Fung G, Gemmiti G, Sampaleanu L, Cronin JT, Kirkitadze M. Pharm Res. 2023 Dec 19. doi: 10.1007/s11095-023-03642-6. Online ahead of print. PMID: 38114802

$CD4^+$ T cells reverse surface antigen persistence in a mouse model of HBV replication.
Bailey JT, Moshkani S, Rexhouse C, Cimino JL, Robek MD. Microbiol Spectr. 2023 Dec 12;11(6):e0344723. doi: 10.1128/spectrum.03447-23. Epub 2023 Nov 10. PMID: 37948314

Exploring Monkeypox: prospects for therapeutics through computational-aided drug discovery.
Grajales DB, Kar S. Mol Divers. 2023 Dec 11. doi: 10.1007/s11030-023-10767-8. Online ahead of print. PMID: 38079063

Dietary environmental factors shape the immune defense against Cryptosporidium infection.
Maradana MR, Marzook NB, Diaz OE, Mkandawire T, Diny NL, Li Y, Liebert A, Shah K, Tolaini M, Kváč M, Stockinger B, Sateriale A. Cell Host Microbe. 2023 Dec 13;31(12):2038-2050.e4. doi: 10.1016/j.chom.2023.11.008. Epub 2023 Dec 4. PMID: 38052207

Zwitterionic Polymer-Decorated Lipid Nanoparticles for mRNA Delivery in Mammalian Cells.
Khunsuk PO, Pongma C, Palaga T, Hoven VP. Biomacromolecules. 2023 Dec 11;24(12):5654-5665. doi: 10.1021/acs.biomac.3c00649. Epub 2023 Nov 13. PMID: 37956106

Bacteriological and molecular characterization of temperature- and CO_2-dependent *Streptococcus pneumoniae* serotype 24F ST162 isolated from Japanese children.
Kobayashi J, Ohkusu M, Matsumoto T, Kubota N, Ishiwada N. Microbiol Spectr. 2023 Dec 12;11(6):e0216523. doi: 10.1128/spectrum.02165-23. Epub 2023 Oct 12. PMID: 37823633

Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y, Xiong L, Chen Y, Cai R, Xu X, Wang T, Guo Y, Ruan L, Fang Y, Zhang Q, Shen B, Ye J, Zhou G. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285902. doi: 10.1080/21645515.2023.2285902. Epub 2023 Nov 27. PMID: 38010104

Forsythoside A inhibits apoptosis and autophagy induced by infectious bronchitis virus through regulation of the PI3K/Akt/NF-κB pathway.
Xu J, Yin P, Liu X, Hou X. Microbiol Spectr. 2023 Dec 12;11(6):e0192123. doi: 10.1128/spectrum.01921-23. Epub 2023 Nov 16. PMID: 37971265

Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals.
Soriano V, Moreno-Torres V, de Mendoza C, Fernández-Montero JV, Treviño A, Corral O, de Jesús F, Barreiro P. AIDS Rev. 2023 Dec 13. doi: 10.24875/AIDSRev.M23000066. Online ahead of print. PMID: 38092029

What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
Prévot-Monsacré P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, Souty C, Mamou T, Hamel J, Antona D, Mathieu P, Vasseur P, Lévy-Bruhl D, Baroux N, Rossignol L, Vaillant L, Guerrisi C, Hanslik T, Dina J, Blanchon T. Vaccine. 2023 Dec 12:S0264-410X(23)01451-2. doi: 10.1016/j.vaccine.2023.12.017. Online ahead of print. PMID: 38092609

Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study.
Urbute A, Frederiksen K, Thomsen LT, Kesmodel US, Kjaer SK. Gynecol Oncol. 2023 Dec 15;181:20-27. doi: 10.1016/j.ygyno.2023.12.002. Online ahead of print. PMID: 38103421

Evaluating COVID-19 Response Within a Tribal Health Care Organization.
Schaefer KR, Triplett B, Lorenzo O, Aregood M, Galbreath D, Dillard DA, Collier AF. Perm J. 2023 Dec 15;27(4):36-43. doi: 10.7812/TPP/23.039. Epub 2023 Sep 21. PMID: 37731363

Thoughts and Experiences of Behçet Disease From Participants on a Reddit Subforum: Qualitative Online Community Analysis.
Li JX, Yacyshyn E. JMIR Form Res. 2023 Dec 12;7:e49380. doi: 10.2196/49380. PMID: 38085563

Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.
Steinberg J, Hughes S, Hui H, Allsop MJ, Egger S, David M, Caruana M, Coxeter P, Carle C, Onyeka T, Rewais I, Monroy Iglesias MJ, Vives N, Wei F, Abila DB, Carreras G, Santero M, O'Dowd EL, Lui G, Tolani MA, Mullooly M, Lee SF, Landy R, Hanley SJB, Binefa G, McShane CM, Gizaw M, Selvamuthu P, Boukheris H, Nakaganda A, Ergin I, Moraes FY, Timilshina N, Kumar A, Vale DB, Molina-Barceló A, Force LM, Campbell DJ, Wang Y, Wan F, Baker AL, Singh R, Salam RA, Yuill S, Shah R, Lansdorp-Vogelaar I, Yusuf A, Aggarwal A, Murillo R, Torode JS, Kliewer EV, Bray F, Chan KKW, Peacock S, Hanna TP, Ginsburg O, Van Hemelrijck M, Sullivan R, Roitberg F, Ilbawi AM, Soerjomataram I, Canfell K. Int J Cancer. 2023 Dec 11. doi: 10.1002/ijc.34798. Online ahead of print. PMID: 38083979

Validation of a multiplex-tandem RT-PCR for the detection of bovine respiratory disease complex using Scottish bovine lung samples.
Fergusson M, Maley M, Geraghty T, Albaladejo JP, Mason C, Rocchi MS. Vet J. 2023 Dec 14:106058. doi: 10.1016/j.tvjl.2023.106058. Online ahead of print. PMID: 38103886

Predicting nearest neighbor free energies of modified RNA with LIE: results for pseudouridine and *N*1-methylpseudouridine within RNA duplexes.
Dutta N, Sarzynska J, Deb I, Lahiri A. Phys Chem Chem Phys. 2023 Dec 13. doi: 10.1039/d3cp02442c. Online ahead of print. PMID: 38088148

Phytocompounds from *Phyllanthus acidus* (L.) Skeels in the management of Monkeypox Virus infections.
Datta S, Sarkar I, Goswami N, Mahanta S, Borah P, Sen A. J Biomol Struct Dyn. 2023 Dec 11:1-18. doi: 10.1080/07391102.2023.2291166. Online ahead of print. PMID: 38079302

Structural definition of babesial RAP-1 proteins identifies a novel protein superfamily across Apicomplexa.
Hötzel I, Suarez CE. Sci Rep. 2023 Dec 15;13(1):22330. doi: 10.1038/s41598-023-49532-0. PMID: 38102310

An artificial protein cage made from a 12-membered ring.
Stupka I, Biela AP, Piette B, Kowalczyk A, Majsterkiewicz K, Borzęcka-Solarz K, Naskalska A, Heddle JG. J Mater Chem B. 2023 Dec 13. doi: 10.1039/d3tb01659e. Online ahead of print. PMID: 38088805

Age-associated Senescent - T Cell Signaling Promotes Type 3 Immunity that Inhibits the Biomaterial Regenerative Response.
Han J, Cherry C, Mejias JC, Krishnan K, Ruta A, Maestas DR Jr, Peña AN, Nguyen HH, Nagaraj S, Yang B, Gray-Gaillard E, Rutkowski N, Browne M, Tam AJ, Fertig EJ, Housseau F, Ganguly S, Moore EM, Pardoll DM, Elisseeff JH. Adv Mater. 2023 Dec 12:e2310476. doi: 10.1002/adma.202310476. Online ahead of print. PMID: 38087458

Mechanical forces control the valency of the malaria adhesin VAR2CSA by exposing cryptic glycan binding sites.
Roessner R, Michelarakis N, Gräter F, Aponte-Santamaría C. PLoS Comput Biol. 2023 Dec 20;19(12):e1011726. doi: 10.1371/journal.pcbi.1011726. Online ahead of print. PMID: 38117828

The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches.
Chan TYH, Wong JSY, Kiang KM, Sun CWY, Leung GK. Cell Death Dis. 2023 Dec 16;14(12):835. doi: 10.1038/s41419-023-06354-2. PMID: 38104126

GGNpTCR: A Generative Graph Structure Neural Network for Predicting Immunogenic Peptides for T-cell Immune Response.
Zhao M, Xu SX, Yang Y, Yuan M. J Chem Inf Model. 2023 Dec 11;63(23):7557-7567. doi: 10.1021/acs.jcim.3c01293. Epub 2023 Nov 22. PMID: 37990917

Gene of the month: cancer testis antigen gene 1b (NY-ESO-1).
Julve M, Kennedy O, Frampton AE, Bagwan I, Lythgoe MP. J Clin Pathol. 2023 Dec 14;77(1):1-7. doi: 10.1136/jcp-2023-209053. PMID: 37857483

Computational approaches to lipid-based nucleic acid delivery systems.
Settanni G. Eur Phys J E Soft Matter. 2023 Dec 14;46(12):127. doi: 10.1140/epje/s10189-023-00385-5. PMID: 38097823

BolA promotes the generation of multicellular behavior in S. Typhimurium by regulating the c-di-GMP pathway genes yeaJ and yhjH.
Chen K, Li L, Zhou Z, Wang N, Dai C, Sun D, Li J, Xu C, Liao M, Zhang J. Int J Food Microbiol. 2023 Dec 12;411:110518. doi: 10.1016/j.ijfoodmicro.2023.110518. Online ahead of print. PMID: 38101189

Healthy aging: Linking causal mechanisms with holistic outcomes.
Montano M, Oursler KK, Marconi VC. Aging Cell. 2023 Dec 18:e14065. doi: 10.1111/acel.14065. Online ahead of print. PMID: 38108552

Bioinspired Spatiotemporal Management toward RNA Therapies.
Ma Y, Li S, Lin X, Chen Y. ACS Nano. 2023 Dec 13. doi: 10.1021/acsnano.3c08219. Online ahead of print. PMID: 38091941

The value of serum neutralizing antibody in evaluating predictability of COVID-19 after recovery and the validation of vaccine.
Guo B, Li Z, Fu G, Li H, Yang J, Zhang Z, Wu L, Wang J. BMC Infect Dis. 2023 Dec 20;23(1):895. doi: 10.1186/s12879-023-08465-9. PMID: 38124038

The Reality of Antimicrobial Resistance and Antibiotic Usage Data in Asia: The CAPTURA Experience.
Leslie T, Parry C, Ondoa P, Walsh T, Moore C, Poudyal N, Marks F, Gordon NC. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S497-S499. doi: 10.1093/cid/ciad580. PMID: 38118008

A potential cure for tumor-associated immunosuppression by Toxoplasma gondii.
Lotfalizadeh N, Sadr S, Morovati S, Lotfalizadeh M, Hajjafari A, Borji H. Cancer Rep (Hoboken). 2023 Dec 18:e1963. doi: 10.1002/cnr2.1963. Online ahead of print. PMID: 38109851

Association of lineage 4.2.2 of *Mycobacterium tuberculosis* with the 63-bp deletion variant of the *mpt64* gene.
Song Z, He W, Pei S, Zhao B, Cao X, Wang Y, He P, Liu D, Ma A, Ou X, Xia H, Wang S, Liu C, Zhao Y. Microbiol Spectr. 2023 Dec 12;11(6):e0184223. doi: 10.1128/spectrum.01842-23. Epub 2023 Nov 10. PMID: 37947405

Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage.
Wang Y, Lin X, Wang Y, Wang G. Invest New Drugs. 2023 Dec 12. doi: 10.1007/s10637-023-01415-x. Online ahead of print. PMID: 38085423

Bacteriophage Endolysin treatment for systemic infection of Streptococcus iniae in hybrid striped bass.
Deshotel MB, Dave UM, Farmer B, Kemboi D, Nelson DC. Fish Shellfish Immunol. 2023 Dec 15:109296. doi: 10.1016/j.fsi.2023.109296. Online ahead of print. PMID: 38104698

A SMART method for isolating monoclonal antibodies from individual rhesus macaque memory B cells.
Weinfurter JT, Bennett SN, Reynolds M. J Immunol Methods. 2023 Dec 14:113602. doi: 10.1016/j.jim.2023.113602. Online ahead of print. PMID: 38103783

Does medical humanities matter? The challenge of COVID-19.
Macnaughton J. Med Humanit. 2023 Dec 19;49(4):545-552. doi: 10.1136/medhum-2022-012602. PMID: 37268405

PEPMatch: a tool to identify short peptide sequence matches in large sets of proteins.
Marrama D, Chronister WD, Westernberg L, Vita R, Koşaloğlu-Yalçın Z, Sette A, Nielsen M, Greenbaum JA, Peters B. BMC Bioinformatics. 2023 Dec 18;24(1):485. doi: 10.1186/s12859-023-05606-4. PMID: 38110863

Malaria.
Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Lancet. 2023 Dec 16;402(10419):2328-2345. doi: 10.1016/S0140-6736(23)01249-7. Epub 2023 Nov 2. PMID: 37924827

Single-cell transcriptome sequencing of plant leaf expressing anti-HER2 VHH-FcK cancer therapeutic protein.
Kim MS, Lee SW, Kim K, Kim Y, Hwang H, Hinterdorfer P, Choi D, Ko K. Sci Data. 2023 Dec 19;10(1):911. doi: 10.1038/s41597-023-02833-5. PMID: 38114492

Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopes.
Custodio JM, Ayres CM, Rosales TJ, Brambley CA, Arbuiso AG, Landau LM, Keller GLJ, Srivastava PK, Baker BM. Proc Natl Acad Sci U S A. 2023 Dec 19;120(51):e2312057120. doi: 10.1073/pnas.2312057120. Epub 2023 Dec 12. PMID: 38085776

Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
Zhao Q, Liu H, Tang L, Wang F, Tolufashe G, Chang J, Guo JT. Antiviral Res. 2023 Dec 16:105782. doi: 10.1016/j.antiviral.2023.105782. Online ahead of print. PMID: 38110058

Innate immunity response of zafirlukast treated-tilapia during foreign body inflammation.
Oliveira SL, Costa CCD, Aracati MF, Rodrigues LF, Conde G, Moraes AC, Camplesi AC, Farias THV, Silva IC, Pereira LAM, Belo MAA. Dev Comp Immunol. 2023 Dec 11:105112. doi: 10.1016/j.dci.2023.105112. Online ahead of print. PMID: 38092068

Novel liposomal glatiramer acetate: Preparation and immunomodulatory evaluation in murine model of multiple sclerosis.
Rahiman N, Zamani P, Arabi L, Alavizadeh SH, Nikpoor A, Mashreghi M, Badiee A, Jaafari MR. Int J Pharm. 2023 Dec 15;648:123620. doi: 10.1016/j.ijpharm.2023.123620. Epub 2023 Nov 18. PMID: 37981250

Open trial of recombinant Der f 2 pullulan-conjugated immunotherapy in cats.
Martini F, Rostaher A, Favrot C, Fischer NM. Vet Dermatol. 2023 Dec 11. doi: 10.1111/vde.13217. Online ahead of print. PMID: 38073305

Tolfenpyrad displays *Francisella*-targeted antibiotic activity that requires an oxidative stress response regulator for sensitivity.
Clarke A, Llabona IM, Khalid N, Hulvey D, Irvin A, Adams N, Heine HS, Eshraghi A. Microbiol Spectr. 2023 Dec 12;11(6):e0271323. doi: 10.1128/spectrum.02713-23. Epub 2023 Oct 6. PMID: 37800934

Expression and self-assembly of virus-like particles from porcine parvovirus and its application in antibody detection.

Li Y, Wang Q, Yue W, Li X, Chen Y, Gao Y. Pol J Vet Sci. 2023 Dec 12;26(4):591-609. doi: 10.24425/pjvs.2023.148280. PMID: 38088304

"We literally worked in parking lots, cars, garages, and separately set up party tents": qualitative study on the experiences of GPs in the frame of the SARS-CoV-2 pandemic in Austria.
Rabady S, Mayrhofer M, Szabo N, Erber P, Hoffmann K. BMC Health Serv Res. 2023 Dec 12;23(1):1394. doi: 10.1186/s12913-023-10363-4. PMID: 38087337

Healthcare resource use and costs of varicella and its complications: A systematic literature review.
Williame I, George M, Shah HA, Homer N, Alderson D, Jamet N. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266225. doi: 10.1080/21645515.2023.2266225. Epub 2023 Oct 27. PMID: 37885425

T Cell Antigen Recognition and Discrimination by Electrochemiluminescence Imaging.
Yan Y, Zhou P, Ding L, Hu W, Chen W, Su B. Angew Chem Int Ed Engl. 2023 Dec 11;62(50):e202314588. doi: 10.1002/anie.202314588. Epub 2023 Nov 10. PMID: 37903724

Systematic identification and repurposing of FDA-approved drugs as antibacterial agents against Streptococcus pyogenes: In silico and in vitro studies.
Gracia J, Perumal D, Dhandapani P, Ragunathan P. Int J Biol Macromol. 2023 Dec 13;257(Pt 2):128667. doi: 10.1016/j.ijbiomac.2023.128667. Online ahead of print. PMID: 38101681

Vidofludimus inhibits porcine reproductive and respiratory syndrome virus infection by targeting dihydroorotate dehydrogenase.
Yang Y, Gao Y, Zhang L, Liu X, Sun Y, Bai J, Jiang P. Vet Res. 2023 Dec 20;54(1):124. doi: 10.1186/s13567-023-01251-0. PMID: 38124181

Changing patterns in the epidemiology of drug allergy.
Doña I, Torres MJ, Celik G, Phillips E, Tanno LK, Castells M. Allergy. 2023 Dec 12. doi: 10.1111/all.15970. Online ahead of print. PMID: 38084822

Advancing pathogen genomics in resource-limited settings.
Pronyk PM, de Alwis R, Rockett R, Basile K, Boucher YF, Pang V, Sessions O, Getchell M, Golubchik T, Lam C, Lin R, Mak TM, Marais B, Twee-Hee Ong R, Clapham HE, Wang L, Cahyorini Y, Polotan FGM, Rukminiati Y, Sim E, Suster C, Smith GJD, Sintchenko V. Cell Genom. 2023 Nov 17;3(12):100443. doi: 10.1016/j.xgen.2023.100443. eCollection 2023 Dec 13. PMID: 38116115

Antimicrobial Resistance Surveillance Methods in Bangladesh: Present and Way Forward.
Sujan MJ, Habib ZH, Rahman A, Rizvi SMS, Barua HT, Aboushady AT, Hasnat MA, Rasul SBG, Joh HS, Prifti K, Chi KK, Kwon SY, Clark A, Gautam S, Holm M, Marks F, Stelling J, Shaw A, Poudyal N. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S549-S559. doi: 10.1093/cid/ciad561. PMID: 38118018

Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a Portuguese hospital.
Ruas R, Palma P, Lamas F, Ruivo A, Malheiro R, Ferraz R. Porto Biomed J. 2023 Dec 13;8(6):e239. doi: 10.1097/j.pbj.0000000000000239. eCollection 2023 Nov-Dec. PMID: 38093791

Arsenic exposure caused male infertility indicated by testis and sperm metabolic dysfunction in SD rats.

Li J, Nan B, Xu Z, Chang H, Xu S, Ren M, Zhang Y, Wu Y, Chen Y, Guo D, Shen H. Sci Total Environ. 2023 Dec 15;904:166838. doi: 10.1016/j.scitotenv.2023.166838. Epub 2023 Sep 9. PMID: 37689206

Serotype distribution, antimicrobial resistance, and molecular characterization of group B *Streptococcus* isolates from Chinese pregnant woman.
Chen Y, Liu L, Liu J, Ji T, Gao Y, Yang D, Zhao M, Zhai Y, Cao Z. J Matern Fetal Neonatal Med. 2024 Dec;37(1):2295805. doi: 10.1080/14767058.2023.2295805. Epub 2023 Dec 20. PMID: 38124302

Coverage, Trends, and Inequalities of Maternal, Newborn, and Child Health Indicators among the Poor and Non-Poor in the Most Populous Cities from 38 Sub-Saharan African Countries.
Blumenberg C, Costa JC, Ricardo LI, Jacobs C, Ferreira LZ, Vidaletti LP, Wehrmeister FC, Barros AJD, Faye C, Boerma T. J Urban Health. 2023 Dec 18. doi: 10.1007/s11524-023-00806-y. Online ahead of print. PMID: 38110773

Diversity for endoribonuclease nsp15-mediated regulation of alpha-coronavirus propagation and virulence.
Xie Y, Chen C, Zhang D, Jiao Z, Chen Y, Wang G, Tan Y, Zhang W, Xiao S, Peng G, Shi Y. Microbiol Spectr. 2023 Dec 12;11(6):e0220923. doi: 10.1128/spectrum.02209-23. Epub 2023 Nov 8. PMID: 37938022

Do vitamin D levels or supplementation play A role in COVID-19 outcomes?-a narrative review.
Shetty AJ, Banerjee M, Prasad TN, Bhadada SK, Pal R. Ann Palliat Med. 2023 Dec 11:apm-23-113. doi: 10.21037/apm-23-113. Online ahead of print. PMID: 38124476

PATHway: Intervention optimization of a prevention program for adolescents at-risk for depression in the primary care setting.
Gladstone TRG, Zhong C, Lowther M, Feinstein RT, Fitzgibbon ML, Gussin HA, Schiffer L, Diviak K, Berbaum ML, Rusiewski C, Ramirez P, Lefaiver C, Canel J, Mitchell J, Buchholz KR, Van Voorhees BW. Contemp Clin Trials. 2023 Dec 17:107413. doi: 10.1016/j.cct.2023.107413. Online ahead of print. PMID: 38114047

Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine.
Guo M, Cao M, Sun J, Chen Z, Wang X, Dai L, Gao GF, Zhao Y, Wang Y, Chen C. Signal Transduct Target Ther. 2023 Dec 16;8(1):462. doi: 10.1038/s41392-023-01718-8. PMID: 38104162

Spatiotemporal genome diversity of SARS-CoV-2 in wastewater: a two-year global epidemiological study.
Mandal M, Mandal S. Environ Monit Assess. 2023 Dec 16;196(1):44. doi: 10.1007/s10661-023-12228-z. PMID: 38102322

An immunoinformatics study reveals a new BoLA-DR-restricted CD4+ T cell epitopes on the Gag protein of bovine leukemia virus.
Pluta A, Taxis TM, van der Meer F, Shrestha S, Qualley D, Coussens P, Rola-Łuszczak M, Ryło A, Sakhawat A, Mamanova S, Kuźmak J. Sci Rep. 2023 Dec 15;13(1):22356. doi: 10.1038/s41598-023-48899-4. PMID: 38102157

Anal Dysplasia Screening in People Living with HIV: Long-Term Follow-Up in a Large Cohort from Northwest Spain.

Pérez-González A, Rodríguez-Rivero S, Fernández-Veiga P, Flores E, Poveda E, González-Carreró J, Pérez-Castro S, Labajo-Leal L, Miralles C, Ocampo A. AIDS Patient Care STDS. 2023 Dec 20. doi: 10.1089/apc.2023.0231. Online ahead of print. PMID: 38117576

Seasonal trends in lysogeny in an Appalachian oak-hickory forest soil.
Jacoby ML, Hogg GD, Assaad MR, Williamson KE. Appl Environ Microbiol. 2023 Dec 12:e0140823. doi: 10.1128/aem.01408-23. Online ahead of print. PMID: 38084945

Dynamic updating of clinical survival prediction models in a changing environment.
Tanner KT, Keogh RH, Coupland CAC, Hippisley-Cox J, Diaz-Ordaz K. Diagn Progn Res. 2023 Dec 12;7(1):24. doi: 10.1186/s41512-023-00163-z. PMID: 38082429

Deciphering the host genetic factors conferring susceptibility to severe COVID-19 using exome sequencing.
Uslu K, Ozcelik F, Zararsiz G, Eldem V, Cephe A, Sahin IO, Yuksel RC, Sipahioglu H, Ozer Simsek Z, Baspinar O, Akalin H, Simsek Y, Gundogan K, Tutar N, Karayol Akin A, Ozkul Y, Yildiz O, Dundar M. Genes Immun. 2023 Dec 20. doi: 10.1038/s41435-023-00232-9. Online ahead of print. PMID: 38123822

The impact of S2 mutations on Omicron SARS-CoV-2 cell surface expression and fusogenicity.
Escalera A, Laporte M, Turner S, Karakus U, Gonzalez-Reiche AS, van de Guchte A, Farrugia K, Khalil Z, van Bakel H, Smith D, García-Sastre A, Aydillo T. Emerg Microbes Infect. 2023 Dec 19:2297553. doi: 10.1080/22221751.2023.2297553. Online ahead of print. PMID: 38112266

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.
Kado J, Salman S, Hla TK, Enkel S, Henderson R, Hand RM, Hort A, Page-Sharp M, Batty K, Moore BR, Bennett J, Anderson A, Carapetis J, Manning L. Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0096223. doi: 10.1128/aac.00962-23. Epub 2023 Nov 16. PMID: 37971244

Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer.
Gunasekaran P, Hwang YS, Lee GH, Park J, Kim JG, La YK, Park NY, Kothandaraman R, Yim MS, Choi J, Kim HN, Park IY, Lee SJ, Kim MH, Cha-Molstad H, Shin SY, Ryu EK, Bang JK. J Med Chem. 2023 Dec 17. doi: 10.1021/acs.jmedchem.3c01493. Online ahead of print. PMID: 38105611

Trends in Age and Disease Severity in Children Hospitalized With RSV Infection Before and During the COVID-19 Pandemic.
Garcia-Maurino C, Brenes-Chacón H, Halabi KC, Sánchez PJ, Ramilo O, Mejias A. JAMA Pediatr. 2023 Dec 11:e235431. doi: 10.1001/jamapediatrics.2023.5431. Online ahead of print. PMID: 38079156

Anti-Bacterial and Immunostimulatory Properties of Ulvan-Loaded Chitosan Nanoparticles for Use in Aquaculture.
Ponce M, Zuasti E, Anguís V, Fernández-Díaz C. Mar Biotechnol (NY). 2023 Dec 19. doi: 10.1007/s10126-023-10272-x. Online ahead of print. PMID: 38110743

Factors Associated with Cancer Prevention/Risk Reduction Behaviors among Latinos.
Rawl SM, Maupome G, Golzarri-Arroyo L, Parker E, O'Leary HA, Espinoza-Gutarra MR, Valenzuela RE, Malloy C, Haunert L, Haggstrom DA. J Racial Ethn Health Disparities. 2023 Dec 20. doi: 10.1007/s40615-023-01895-w. Online ahead of print. PMID: 38117442

Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics.
Chen SP, Blakney AK. Curr Opin Biotechnol. 2023 Dec 19;85:103049. doi: 10.1016/j.copbio.2023.103049. Online ahead of print. PMID: 38118363

Predictors of mortality among under-five children in rural Ethiopia: a cross sectional study.
Gebrerufael GG, Hagos BT. BMC Pediatr. 2023 Dec 15;23(1):633. doi: 10.1186/s12887-023-04440-0. PMID: 38102580

Development of a cervical cancer prevention text-messaging program for women living with HIV.
Ciceron AC, Berg CJ, Clausen M, Jeon MJ, Abroms LC, Le D. Health Educ Res. 2023 Dec 11;38(6):587-596. doi: 10.1093/her/cyad024. PMID: 37436827

A pilot study of the acceptability, efficacy, and iatrogenic effects of a brief dynamic norms intervention for reducing young adult alcohol use.
Graupensperger S, Jaffe AE, Blayney JA, Duckworth JC, Stappenbeck CA. Alcohol Clin Exp Res (Hoboken). 2023 Dec 11. doi: 10.1111/acer.15202. Online ahead of print. PMID: 38078844

Evolution of influenza A viruses in exhibition swine and transmission to humans, 2013-2015.
Szablewski CM, McBride DS, Trock SC, Habing GG, Hoet AE, Nelson SW, Nolting JM, Bowman AS. Zoonoses Public Health. 2023 Dec 18. doi: 10.1111/zph.13104. Online ahead of print. PMID: 38110691

A non-socially-sensitive predictive model of prostate cancer for Asian males with benign prostatic hyperplasia: A multi-site cross-sectional case-control study.
Chang HJ, Moi SH, Chan YJ, Lan TY. PLoS One. 2023 Dec 11;18(12):e0295608. doi: 10.1371/journal.pone.0295608. eCollection 2023. PMID: 38079423

Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases.
Gulati N, Chellappan DK, MacLoughlin R, Gupta G, Singh SK, Oliver BG, Dua K, Dureja H. Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec 11. doi: 10.1007/s00210-023-02882-y. Online ahead of print. PMID: 38078921

Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta).
Islam D, Ruamsap N, Imerbsin R, Khanijou P, Gonwong S, Wegner MD, McVeigh A, Poly FM, Crawford JM, Swierczewski BE, Kaminski RW, Laird RM. PLoS One. 2023 Dec 13;18(12):e0294021. doi: 10.1371/journal.pone.0294021. eCollection 2023. PMID: 38091314

Delphi Consensus on Clinical Applications of GOLD 2023 Recommendations in COPD Management: How Aligned are Recommendations with Clinical Practice?

Anzueto A, Cohen M, Echazarreta AL, Elassal G, Godoy I, Paramo R, Sayiner A, Torres-Duque CA, Acharya S, Aggarwal B, Erkus H, Levy G. Pulm Ther. 2023 Dec 19. doi: 10.1007/s41030-023-00248-6. Online ahead of print. PMID: 38112909

Pediatric and adult patients with ME/CFS following COVID-19: A structured approach to diagnosis using the Munich Berlin Symptom Questionnaire (MBSQ).
Peo LC, Wiehler K, Paulick J, Gerrer K, Leone A, Viereck A, Haegele M, Stojanov S, Warlitz C, Augustin S, Alberer M, Hattesohl DBR, Froehlich L, Scheibenbogen C, Jason LA, Mihatsch LL, Pricoco R, Behrends U. Eur J Pediatr. 2023 Dec 14. doi: 10.1007/s00431-023-05351-z. Online ahead of print. PMID: 38095713

Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Demel I, Skopal D, Šafránková E, Rozsívalová P, Jindra P, Šrámek J, Turková A, Vydra J, Labská K, Vedrová J, Čerňan M, Szotkowski T, Móciková H, Hynková L, Šušol O, Kováčová I, Belada D, Hájek R. Ann Hematol. 2023 Dec 14. doi: 10.1007/s00277-023-05572-0. Online ahead of print. PMID: 38092996

HEAD-TO-HEAD COMPARISON BETWEEN RESPIRATORY SYNCYTIAL VIRUS AND HUMAN METAPNEUMOVIRUS BRONCHIOLITIS IN THE SETTING OF INCREASED VIRAL TESTING.
Ramanathan A, Lee W, Peplinski J, Mace AO, Foley DA. Pediatr Infect Dis J. 2023 Dec 14. doi: 10.1097/INF.0000000000004217. Online ahead of print. PMID: 38100724

The overlooked bacterial pandemic.
Moriel DG, Piccioli D, Raso MM, Pizza M. Semin Immunopathol. 2023 Dec 11. doi: 10.1007/s00281-023-00997-1. Online ahead of print. PMID: 38078911

Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.
McShan AC, Flores-Solis D, Sun Y, Garfinkle SE, Toor JS, Young MC, Sgourakis NG. Nat Commun. 2023 Dec 11;14(1):8204. doi: 10.1038/s41467-023-43654-9. PMID: 38081856

Safety and Efficacy of Intramuscular Tixagevimab-Cilgavimab in Prevention of COVID-19 in Patients Who Are Immunocompromised.
Moon R, Tien A, Chung J, Pinnelas R, Lee R, Hwang J, Brasfield F, Sahota A. Perm J. 2023 Dec 15;27(4):44-54. doi: 10.7812/TPP/22.180. Epub 2023 Sep 18. PMID: 37718610

An expanded RT-PCR melting temperature coding assay to rapidly identify all known SARS-CoV-2 variants and sub-variants of concern.
Banada PP, Green R, Streck D, Kurvathi R, Reiss R, Banik S, Daivaa N, Montalvan I, Jones R, Marras SAE, Chakravorty S, Alland D. Sci Rep. 2023 Dec 11;13(1):21927. doi: 10.1038/s41598-023-48647-8. PMID: 38081834

Associations of a Prenatal Serum Per- and Polyfluoroalkyl Substance Mixture with the Cord Serum Metabolome in the HOME Study.
Hall AM, Fleury E, Papandonatos GD, Buckley JP, Cecil KM, Chen A, Lanphear BP, Yolton K, Walker DI, Pennell KD, Braun JM, Manz KE. Environ Sci Technol. 2023 Dec 13. doi: 10.1021/acs.est.3c07515. Online ahead of print. PMID: 38091497

Infectious diseases in Afghanistan: Strategies for health system improvement.
Essar MY, Siddiqui A, Head MG. Health Sci Rep. 2023 Dec 18;6(12):e1775. doi: 10.1002/hsr2.1775. eCollection 2023 Dec. PMID: 38116172

Risk factors for preterm birth: an umbrella review of meta-analyses of observational studies.
Mitrogiannis I, Evangelou E, Efthymiou A, Kanavos T, Birbas E, Makrydimas G, Papatheodorou S. BMC Med. 2023 Dec 13;21(1):494. doi: 10.1186/s12916-023-03171-4. PMID: 38093369

Spatiotemporal observations of host-pathogen interactions in mucosa during SARS-CoV-2 infection indicate a protective role of ILC2s.
Hu W, Meng L, Wang C, Lu W, Tong X, Lin R, Xu T, Chen L, Cui A, Xu X, Li A, Tang J, Gao H, Pei Z, Zhang R, Wang Y, Wang Y, Han W, Jiang N, Xiong C, Feng Y, Lee K, Chen M. Microbiol Spectr. 2023 Dec 12;11(6):e0087823. doi: 10.1128/spectrum.00878-23. Epub 2023 Nov 8. PMID: 37937994

Efficacy of probiotic treatment as post-exposure prophylaxis for COVID-19: A double-blind, Placebo-Controlled Randomized trial.
Wischmeyer PE, Tang H, Ren Y, Bohannon L, Jiang D, Bergens M, Ramirez ZE, Andermann TM, Messina JA, Sung JA, Jensen D, Jung SH, Artica A, Britt A, Bush A, Johnson E, Lew MV, Winthrop H, Pamanes C, Racioppi A, Zhao AT, Wan Z, Surana NK, Sung AD. Clin Nutr. 2023 Dec 11;43(1):259-267. doi: 10.1016/j.clnu.2023.11.043. Online ahead of print. PMID: 38103462

Digital PCR to Measure SARS-CoV-2 RNA, Variants, and Outcomes in Youth.
Hijano DR, Ferrolino JA, Gu Z, Brazelton JN, Zhu H, Suganda S, Glasgow HL, Dallas RH, Allison KJ, Maron G; St. Jude COVID-19 Patients Study Team; Darji H, Tang L, Fabrizio TP, Webby RJ, Hayden RT. J Pediatric Infect Dis Soc. 2023 Dec 16;12(12):618-626. doi: 10.1093/jpids/piad101. PMID: 37956414

Clostridioides difficile utilizes siderophores as an iron source and FhuDBGC contributes to ferrichrome uptake.
Hastie JL, Carmichael HL, Werner BM, Dunbar KE, Carlson PE Jr. J Bacteriol. 2023 Dec 19;205(12):e0032423. doi: 10.1128/jb.00324-23. Epub 2023 Nov 16. PMID: 37971230

Prevention of respiratory virus transmission by resident memory $CD8^+$ T cells.
Uddbäck I, Michalets SE, Saha A, Mattingly C, Kost KN, Williams ME, Lawrence LA, Hicks SL, Lowen AC, Ahmed H, Thomsen AR, Russell CJ, Scharer CD, Boss JM, Koelle K, Antia R, Christensen JP, Kohlmeier JE. Nature. 2023 Dec 12. doi: 10.1038/s41586-023-06937-1. Online ahead of print. PMID: 38086420

Utility and Evaluation of Applied Project Management Processes Within a Large Multicountry Health Systems Development Project Conducted During the Coronavirus Disease 2019 (COVID-19) Pandemic.
Kwon SY, Gautam S, Poudel K, Banneheke H, Ferreira D, Gautam M, Hau'ofa M, Mahmood N, Phommalad B, Sujan MJ, Yangzom P, Joh HS, Shaw A, Dolabella B, Seo HJ, Kim JH, Gallagher P, MacWright WR, Poudyal N, Marks F, Holm M. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S543-S548. doi: 10.1093/cid/ciad549. PMID: 38118010

Experience with German Research Consortia in the Field of Chemical Biology of Native Nucleic Acid Modifications.
Helm M, Bohnsack MT, Carell T, Dalpke A, Entian KD, Ehrenhofer-Murray A, Ficner R, Hammann C, Höbartner C, Jäschke A, Jeltsch A, Kaiser S, Klassen R, Leidel SA, Marx A, Mörl M, Meier JC, Meister G,

Rentmeister A, Rodnina M, Roignant JY, Schaffrath R, Stadler P, Stafforst T. ACS Chem Biol. 2023 Dec 15;18(12):2441-2449. doi: 10.1021/acschembio.3c00586. Epub 2023 Nov 14. PMID: 37962075

Effects of User-Reported Risk Factors and Follow-Up Care Activities on Satisfaction With a COVID-19 Chatbot: Cross-Sectional Study.
Singh A, Schooley B, Patel N. JMIR Mhealth Uhealth. 2023 Dec 14;11:e43105. doi: 10.2196/43105. PMID: 38096007

Evaluating Quality Management and Diagnostics Microbiology Performance Within an International External Quality Assessment (EQA) Program Serving National One Health Sector Reference Laboratories Across Asia: Experience Amid the Coronavirus Disease 2019 (COVID-19) Pandemic.
Abegaz FA, Dos Santos PT, Mogeni OD, Guarnacci T, Poudyal N, Hong J, Kwon SY, Braae R, Prathan R, Tongkum TL, Kamjumpho W, Chuanchuen R, Marks F, Hendriksen RS, Holm M. Clin Infect Dis. 2023 Dec 20;77(Supplement_7):S588-S596. doi: 10.1093/cid/ciad569. PMID: 38118017

Plasmodium falciparum ring-stage plasticity and drug resistance.
Platon L, Ménard D. Trends Parasitol. 2023 Dec 15:S1471-4922(23)00287-8. doi: 10.1016/j.pt.2023.11.007. Online ahead of print. PMID: 38104024

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.
Bolland W, Michel V, Planas D, Hubert M, Staropoli I, Guivel-Benhassine F, Porrot F, N'Debi M, Rodriguez C, Fourati S, Prot M, Planchais C, Hocqueloux L, Simon-Lorière E, Mouquet H, Prazuck T, Pawlotsky J-M, Bruel T, Schwartz O, Buchrieser J. J Virol. 2023 Dec 13:e0135123. doi: 10.1128/jvi.01351-23. Online ahead of print. PMID: 38088562

Prevalence and genotype distribution of human papillomavirus infection among women in Jingzhou, China: a population-based study of 51,720 women.
Liu S, Mei B, Ouyang Y, Li C. Virol J. 2023 Dec 15;20(1):297. doi: 10.1186/s12985-023-02262-1. PMID: 38102627

Detection and disease diagnosis trends (2017-2022) for Streptococcus suis, Glaesserella parasuis, Mycoplasma hyorhinis, Actinobacillus suis and Mycoplasma hyosynoviae at Iowa State University Veterinary Diagnostic Laboratory.
Silva APSP, Almeida M, Michael A, Rahe MC, Siepker C, Magstadt DR, Piñeyro P, Arruda BL, Macedo NR, Sahin O, Gauger PC, Krueger KM, Mugabi R, Streauslin JS, Trevisan G, Linhares DCL, Silva GS, Fano E, Main RG, Schwartz KJ, Burrough ER, Derscheid RJ, Sitthicharoenchai P, Clavijo MJ. BMC Vet Res. 2023 Dec 12;19(1):268. doi: 10.1186/s12917-023-03807-w. PMID: 38087358

Poxvirus infections in dermatology - the neglected, the notable, and the notorious.
Obermeier PE, Buder SC, Hillen U. J Dtsch Dermatol Ges. 2023 Dec 12. doi: 10.1111/ddg.15257. Online ahead of print. PMID: 38085140

Comparative proteomic analysis of wall-forming bodies and oocyst wall reveals the molecular basis underlying oocyst wall formation in Eimeria necatrix.
Wang L, Liu D, Zhu Y, Wang F, Cai W, Feng Q, Su S, Hou Z, Xu J, Hu J, Tao J. Parasit Vectors. 2023 Dec 18;16(1):460. doi: 10.1186/s13071-023-06076-6. PMID: 38111000

Human Papillomavirus 16 Lineage A Variants Associated With Persistent Genital Infections in Men: The HPV Infection in Men (HIM) Study.
Ferreira MT, Mendoza López RV, Gonçalves MG, Ferreira S, Sirak B, Baggio ML, Lazcano-Ponce E, Nyitray AG, Giuliano AR, Villa LL, Sichero L; HIM Study group. J Infect Dis. 2023 Dec 20;228(12):1748-1757. doi: 10.1093/infdis/jiad204. PMID: 37279655

The 2023 Orthopaedic Research Society's International Consensus Meeting on musculoskeletal infection: Summary from the host immunity section.
Schwarz EM, Archer NK, Atkins GJ, Bentley KLM, Botros M, Cassat JE, Chisari E, Coraça-Huber DC, Daiss JL, Gill SR, Goodman SB, Harro J, Hernandez CJ, Ivashkiv LB, Kates SL, Marques CNH, Masters EA, Muthukrishnan G, Owen JR, Raafat D, Saito M, Veis DJ, Xie C. J Orthop Res. 2023 Dec 16. doi: 10.1002/jor.25758. Online ahead of print. PMID: 38102985

An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti-Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike.
Chêne A, Desrames A, Tomlinson A, Ruffié C, Tangy F, Gamain B. J Infect Dis. 2023 Dec 20;228(12):1675-1679. doi: 10.1093/infdis/jiad329. PMID: 37562051

Vpr attenuates antiviral immune responses and is critical for full pathogenicity of SIV_{mac239} in rhesus macaques.
Laliberté A, Prelli Bozzo C, Stahl-Hennig C, Hunszinger V, Joas S, Sauermann U, Roshani B, Klippert A, Daskalaki M, Mätz-Rensing K, Stolte-Leeb N, Tharp GK, Fuchs D, Gupta PM, Silvestri G, Nelson SA, Parodi L, Giavedoni L, Bosinger SE, Sparrer KMJ, Kirchhoff F. iScience. 2023 Oct 26;26(12):108351. doi: 10.1016/j.isci.2023.108351. eCollection 2023 Dec 15. PMID: 38025783

Emergence and genomic insights of non-pandemic O1 *Vibrio cholerae* in Zhejiang, China.
Luo Y, Payne M, Kaur S, Octavia S, Jiang J, Lan R. Microbiol Spectr. 2023 Dec 12;11(6):e0261523. doi: 10.1128/spectrum.02615-23. Epub 2023 Oct 11. PMID: 37819129

Cutting Edge: CCR8 Signaling Regulates IL-25- and IL-33-Responsive Skin Group 2 Innate Lymphoid Cell Migration and Function.
Sun Z, Sen H, Zhu X, Islam SA. J Immunol. 2023 Dec 15;211(12):1751-1755. doi: 10.4049/jimmunol.2200829. PMID: 37921466

Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma.
Jia X, Wang L, Feng X, Liu W, Wang X, Li F, Liu X, Yu J, Yu B, Yu X. Nano Lett. 2023 Dec 13;23(23):11120-11128. doi: 10.1021/acs.nanolett.3c03516. Epub 2023 Nov 30. PMID: 38032110

High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. Nat Commun. 2023 Dec 14;14(1):8299. doi: 10.1038/s41467-023-43384-y. PMID: 38097552

Lasso peptide MccY alleviates non-typhoidal salmonellae-induced mouse gut inflammation via regulation of intestinal barrier function and gut microbiota.
Li Y, Li W, Zeng Z, Han Y, Chen Q, Dong X, Wang Z, Feng S, Cao W. Microbiol Spectr. 2023 Dec 12;11(6):e0178423. doi: 10.1128/spectrum.01784-23. Epub 2023 Oct 11. PMID: 37819128

A single C-terminal residue controls SARS-CoV-2 spike trafficking and incorporation into VLPs.
Dey D, Qing E, He Y, Chen Y, Jennings B, Cohn W, Singh S, Gakhar L, Schnicker NJ, Pierce BG, Whitelegge JP, Doray B, Orban J, Gallagher T, Hasan SS. Nat Commun. 2023 Dec 15;14(1):8358. doi: 10.1038/s41467-023-44076-3. PMID: 38102143

The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13.
Fujiwara K, Maekawa M, Iimori Y, Ogawa A, Urano T, Kono N, Takeda H, Higashiyama S, Arita M, Murai J. iScience. 2023 Nov 23;26(12):108529. doi: 10.1016/j.isci.2023.108529. eCollection 2023 Dec 15. PMID: 38125019

Effect of Nk-lysin peptides on bacterial growth, MIC, antimicrobial resistance, and viral activities.
Yacoub HA, Mahmoud MM, Al-Hejin AM, Abujamel TS, Tabrez S, Abd-Elmaksoud S. Anim Biotechnol. 2023 Dec 15:1-19. doi: 10.1080/10495398.2023.2290520. Online ahead of print. PMID: 38100547

Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper.
Mayorga C, Çelik GE, Pascal M, Hoffmann HJ, Eberlein B, Torres MJ, Brockow K, Garvey LH, Barbaud A, Madrigal-Burgaleta R, Caubet JC, Ebo DG. Allergy. 2023 Dec 12. doi: 10.1111/all.15957. Online ahead of print. PMID: 38084472

Chitosan and hyaluronic acid-based nanocarriers for advanced cancer therapy and intervention.
Rohtagi P, Garg U, Triveni, Jain N, Pandey M, Amin MCIM, Gorain B, Kumar P. Biomater Adv. 2023 Dec 12;157:213733. doi: 10.1016/j.bioadv.2023.213733. Online ahead of print. PMID: 38118207

Antiviral properties of Penaeus monodon cyclophilin A in response to white spot syndrome virus infection in the black tiger shrimp.
Vatanavicharn T, Matjank W, Masrinoul P, Supungul P, Tassanakajon A, Rimphanitchayakit V, Ponprateep S. Fish Shellfish Immunol. 2023 Dec 15:109299. doi: 10.1016/j.fsi.2023.109299. Online ahead of print. PMID: 38104700

Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.
Xie Y, Choi T, Al-Aly Z. Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684-9. doi: 10.1016/S1473-3099(23)00684-9. Online ahead of print. PMID: 38104583

Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity.
Zhu Y, Ma J, Shen R, Lin J, Li S, Lu X, Stelzel JL, Kong J, Cheng L, Vuong I, Yao ZC, Wei C, Korinetz NM, Toh WH, Choy J, Reynolds RA, Shears MJ, Cho WJ, Livingston NK, Howard GP, Hu Y, Tzeng SY, Zack DJ, Green JJ, Zheng L, Doloff JC, Schneck JP, Reddy SK, Murphy SC, Mao HQ. Nat Biomed Eng. 2023 Dec 11. doi: 10.1038/s41551-023-01131-0. Online ahead of print. PMID: 38082180

Viral Attachment Blocking Chimera Composed of DNA Origami and Nanobody Inhibits Pseudorabies Virus Infection In Vitro.
Pradhan S, Swanson CJ, Leff C, Tengganu I, Bergeman MH, Wisna GBM, Hogue IB, Hariadi RF. ACS Nano. 2023 Dec 12;17(23):23317-23330. doi: 10.1021/acsnano.3c01408. Epub 2023 Nov 20. PMID: 37982733

Carbapenem resistance in extensively drug-resistant *Salmonella enterica* serovar Agona and AmpC β-lactamase-producing *S.* Infantis.
Hsu P-C, Wang Y-W, Chen B-H, Hong Y-P, Teng R-H, Liu P-Y, Chiou C-S. Microbiol Spectr. 2023 Dec 12;11(6):e0292223. doi: 10.1128/spectrum.02922-23. Epub 2023 Oct 3. PMID: 37787563

The Social, Mental, and Physical Health Impacts of the COVID-19 Pandemic on People With HIV: Protocol of an Observational International Multisite Study.
Cuca YP, Horvat Davey C, Corless IB, Phillips JC, Sierra-Perez ÁJ, Solís Báez S, Iwu E, Sabone M, Mulaudzi MT, Murphey C, Shaibu S, Chen WT, Santa Maria D, Schnall R, Palmieri P, Apiruknapanond P, Wang T, de Jesús T, Huang E, Broussard J, Dawson-Rose C. J Assoc Nurses AIDS Care. 2023 Dec 14. doi: 10.1097/JNC.0000000000000444. Online ahead of print. PMID: 38096186

Association of skeletal muscle function, quantity, and quality with gut microbiota in Japanese adults: A cross-sectional study.
Iwasaka C, Nanri H, Nakagata T, Ohno H, Tanisawa K, Konishi K, Murakami H, Hosomi K, Park J, Yamada Y, Ono R, Mizuguchi K, Kunisawa J, Miyachi M. Geriatr Gerontol Int. 2023 Dec 14. doi: 10.1111/ggi.14751. Online ahead of print. PMID: 38098315

International travel increases risk of urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacterales-three-arm case-control study.
Patjas A, Martelius A, Ollgren J, Kantele A. J Travel Med. 2023 Dec 20:taad155. doi: 10.1093/jtm/taad155. Online ahead of print. PMID: 38123504

Exploration of the novel fluoroquinolones with high inhibitory effect against quinolone-resistant DNA gyrase of *Salmonella* Typhimurium.
Toyting J, Miura N, Utrarachkij F, Tanomsridachchai W, Belotindos LP, Suwanthada P, Kapalamula TF, Kongsoi S, Koide K, Kim H, Thapa J, Nakajima C, Suzuki Y. Microbiol Spectr. 2023 Dec 12;11(6):e0133023. doi: 10.1128/spectrum.01330-23. Epub 2023 Oct 5. PMID: 37795999

Detecting residual chronic Salmonella Typhi carriers on the road to typhoid elimination in Santiago, Chile, 2017-2019.
Lagos RM, Sikorski MJ, Hormazábal JC, Fernandez A, Duarte S, Pasetti MF, Rasko DA, Higginson E, Nkeze J, Kasumba IN, Dougan G, Maes M, Lees A, Tennant SM, Levine MM. J Infect Dis. 2023 Dec 20:jiad585. doi: 10.1093/infdis/jiad585. Online ahead of print. PMID: 38123455

IgA coating of vaginal bacteria is reduced in the setting of bacterial vaginosis (BV) and preferentially targets BV-associated species.
Murphy K, Gromisch M, Srinivasan S, Wang T, Wood L, Proll S, Liu C, Fiedler T, Valint DJ, Fredricks DN, Keller MJ, Herold BC. Infect Immun. 2023 Dec 15:e0037323. doi: 10.1128/iai.00373-23. Online ahead of print. PMID: 38099624

Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates.
Petty NE, Radtke S, Fields E, Humbert O, Llewellyn MJ, Laszlo GS, Zhu H, Jerome KR, Walter RB, Kiem HP. Mol Ther Methods Clin Dev. 2023 Sep 26;31:101121. doi: 10.1016/j.omtm.2023.101121. eCollection 2023 Dec 14. PMID: 37868209

Role of Exosomes in Epithelial-Mesenchymal Transition.
Bhattacharya B, Nag S, Mukherjee S, Kulkarni M, Chandane P, Mandal D, Mukerjee N, Mirgh D, Anand K, Adhikari MD, Gorai S, Thorat N. ACS Appl Bio Mater. 2023 Dec 18. doi: 10.1021/acsabm.3c00941. Online ahead of print. PMID: 38108852

Correction to: Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy.
Menniti-Ippolito F, Mele A, Da Cas R, De Masi S, Chiarotti F, Fabiani M, Baglio G, Traversa G, Colavita F, Castilletti C, Salomone M, Zoccali C, Messa P; COVIDVaxDia Study Group. J Nephrol. 2023 Dec 20. doi: 10.1007/s40620-023-01864-w. Online ahead of print. PMID: 38114883

Diagnostic value of rapid test for malaria among febrile neonates in a tertiary hospital in North-East Nigeria: a prospective cross-sectional study.
Adeniji YR, Jalo I, Okonkwo I, Poksireni MR, Manga M, Wariri O, Alhassan HA, Warnow EI. Arch Dis Child. 2023 Dec 14;109(1):11-15. doi: 10.1136/archdischild-2023-325906. PMID: 37879855

Improving antibiotic prescribing quality in out-of-hours primary care: a mixed-methods study using participatory action research.
Colliers A, Coenen S, Teughels S, Boogaerts Y, Vandeput O, Tans A, Vermeulen H, Remmen R, Philips H, Anthierens S. JAC Antimicrob Resist. 2023 Dec 11;5(6):dlad131. doi: 10.1093/jacamr/dlad131. eCollection 2023 Dec. PMID: 38089462

Economic evaluation of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: A modelling study.
Goscé L, Allel K, Hamada Y, Korobitsyn A, Ismail N, Bashir S, Denkinger CM, Abubakar I, White PJ, Rangaka MX. PLOS Glob Public Health. 2023 Dec 20;3(12):e0002573. doi: 10.1371/journal.pgph.0002573. eCollection 2023. PMID: 38117825

Early cellular and molecular signatures correlate with severity of West Nile virus infection.
Lee HJ, Zhao Y, Fleming I, Mehta S, Wang X, Wyk BV, Ronca SE, Kang H, Chou CH, Fatou B, Smolen KK, Levy O, Clish CB, Xavier RJ, Steen H, Hafler DA, Love JC, Shalek AK, Guan L, Murray KO, Kleinstein SH, Montgomery RR. iScience. 2023 Nov 2;26(12):108387. doi: 10.1016/j.isci.2023.108387. eCollection 2023 Dec 15. PMID: 38047068

Inhibition potential of natural flavonoids against selected omicron (B.1.19) mutations in the spike receptor binding domain of SARS-CoV-2: a molecular modeling approach.
Kumar A, Dutt M, Dehury B, Sganzerla Martinez G, Swan CL, Kelvin AA, Richardson CD, Kelvin DJ. J Biomol Struct Dyn. 2023 Dec 19:1-15. doi: 10.1080/07391102.2023.2291165. Online ahead of print. PMID: 38115191

Exploring the limitations of language interpretation: A qualitative study on clinicians' experiences at French Office of Immigration and Integration.
Brown C, Roucoux G, Dimi S, Fahmi S, Banou Jeevan R, Chassany O, Chaplin JE, Duracinsky M. PLOS Glob Public Health. 2023 Dec 18;3(12):e0002436. doi: 10.1371/journal.pgph.0002436. eCollection 2023. PMID: 38109295

Does a school-based intervention increase girls' sexual and reproductive health attitudes and intentions? Results from a mixed-methods cluster-randomized trial in Burkina Faso.
Hinson L, Pliakas T, Schaub E, Nourou AM, Angelone C, Brooks MI, Abga AA, Congo Z, Ki B, Trasi R. PLOS Glob Public Health. 2023 Dec 11;3(12):e0000910. doi: 10.1371/journal.pgph.0000910. eCollection 2023. PMID: 38079379

Using viral sequence diversity to estimate time of HIV infection in infants.
Russell ML, Fish CS, Drescher S, Cassidy NAJ, Chanana P, Benki-Nugent S, Slyker J, Mbori-Ngacha D, Bosire R, Richardson B, Wamalwa D, Maleche-Obimbo E, Overbaugh J, John-Stewart G, Matsen FA 4th, Lehman DA. PLoS Pathog. 2023 Dec 20;19(12):e1011861. doi: 10.1371/journal.ppat.1011861. eCollection 2023 Dec. PMID: 38117834

Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women using the Dapivirine Vaginal Ring.
Stalter RM, Dong TQ, Hendrix CW, Palanee-Phillips T, van der Straten A, Hillier SL, Kiweewa FM, Mgodi NM, Marzinke MA, Bekker LG, Soto-Torres L, Baeten JM, Brown ER; MTN-020/ASPIRE Study Team. J Infect Dis. 2023 Dec 14:jiad550. doi: 10.1093/infdis/jiad550. Online ahead of print. PMID: 38099506

Development of 3-acetylindole derivatives that selectively target BRPF1 as new inhibitors of receptor activator of NF-κB ligand (RANKL)-Induced osteoclastogenesis.
Zhang W, Ning R, Ran T, Peng Q, Liu Y, Lu T, Chen Y, Jiang M, Jiao Y. Bioorg Med Chem. 2023 Dec 15;96:117440. doi: 10.1016/j.bmc.2023.117440. Epub 2023 Aug 9. PMID: 37951134

Viral uptake and pathophysiology of the lung endothelial cells in age-associated severe SARS-CoV-2 infection models.
Tsumita T, Takeda R, Maishi N, Hida Y, Sasaki M, Orba Y, Sato A, Toba S, Ito W, Teshirogi T, Sakurai Y, Iba T, Naito H, Ando H, Watanabe H, Mizuno A, Nakanishi T, Matsuda A, Zixiao R, Lee JW, Iimura T, Sawa H, Hida K. Aging Cell. 2023 Dec 14:e14050. doi: 10.1111/acel.14050. Online ahead of print. PMID: 38098255

Prediction of malaria positivity using patients' demographic and environmental features and clinical symptoms to complement parasitological confirmation before treatment.
Ojurongbe TA, Afolabi HA, Bashiru KA, Sule WF, Akinde SB, Ojurongbe O, Adegoke NA. Trop Dis Travel Med Vaccines. 2023 Dec 15;9(1):24. doi: 10.1186/s40794-023-00208-7. PMID: 38098124

Resting phase-administration of lemborexant ameliorates sleep and glucose tolerance in type 2 diabetic mice.
Tsuneki H, Sugiyama M, Sato K, Ito H, Nagai S, Kon K, Wada T, Kobayashi N, Okada T, Toyooka N, Kawasaki M, Ito T, Otsubo R, Okuzaki D, Yasui T, Sasaoka T. Eur J Pharmacol. 2023 Dec 15;961:176190. doi: 10.1016/j.ejphar.2023.176190. Epub 2023 Nov 11. PMID: 37952563

Rapid and sensitive detection of SARS-CoV-2 virus in human saliva samples using glycan based nanozyme: a clinical study.
Rokni M, Rohani Bastami T, Meshkat Z, Reza Rahimi H, Zibaee S, Meshkat M, Fotouhi F, Serki E, Khoshakhlagh M, Dabirifar Z. Mikrochim Acta. 2023 Dec 18;191(1):36. doi: 10.1007/s00604-023-06120-3. PMID: 38108890

Population confidence in the health system in 15 countries: results from the first round of the People's Voice Survey.
Kruk ME, Kapoor NR, Lewis TP, Arsenault C, Boutsikari EC, Breda J, Carai S, Croke K, Dayalu R, Fink G, Garcia PJ, Kassa M, Mohan S, Moshabela M, Nzinga J, Oh J, Okiro EA, Prabhakaran D, SteelFisher GK, Tarricone R, Garcia-Elorrio E. Lancet Glob Health. 2024 Jan;12(1):e100-e111. doi: 10.1016/S2214-109X(23)00499-0. Epub 2023 Dec 11. PMID: 38096882

Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19).
Fanshawe TR, Tonner S, Turner PJ, Cogdale J, Glogowska M, De Lusignan S, Okusi C, Perera R, Sebastianpillai P, Williams A, Zambon M, Nicholson BD, Hobbs FDR, Hayward GN; RAPTOR-C19 STUDY GROUP. Clin Microbiol Infect. 2023 Dec 14:S1198-743X(23)00599-2. doi: 10.1016/j.cmi.2023.12.009. Online ahead of print. PMID: 38103638

Performance of established disease severity scores in predicting severe outcomes among adults hospitalized with influenza-FluSurv-NET, 2017-2018.
Doyle JD, Garg S, O'Halloran AC, Grant L, Anderson EJ, Openo KP, Alden NB, Herlihy R, Meek J, Yousey-Hindes K, Monroe ML, Kim S, Lynfield R, McMahon M, Muse A, Spina N, Irizarry L, Torres S, Bennett NM, Gaitan MA, Hill M, Cummings CN, Reed C, Schaffner W, Talbot HK, Self WH, Williams D. Influenza Other Respir Viruses. 2023 Dec 17;17(12):e13228. doi: 10.1111/irv.13228. eCollection 2023 Dec. PMID: 38111901

Burden of Herpes Zoster in Individuals with Immunocompromised Conditions and Autoimmune Diseases in the Republic of Korea: A Nationwide Population-Based Database Study.
Chen J, Shin JY, Shantakumar S, Bea S, Ye BD, Lee DG, Kim H, Choi WS, Kaan I. Infect Dis Ther. 2023 Dec 12. doi: 10.1007/s40121-023-00894-y. Online ahead of print. PMID: 38085494

Expert guidance on target product profile development for AMR diagnostic tests.
Bachmann TT, Mitsakakis K, Hays JP, van Belkum A, Russom A, Luedke G, Simonsen GS, Abel G, Peter H, Goossens H, Moran-Gilad J, Vila J, Becker K, Moons P, Sampath R, Peeling RW, Luz S, van Staa T, Di Gregori V; JPIAMR AMR-RDT Working Group. BMJ Glob Health. 2023 Dec 18;8(12):e012319. doi: 10.1136/bmjgh-2023-012319. PMID: 38114235

Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice.
Vasquez Ayala A, Hsu CY, Oles RE, Matsuo K, Loomis LR, Buzun E, Carrillo Terrazas M, Gerner RR, Lu HH, Kim S, Zhang Z, Park JH, Rivaud P, Thomson M, Lu LF, Min B, Chu H. J Exp Med. 2024 Jan 1;221(1):e20230063. doi: 10.1084/jem.20230063. Epub 2023 Dec 12. PMID: 38085267

A distinct human cell type expressing MHCII and RORγt with dual characteristics of dendritic cells and type 3 innate lymphoid cells.

Ulezko Antonova A, Lonardi S, Monti M, Missale F, Fan C, Coates ML, Bugatti M, Jaeger N, Fernandes Rodrigues P, Brioschi S, Trsan T, Fachi JL, Nguyen KM, Nunley RM, Moratto D, Zini S, Kong L, Deguine J, Peeples ME, Xavier RJ, Clatworthy MR, Wang T, Cella M, Vermi W, Colonna M. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2318710120. doi: 10.1073/pnas.2318710120. Epub 2023 Dec 18. PMID: 38109523

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation.
Wong CKH, Lau JJ, Au ICH, Lau KTK, Hung IFN, Peiris M, Leung GM, Wu JT. Nat Commun. 2023 Dec 16;14(1):8377. doi: 10.1038/s41467-023-43706-0. PMID: 38104114

The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates.
Brickey WJ, Caudell DL, Macintyre AN, Olson JD, Dai Y, Li S, Dugan GO, Bourland JD, O'Donnell LM, Tooze JA, Huang G, Yang S, Guo H, French MN, Schorzman AN, Zamboni WC, Sempowski GD, Li Z, Owzar K, Chao NJ, Cline JM, Ting JPY. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2122178120. doi: 10.1073/pnas.2122178120. Epub 2023 Dec 5. PMID: 38051771

Intranasal mask for protecting the respiratory tract against viral aerosols.
Hu X, Wang S, Fu S, Qin M, Lyu C, Ding Z, Wang Y, Wang Y, Wang D, Zhu L, Jiang T, Sun J, Ding H, Wu J, Chang L, Cui Y, Pang X, Wang Y, Huang W, Yang P, Wang L, Ma G, Wei W. Nat Commun. 2023 Dec 18;14(1):8398. doi: 10.1038/s41467-023-44134-w. PMID: 38110357

External validation of a multivariable prediction model for identification of pneumonia and other serious bacterial infections in febrile immunocompromised children.
Martin AJ, van der Velden FJS, von Both U, Tsolia MN, Zenz W, Sagmeister M, Vermont C, de Vries G, Kolberg L, Lim E, Pokorn M, Zavadska D, Martinón-Torres F, Rivero-Calle I, Hagedoorn NN, Usuf E, Schlapbach L, Kuijpers TW, Pollard AJ, Yeung S, Fink C, Voice M, Carrol E, Agyeman PKA, Khanijau A, Paulus S, De T, Herberg JA, Levin M, van der Flier M, de Groot R, Nijman R, Emonts M; PERFORM consortium. Arch Dis Child. 2023 Dec 14;109(1):58-66. doi: 10.1136/archdischild-2023-325869. PMID: 37640431

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20231211:20231220 as the publication date 26 records*

1.WO/2023/240211STAPHYLOCOCCUS AUREUS VACCINE
WO - 14.12.2023
Clasificación Internacional A61K 39/085 Nº de solicitud PCT/US2023/068158 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a LIU, George Yen-Hsi
A vaccine for Staphylococcus aureus is disclosed. A method for producing a vaccine for S. aureus is also disclosed. A method for immunizing a human against S. aureus infection is further disclosed.

2.WO/2023/236822DEVELOPMENT AND USE OF H5N6 AVIAN INFLUENZA BROAD-SPECTRUM VACCINE
WO - 14.12.2023

Clasificación Internacional C12N 7/01 Nº de solicitud PCT/CN2023/097257 Solicitante NANJING ADVANCED ACADEMY OF LIFE AND HEALTH Inventor/a WANG, Guiqin
Disclosed are development and use of an H5N6 avian influenza broad-spectrum vaccine. Provided are preparation methods for a recombinant protein vaccine, an inactivated vaccine and a nucleic acid vaccine, and use thereof. Experiments show that the prepared recombinant protein vaccine, inactivated vaccine and nucleic acid vaccine can effectively prevent the infection of avian influenza virus.

3.WO/2023/240148HYBRID FLU-CORONAVIRUS VACCINE
WO - 14.12.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2023/068080 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a BENMOHAMED, Lbachir
A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike (S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike (S) protein is highly conserved among human and animal *coronaviruses*. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.

4.WO/2023/236041MRNA VACCINE ENCODING PCRV AND/OR OPRF-I PROTEIN
WO - 14.12.2023
Clasificación Internacional C12N 15/31 Nº de solicitud PCT/CN2022/097390 Solicitante SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor/a HE, Yunjiao
The present invention provides an mRNA vaccine encoding the protein(s) PcrV and/or OprF-I. The mRNA molecule encodes at least one of 1) the protein PcrV; and 2) the protein OprF and the protein OprI. The vaccine prepared from the mRNA designed by the present invention has an excellent prophylactic and/or therapeutic effect on diseases caused by Pseudomonas aeruginosa.

5.WO/2023/240278USES OF GLYCOLIPIDS AS A VACCINE ADJUVANT AND METHODS THEREOF
WO - 14.12.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2023/068255 Solicitante THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Inventor/a HO, David, D.
The subject matter described herein related to a messenger RNA (mRNA)-vaccine adjuvant comprising a glycolipid compound.

6.4288087IMPFSTOFF UND VERFAHREN ZUR VORBEUGUNG VON FILARIASIS UND DIROFILARIASIS
EP - 13.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 22705643 Solicitante UNIV ILLINOIS Inventor/a KALYANASUNDARAM RAMASWAMY
The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some aspects, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

7.WO/2023/236330CANCER VACCINE BASED ON ANTIGEN-PRESENTING CELL MEMBRANE COMPONENTS, METHOD FOR PREPARING SAME, AND USE THEREOF
WO - 14.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2022/108960 Solicitante SUZHOU ERSHENG BIOMEDICAL CO., LTD. Inventor/a LIU, Mi

Provided are a cancer vaccine based on antigen-presenting cell membrane components, a method for preparing same, and use thereof. The cancer vaccine comprises one of the following: (1) a nanovesicle prepared from cell membrane components of an activated antigen-presenting cell; and (2) a second delivery particle carrying total cell components of a cancer cell in the interior and/or exterior and carrying the activated antigen-presenting cell membrane components on the surface. The method solves the difficulties in maintaining the activity of dendritic cells and long-term preservation of lyophilized cells in existing living cell vaccines, while achieving the loading of various cancer cell antigens on vaccines derived from dendritic cells. The present invention can be used for preparing a cancer vaccine carrying antigen epitopes of various cancer cells for preventing and treating cancers.

8.WO/2023/236331METHOD FOR PREPARING VACCINE OF AUTOIMMUNE DISEASE DERIVED FROM PRE-ACTIVATED ANTIGEN-PRESENTING CELL AND USE THEREOF
WO - 14.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2022/108962 Solicitante SUZHOU ERSHENG BIOMEDICAL CO., LTD. Inventor/a LIU, Mi
Provided are a method for preparing a vaccine of an autoimmune disease derived from a pre-activated antigen-presenting cell and use thereof. The method comprises the following steps: co-incubating the antigen-presenting cell and a first delivery particle carrying total cell antigens of the autoimmune disease to give the pre-activated antigen-presenting cell; and preparing, from the cell membrane of the pre-activated antigen-presenting cell, a nanovesicle or a nanoparticle or microparticle with components of the cell membrane loaded on the surfaces of the particles to give the vaccine of the autoimmune disease. The method solves the difficulties in maintaining the activity of dendritic cells and long-term preservation of lyophilized cells in existing living cell vaccines, while achieving the loading of various cancer cell antigens on vaccines derived from dendritic cells. The present invention can be used for preparing a vaccine carrying antigen epitopes of various autoimmune diseases for preventing and treating autoimmune diseases.

9.4288964EINSTUFUNG VON NEOANTIGENEN FÜR PERSONALISIERTEN KREBSIMPFSTOFF
EP - 13.12.2023
Clasificación Internacional G16B 20/20 Nº de solicitud 22705329 Solicitante AMAZON TECH INC Inventor/a PRICE LAYNE CHRISTOPHER
Disclosed herein are methods for ranking tumor-specific neoantigens from a tumor of a subject that are suitable for subject-specific immunogenic compositions. Suitable tumor-specific neoantigens are tumor-specific neoantigens that are likely presented on the cell surface of the tumor, are likely to be immunogenic, are predicted to be expressed in sufficient amounts to elicit an immune response in the subject, optionally represent sufficient diversity across the tumor, and have relatively high manufacture feasibility. The present methods take a set of neoantigens (peptide vaccine candidates) and ranks the neoantigens in a way such that a group of top-ranked neoantigens simultaneously promotes cell-surface presentation of important neoantigens for Class I and Class II MHC molecules. The top-ranked neoantigens can then be further narrowed according manufacturability and/or other criteria.

10.3407899IMMUNPROFYLAKSE MOD TILBAGEVENDENDE BAKTERIELLE INFEKTIONER
DK - 11.12.2023
Clasificación Internacional A61K 31/721 Nº de solicitud 17702813 Solicitante Strathmann GmbH & Co. KG Inventor/a BEHNKE, Bert
Die vorliegende Erfindung betrifft die Verwendung von Dextran als Impfstoff, insbesondere zur prophylaktischen Behandlung von rezidivierenden Infektionen bakterieller Herkunft. Außerdem betrifft die vorliegende Erfindung eine Impfstoffzusammensetzung, die Dextran als einzigen Impfstoff und ein

Adjuvans, vorzugsweise eine Aluminiumverbindung, enthält sowie einen Arzneimittel-Kit zur Herstellung der Impfstoffzusammensetzung.

11.4288094IMPFUNG ZUM SCHUTZ VON GEFLÜGEL GEGEN GEFLÜGELPATHOGENE
EP - 13.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 22708794 Solicitante INTERVET INT BV Inventor/a PULSKENS WILLEM PIETER CORNELIS
The invention pertains to a vaccine comprising non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, for use in boosting an immune response in a poultry animal directed against the poultry pathogen by administering the vaccine mucosally to the poultry animal. The invention also pertains to a vaccine comprising a liquid pharmaceutically acceptable carrier, a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, as well as a method of boosting an immune response in a poultry animal, which immune response is directed against a poultry pathogen, by administering a vaccine mucosally to the poultry animal, the vaccine comprising a non-live antigen of the said poultry pathogen and a mucoadhesive adjuvant.

12.4288526ABGESCHWÄCHTES AFRIKANISCHES SCHWEINEPESTVIRUS UND SEINE VERWENDUNG ALS IMPFSTOFF
EP - 13.12.2023
Clasificación Internacional C12N 7/00 Nº de solicitud 22703602 Solicitante AGENCE NAT DE SECURITE SANITAIRE DE LALIMENTATION DE LENVIRONNEMENT ET DU TRAVAIL Inventor/a BLOT LE POTIER MARIE-FRÉDÉRIQUE
The present invention relates to an attenuated African Swine Fever (ASF) virus, wherein : • genes MGF 360-12L, 360-13L, 360-14L, 505-2R, 505-3R are deleted or are interrupted or mutated such that the genes are not transcribed and/or translated, • ORF of ASFV_G_ACD_00520 is deleted or is interrupted or mutated such that it is not transcribed and/or translated, and • genes MGF 505-1 R et 505-4R are truncated, compared to the genome of the corresponding unattenuated virus. The present invention also refers to a vaccine comprising the attenuated ASF virus, and its use in preventing African Swine Fever in a subject. The present invention also relates to an in-vitro method for obtaining the attenuated ASF virus, which comprises at least one step of thermal- attenuation of a virulent ASFV virus strain selected among Georgia 2007/1, Pig/HLJ/2018, a strain of ASF virus of genotype II or a genetically close ASF virus strain, and amplification by inoculation of Specific-Pathogen- Free pigs and selecting said attenuated ASF virus. The present invention refers to an in vitro method for the differential detection of the attenuated ASF virus and of the corresponding non- attenuated ASF virus as well.

13.WO/2023/239265HYBRID GENE FOR PRODUCING RECOMBINANT RBD ANTIGEN
WO - 14.12.2023
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/RU2023/050144 Solicitante OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTUY "BETUVAKS" Inventor/a KRASILNIKOV, Igor Viktorovich
The invention relates to biotechnology, immunology and virology, and more particularly to the creation of a vaccine against coronavirus infection and to a method for producing same, for producing a hybrid gene that codes for the recombinant antigen RBD/S21/S14-Fc, and for producing a recombinant antigen capable of inducing a specific humoral and cellular immune response to the requisite epitope of the viral envelope protein of SARS-CoV-2. The technical result of the claimed invention is the creation of a vaccine composition containing a recombinant antigen, with betulin as an adjuvant. This technical result is achieved by the creation of a gene, a gene construct, a cell line (production strain) producing the target RBD/S21/S14-Fc recombinant antigen of SARS-CoV-2, which is fused with the Fc fragment of immunoglobulin by a linker, and a method for purifying a recombinant protein, producing a vaccine

composition containing a recombinant antigen and a particulate adjuvant, and also administering same to produce an immune response to the coronavirus.

14.WO/2023/239593METHOD FOR SUSTAINED DELIVERY OF MRNA VACCINES
WO - 14.12.2023
Clasificación Internacional A61K 48/00 Nº de solicitud PCT/US2023/024220 Solicitante MERCK SHARP & DOHME LLC Inventor/a BETT, Andrew
The invention relates to a method of treating a disease or disorder in a patient in need thereof that includes providing an active pharmaceutical ingredient (API) to the patient by administering more than one split-dose of the API over a pre-determined period of time. In embodiments of the invention, the API is an mRNA encoding an antigen. The attractiveness of mRNA as a vaccine modality is supported by several advantages. As a non-infectious agent that does not require incorporation into the host's genome to confer activity along with its well-defined chemical composition, mRNA is regarded as a relatively safe vaccine modality.

15.WO/2023/237649RSV VACCINATION WITH TRIMERIC RSV F FUSION PROTEIN
WO - 14.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2023/065335 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a DAVID, Marie-Pierre Paule
The present invention relates to vaccination against respiratory syncytial virus (RSV), in particular to the use of a vaccine formulation comprising an RSV F fusion protein (RSV F protein) antigen and an adjuvant in methods of prevention of RSV infection and disease in older adults.

16.WO/2023/236563MONKEYPOX VIRUS-SPECIFIC DETECTION TARGET, AND OLIGONUCLEOTIDE AND KIT THEREOF
WO - 14.12.2023
Clasificación Internacional C12Q 1/70 Nº de solicitud PCT/CN2023/074725 Solicitante ACON BIOTECH (HANGZHOU) CO., LTD. Inventor/a ZHANG, Taisong
The present invention relates to a monkeypox virus-specific detection target, and an oligonucleotide, a kit and a method for detecting a monkeypox virus. The method comprises designing a specific primer and probe for an F3L gene region in a monkeypox virus genome, and utilizing fluorescent PCR technology to detect monkeypox virus nucleic acid after rapid extraction of a nucleic acid from a sample. The operation is simple, and a monkeypox virus target gene is detected by using a TaqMan probe, so that a vaccinia virus with very high sequence similarity can be specifically distinguished. False detection and detection failure can be avoided.

17.WO/2023/236468CORONAVIRUS S PROTEIN VARIANT AND USE THEREOF
WO - 14.12.2023
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/CN2022/136551 Solicitante FUDAN UNIVERSITY Inventor/a LIN, Jinzhong
Provided is an S protein variant, which does not contain a complete cytoplasmic tail domain compared to the S protein of a wild-type coronavirus. Further provided are a nucleic acid molecule encoding the S protein variant, and the use of the S protein variant and the nucleic acid molecule in the preparation of a vaccine.

18.WO/2023/239197NOVEL CRS FRAGMENT PEPTIDE WITH IMMUNOPOTENTIATING ACTIVITY, AND USE THEREOF
WO - 14.12.2023
Clasificación Internacional A61K 38/53 Nº de solicitud PCT/KR2023/007930 Solicitante ZYMEDI CO., LTD. Inventor/a CHO, Seongmin

The present invention relates to a novel CRS fragment peptide with immunopotentiating activity and a use thereof. More specifically, the present invention relates to a novel peptide composed of the amino acid sequence of SEQ IS NO: 2 or an amino acid sequence having a sequence homology of 95% or higher therewith and a vaccine adjuvant thereof, a use as a cancer treatment agent, and an antiviral composition. The peptide disclosed in the present invention, which is a CRS fragment peptide disclosed first herein, exhibits an anticancer activity, immunopotentiation, and an antiviral activity.

19.WO/2023/240085VIRAL PEPTIDES AND USES THEREOF
WO - 14.12.2023
Clasificación Internacional C07K 7/00 Nº de solicitud PCT/US2023/067999 Solicitante REGENERON PHARMACEUTICALS, INC. Inventor/a CHOY, Augustine
The present disclosure provides isolated peptides derived from hepatitis B virus (HBV), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treatment or prevention of HBV infection and/or HBV-induced diseases. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treatment or prevention of HBV infection and/or HBV-induced diseases. The present disclosure further provides methods and systems for identifying immunogenic virus-derived peptides.

20.4129330SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL KIMÆRE DENGUE VIRUS-KONSTRUKTIONER I VACCINER
DK - 11.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 22182269 Solicitante Takeda Vaccines, Inc. Inventor/a STINCHCOMB, Dan T.
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

21.4288076VIRALE KONSTRUKTE ZUR VERWENDUNG BEI DER VERBESSERUNG DES T-ZELL-PRIMINGS WÄHREND DER IMPFUNG
EP - 13.12.2023
Clasificación Internacional A61K 35/768 Nº de solicitud 22750341 Solicitante GEOVAX INC Inventor/a HAUSER MARY JO
The invention provides virus-based expression vectors comprising immune-checkpoint inhibitor inserts for use as effective adjuvants in enhancing T-cell priming to an antigen in a host during a vaccination regimen. In particular, the compositions described herein are novel recombinant modified vaccinia Ankara (MVA) viral constructs encoding one or more peptides which, upon administration, are expressed in a multimer conformation and subsequently cleaved and secreted from the cell. Such peptides are capable of downregulating an immune checkpoint pathway, for example, by inhibiting the activation of programmed-cell death protein 1 (PD-1), programed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or another immune checkpoint regulator, or a combination thereof. When used in concert with the administration of an antigen during a vaccination strategy, the immune checkpoint expressing MV A viral construct provides significantly improved antigen-specific CD8+ T cell expansion, increased antigenic responses, and improved vaccination efficacy.

22.WO/2023/237126STEM CELL COMPOSITIONS FOR CULTURING CORONAVIRUSES AND METHODS OF MAKING AND USING THEREOF
WO - 14.12.2023
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/CN2023/105028 Solicitante CENTRE FOR TRANSLATIONAL STEM CELL BIOLOGY LIMITED Inventor/a RUAN, Degong
Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-nucleated or mature cells. The methods can also include assessing the eSTBs for coronavirus susceptible markers. Also disclosed are compositions and methods (i) for inducing the differentiation of eSTBs and mature STBs from trophoblast stem cells (TSCs), (ii) for inducing the differentiation of TSCs from EPSCs, primed and naïve stem cells, pre-implantation embryos, placental stem cells, and iPSCs, and (ii) for producing TSCs by reprogramming non-trophoblast cells. The disclosed compositions and methods can be used for producing large quantities of coronavirus particles, including human, non-human, and variant coronavirus particles for virus production, the vaccine inductry, disease modeling studies, screening and evaluation of antiviral reagents, compound candidates, testing kits, and evaluation of clinical therapies.

23.2619625Compositions and methods of manufacturing trivalent filovirus vaccines
GB - 13.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 202312320 Solicitante SOLIGENIX INC Inventor/a OREOLA DONINI
A stable immunogenic composition or vaccine comprising at least one antigen, wherein the antigen comprises a viral glycoprotein, and at least one adjuvant, wherein the adjuvant comprises sucrose fatty acid sulphate esters, and wherein the antigen and adjuvant are co-lyophilised. The composition may not comprise alum. The composition may comprise two or more antigens, wherein each antigen is specific to a different virus. Also claimed is a method of making a composition comprising at least two antigens specific to a different virus from the same or different families, and providing at least one adjuvant, wherein the adjuvant comprises sucrose fatty acid sulphate esters and not alum, wherein the antigens and adjuvant are co-lyophilised. The composition may be administered to a mammal for up to three separate occasions to protect the mammal from subsequent infections. Also claimed is a composition comprising at least two antigens and at least one adjuvant, wherein the adjuvant comprises sucrose fatty acid sulphate esters, and wherein each antigen is a viral glycoprotein specific to a different genus of filovirus. The viral glycoprotein may be from Marburg Marburgvirus (MARV), Sudan ebolavirus (SUDV), or Zaire ebolavirus (EBOV).

24.WO/2023/237726AN INTRACELLULAR TUMOR-SPECIFIC VARIANT OF HUMAN ZONA PELLUCIDA GLYCOPROTEIN 3 AND NUCLEIC ACIDS CODING THEREFOR FOR USE IN THE TREATMENT OF CANCER
WO - 14.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/EP2023/065466 Solicitante PANTARHEI ONCOLOGY B.V. Inventor/a SCHULTZ, Iman Johannes
The present invention relates an intracellular tumor-specific variant of human Zona Pellucida Glycoprotein 3 (hZP3) and the use thereof in a therapeutic and/or prophylactic treatment of a cancer, preferably a ZP3-expressing cancer. More specifically, the invention relates to such therapeutic use of antigen sources providing the intracellular tumor-specific variant of hZP3, preferably for inducing at least a cellular immune response against the cancer cells. The source of the intracellular tumor-specific variant of hZP3 can be a proteinaceous composition or can be a composition comprising nucleic acid encoding the intracellular tumor-specific variant of hZP3, such as an RNA vaccine for translation of the intracellular tumor-specific hZP3 variant in a human cell. The invention further relates to a pharmaceutical composition comprising a

source of a nucleic acid molecule comprising a nucleotide sequence that is substantially complementary to a target sequence in an RNA encoding an intracellular tumor-specific variant of hZP3, for use in a therapeutic and/or prophylactic treatment of a cancer, wherein preferably binding of the substantially complementary sequence to the target sequence reduces expression of the intracellular tumor-specific variant of hZP3 in a cancer cell expressing the variant.

25.4288438IMIDAZO[4,5-D PYRIDAZINDERIVATE, IHRE HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG
EP - 13.12.2023
Clasificación Internacional C07D 487/04 Nº de solicitud 22703615 Solicitante SANOFI SA Inventor/a ZHANG JIDONG
The present invention relates to a compound of formula (I) wherein R_1 represents H, (C_1-C_6)alkyl-; hydroxy-(C_1-C_6)alkyl-; NH_2-(C_1-C_6)alkyl-; NH-(C_1-C_6)alkyl-(C_1-C_6)alkyl-; N((C_1-C_6)alkyl)$_2$-(C_1-C_6)alkyl-; (C_2-C_6)alkenyl-; (C_2-C_6)alkynyl-; phenyl(C_1-C_6)alkyl-; (C_3-C_{10})cycloalkyl(C_1-C_6)alkyl-; (C_3-C_{10})membered heterocycloalkyl(C_1-C_6)alkyl-; (C_5-C_{10})membered heteroaryl(C_1-C_6)alkyl-; (C_3-C_{10})membered heterocycloalkyl- NH-(C_1-C_{16})alkyl-; and (C_3-C_{10})membered heterocycloalkyl-N(C(O)-(C_1-C_6)alkyl)-(C_1-C_{16})alkyl-; R_2 represents a halogen atom, a (C_1-C_6)alkyl- group or other well defined groups; and R_3 represents a deuterium atom; H, (C_1-C_6)alkyl-; (C_2-C_6)alkenyl-; (C_2-C_6)alkynyl-; (C_1-C_6)alkylthio-; -OR_6; -NR_7R_8; (C_3-C_{10})membered heterocycloalkyl-; (C_5-C_{10})membered heteroaryl-; -(C_6-C_{10})membered aryl; and (C_3-C_{10})cycloalkyl-. The present invention further relates to intermediates of these compounds, processes for their preparation, a medicament and a pharmaceutical composition comprising them, and their therapeutic uses, in particular as TLR7 and /or TLR8 agonists, as well as their use in a vaccine.

26.3162727PROTEOLIPOSOMES COMPRISING A SARS-COV-2 S GLYCOPROTEIN ECTODOMAIN AND THEIR USE AS A VACCINE
CA - 15.12.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 3162727 Solicitante UNIVERSITY GRENOBLE ALPES Inventor/a WEISSENHORN, WINFRIED
A recombinant SARS-CoV-2 S glycoprotein ectodomain trimer is disclosed, comprising three recombinant protomers each containing at least the SARS-CoV-2 S glycoprotein ectodomain, and wherein: in each protomer, the furin cleavage site is inactivated/disrupted; Arg408 of one of said protomers is covalently linked to Lys378 of another one of said protomers; and Lys947 of one of said protomers is covalently linked to Arg1019 and/or to Lys776 of another one of said protomers.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES

CUBA